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Neuroimaging of function in Alzheimer’s disease and other
dementias 
Robert Hunter 
SUMMARY
Interest in Alzheimer's disease (AD) has increased considerably 
in the last decade. As a result of demographic changes the number of 
AD sufferers is steadily increasing and AD is recognised as a major 
public health challenge. This has been paralleled by recent advances 
in understanding the biology of AD, particularly using neuroimaging 
and molecular biological methods. This thesis describes an 
investigation using functional brain imaging techniques of presenile AD 
patients, and two control groups, Korsakoff’s psychosis (KOR) and 
healthy subjects.
Current understanding of the concept of AD is reviewed, 
together with the contribution of clinical and neuropathological findings 
to the establishment of diagnostic criteria. The experimental chapters 
describe investigations carried out on presenile AD patients, therefore 
the relationship of early onset AD to that presenting at an older age is 
also discussed.
The rationale of using cerebral blood flow (CBF) as an index of 
brain metabolism rests on evidence that supports the hypothesis that 
there is close coupling of CBF and brain metabolism during 'resting' 
conditions, and possibly also under at least some conditions of brain 
activation. The development of methods for measuring CBF, from the 
early estimates of global CBF provided by the Kety-Schmidt technique 
to the introduction of functional tomographic imaging, such as single
13
photon emission computed tomography (SPECT) and positron 
emission tomography (PET), in the last decade is described. The 
contribution of these techniques to understanding the brain dysfunction 
of AD is critically reviewed.
A method for measuring the cerebral vascular transit time of 
pertechnetate (99mTc), after intravenous bolus injection using a gamma 
camera is described. Estimates of net mean transit time (net MTT) in a 
planar non-tomographic vertex projection of brain were determined in 
17 patients with presenile AD, 9 abstinent patients with Korsakoff’s 
psychosis (KOR), and 10 healthy matched controls. The CAMDEX was 
used to assess patients and the CAMCOG to describe cognitive 
function. In both AD and KOR groups net MTTs were significantly 
lengthened compared with controls, although without information on 
volume of distribution it is not possible to relate net MTT results to CBF. 
There was no significant difference between net MTT results of AD and 
KOR groups. More importantly, examination of individual net MTT 
scores in the three groups showed some degree of overlap. Using net 
MTT data from healthy control subjects, ‘normal’ cut-off values of net 
MTT for all regions were established, and positive predictive values 
calculated. For posterior cortical regions in AD patients, positive 
predictive values were greater than 70% suggesting that for this region 
the method may have some degree of clinical utility. The pattern of 
cognitive function was differentially impaired in AD and KOR groups 
and there was a tendency for estimates of net MTT to be inversely 
associated with CAMCOG measures. The prolongation of transit times 
in cortex of KOR patients suggests cortical involvement in a disorder 
usually considered primarily subcortical. Positive predictive value of 
net MTT in posterior regions of interest in AD patients support the case 
for further investigation of the clinical utility of the method.
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The radiotracer " mTc-HMPAO was used with SPECT to 
determine patterns of regional uptake of radiolabel into brain regions of 
patients with presenile Alzheimer's disease and Korsakoff's psychosis, 
and age-matched controls. Using occipital cortical uptake as a 
reference area, the pattern of relative regional cerebral blood flow 
(rCBF) was determined in other cortical areas and basal ganglia. In 
Alzheimer's disease reduction in rCBF occurred in posterior temporal 
and parietal areas. By contrast, in Korsakoff's psychosis posterior 
temporal rCBF was maintained, although there was a trend to reduced 
tracer uptake in other cortical areas. There was considerable overlap 
of individual relative rCBF values in both patient groups and controls.
As a result positive predictive values are low and only greater than 50% 
in posterior temporal regions of AD patients. The degree of overlap of 
individual test results of different diagnositc groups casts doubt on the 
diagnostic utility of SPECT imaging using HMPAO. These impairments 
of flow were correlated with impairments of neuropsychological 
function. In Alzheimer's disease left posterior temporal and left parietal 
regions in particular showed rCBF to be correlated with most aspects of 
cognitive function. In Korsakoff's psychosis, however, impaired flow in 
frontal regions was correlated with impaired performance on tests of 
memory and orientation. The findings in Alzheimer's disease show 
parallels with quantitative studies using PET, and help extend our 
understanding of the relationship between cognition and regional brain 
function in dementia. The findings in Korsakoff's psychosis offer 
evidence linking frontal lobe dysfunction with the cognitive impairment 
seen clinically in the disorder. The complementary nature of SPECT 
imaging and structural imaging techniques, such as x-ray CT is 
illustrated in a case of the rare presenile dementia, Creutzfeldt-Jacob 
Disease.
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99mjc_HMPAO SPECT was used to study the effects of 
physostigmine, a drug known to potentiate cholinergic function, on 
patterns of rCBF in patients with presenile Alzheimer's disease.
Relative regional CBF appeared to increase in left cortex relative to 
right, with the most significant effect detected in left frontal and higher 
frontal regions. This study shows that measures of regional brain 
function, such as SPECT, may be a useful complement to 
psychological test batteries in understanding the effects in brain of 
putative anti-dementia drugs, such as physostigmine. Using this type 
of approach, SPECT brain imaging could be used to extend our 
understanding of the action of other psychotropic drugs in major 
psychiatric illnesses.
A SPECT technique using a split-dose of the tracer99mTc- 
HMPAO, that permits the effects of physiological, pharmacological or 
psychological challenge on patterns of rCBF to be imaged is described. 
In a group of 9 patients with different brain pathologies the test-retest 
reliability of the method was measured. Precision values varied from 
+/- 3.6% in superior frontal cortex to 15.9% in basal ganglia. The split- 
dose paradigm may extend the use of the radiotracer HMPAO from 
basal SPECT imaging of brain states to investigation of the effects of 
challenge on patterns of rCBF. Other sources of error in test-retest 
SPECT paradigms were investigated in a series of experiments to 
(assess: errors in data acquisition and image reconstruction, the effect of 
head movement during a scan, the effect of re-aligning the patient in 
the scanner, and serial scanning after one week, as in the 
physostigmine experiment.
Functional imaging techniques, such as SPECT, have 
only been available for a relatively short period of time. In 
neurodegenerative conditions such as AD or KOR, as well as in the
16
normal brain, they offer new opportunities to study brain metabolism in 
vivo. Initial studies have focussed on basal brain function and its 
relationship to cognitive impairment, however it is the potential of these 
techniques to image change in brain function in response to challenge, 
either pharmacological or neuropsychological, together with receptor 
imaging studies, that should contribute to future understanding of the 
biological basis of AD.
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CHAPTER 1 
THE NATURE OF ALZHEIMER'S DISEASE
18
1.1 Introduction
Alzheimer's disease (AD) is the commonest dementia, accounting for 
at least half of all cases of dementia examined at necropsy. It is a primary 
disorder of nerve cells leading to neuronal cell death and extensive brain 
atrophy. Although it is over eighty years since Alzheimer presented his 
case report; the disease that bears his name has only assumed major 
importance in the last decade.
The prevalence of AD increases with age, affecting at least 5% of 
those aged over 65 and as many as 25% of those over 80. As the numbers 
of elderly increase, AD will become a common cause of death, especially in 
developed countries. In both developed and less developed countries the 
proportion of elderly in the population is increasing at an unprecedented 
rate. In 1950 there were 214 million persons aged 60 years and over, by 
2025 there will be 1 billion (Henderson, 1986). This will result in a large 
increase in the number of AD sufferers, many of whom will live longer as a 
result of improved medical and nursing care. The coming epidemic of AD 
is therefore a major challenge for public health services in terms of 
provision of adequate care and the economic resources needed to provide 
it. In the UK such resources are limited at the present time, and this is 
despite 80% of sufferers living in the community rather than in nursing 
homes or hospital. Major economic resources are needed for the care of 
Alzheimer patients. For example, in the USA it has been estimated that of 
the 21 billion dollars spent on nursing care in 1982, over 10 billion was 
spent on care of patients with AD (Terry & Katzman, 1983).
In recent years the application of biochemical and molecular genetic 
approaches to AD has increased understanding at a cellular level. Along 
with these advances in basic science, there have also been advances in the 
clinical understanding of AD. The importance of proper clinical evaluation 
and investigation of patients presenting with signs of dementia, in order to
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establish the likely type of dementing process, is now widely recognised. 
Definitive diagnosis, however, requires histological examination, which is 
usually only possible post-mortem as brain biopsy is usually difficult to 
justify clinically. With more accurate diagnosis, better evaluation of 
management approaches and service planning is possible, as well as 
research into pathogenesis.
1.2 Concept of Alzheimer's disease
In November 1906 at a meeting of the South West German Society of 
Alienists, Alois Alzheimer presented a clinico-neuropathological report of a 
51 years old woman whose symptoms began with loss of memory and 
disorientation. Later she suffered from depression, hallucinations and 
behavioural disturbance, and in four years profound dementia and death.
At autopsy, her brain was found to be atrophied and the cerebral cortex 
contained miliary lesions (‘herdchen’). Alzheimer also noted, using a silver 
impregnation method, a distortion and clumping of the cortical neurofibrils.
Alzheimer’s presentation was published by title only in the 
Neurologische Zentralblatt in 1906 and his case report, 'Uber eine 
eigenartige Erkankung der Hirndrinde' ('on a peculiar disease of the 
cerebral cortex’) in Allgemeine Zeitschrift fur Psychiatrie und Psychisch- 
gerichtliche Medizin in 1907. In 1910 the Italian, Perusini, described a 
further four cases of this disorder, which he believed was distinct from 
senility (Perusini, 1910). The following year Kraepelin proposed that the 
condition be called Alzheimer’s disease, in recognition of Alzheimer’s 
contribution. This tradition continues to be recognised and today the terms 
primary degenerative dementia of the Alzheimer type (DSM-III-R, 1987) and 
Alzheimer's disease (AD) are widely used.
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However, more than 70 years earlier in England, James Cowles 
Prichard had described a syndrome that he called ‘senile dementia’ or 
‘incoherence’, which he said was characterised by 'forgetfulness of recent 
impressions, while the memory retains a comparatively firm hold of ideas 
laid up in the recesses from times long past’ (Prichard, 1835). As is now 
recognised, Prichard’s senile dementia and that described by Alzheimer in 
a younger case share a similar neuropathology, and the consensus of 
opinion at present, is that they represent the same disease process (Roth 
1978a).
The neuropathological changes in AD are characteristic: neuronal 
loss, senile plaques, and neurofibrillary tangles. It has therefore been 
argued that AD is a single disease entity, with its own causes and natural 
course. Such a conclusion gained support from the discovery of the 
cholinergic deficit in AD. As central cholinergic systems had already been 
implicated in pharmacological models of memory, it seemed plausible that 
the memory deficits of AD could be caused by selective loss of cholinergic 
neurones (Coyle et al 1983). However other neurochemical deficits (Hardy 
et al 1985) also characterise AD, and the disease process is more complex 
than previously thought. It is not known if the different patterns of 
neurochemical deficit represent different stages of a single disease process 
or different processes. The cause of neuronal death in AD is not known, 
but there does appear to be a consistent pattern of cell death leading to a 
characteristic clinical syndrome. AD may be the endpoint of many distinct 
causal pathways, each of which can lead to the pattern of neuronal damage 
found in AD.
The existence of AD as a distinct disease entity has been questioned, 
however, and it has been viewed as part of the normal aging process 
(Brody, 1982). Support for this view comes from studies in which screening 
tests aimed at detecting individuals at high risk of AD in the community
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showed a unimodal rather than bimodal distribution (Katzman, 1988). 
However this work can be criticised as selecting out only those individuals 
able to answer the questionnaire, and not the more severely impaired. 
Perhaps a more interesting question is the way in which aging and AD 
interact, but this has received relatively little study (Lancet, 1989).
1.3 Clinical features, course and outcome
The onset of AD, although difficult to determine with any precision, is 
usually after the age of 40 years. Insidious memory impairment, 
dysphasia, dyspraxia, and visuospatial abnormalities and the progressive 
development of global dementia are usually recognised as the cardinal 
features of AD, although it is well recognised that behavioural, affective, 
psychotic and neurological symptoms may also occur (Blessed, 1980).
Memory difficulties occur as the earliest feature more often in AD than 
in any other type of presenile dementia (Sim et al 1966). The National 
Institute of Neurological and Communicative Disorders and Stroke 
(NINCDS) and Alzheimer's Disease and Related Disorders Association 
(ADRDA) work group on the diagnosis of AD (McKhann et al 1984) have 
defined dementia as: ‘the decline of memory and other cognitive functions 
in comparison with the patient's previous level of function as determined by 
a history of decline in performance and by abnormalities noted from clinical 
examination and neuropsychological tests’. Furthermore, a diagnosis of 
dementia cannot be made when consciousness is impaired by delirium, 
drowsiness, stupor, or coma or when other clinical abnormalities prevent 
adequate evaluation of mental status.
The studies of Sjogren (1950) and Sjogren et al (1952) provide a 
clear account of the course of AD. Although a degenerative continuum, the 
progression of AD can be considered as three broad, but merging stages.
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In the first stage, considerable social competence is often preserved along 
with gradual memory failure, muddled mental inefficiency for simple matters 
and spatial and temporal disorientation. Mood disturbances are well 
recognised at this time, but psychotic symptoms rarely occur. The change 
in mood may be manifest as agitation or restless perplexity or alternatively 
as apathy and lack of interest.
In the next phase memory failure progresses until the patient has little 
recognition of the major events in his or her life and may even fail to 
recognise close relatives. Along with intellectual and personality 
deterioration, focal symptoms appear. Language dysfunction is common 
with the development of expressive, and later receptive dysphasia. Parietal 
lobe dysfunction leads to dyspraxia and agnosia, although neuronal loss 
and tangle formation are often less in parietal regions than in frontal and 
temporal areas. However parietal association cortex has major 
connections with superior and inferior temporal cortex and with prefrontal 
cortex (Goldman-Rakic, 1984) and therefore structural and neurochemical 
deficits in frontal cortex may contribute to dyspraxia (Roth 1986).
As the patient becomes more demented, insight is lost and the 
emotions often become shallow and the patient apathetic. Psychotic 
symptoms may also occur at this stage and in one series, delusions 
occurred in 30% of AD patients (Cummings et al 1987). Delusions of theft 
and infidelity are common themes and accusatory beliefs can cause serious 
difficulties for carers (Rabins et al 1982). Hallucinations are less frequent, 
occurring in about 25% of subjects (Merriam et al 1988; Burns et al 1990a). 
Visual hallucinations tend to be more common than auditory hallucinations 
and may reflect the presence of an intercurrent delirium. Misidentifications 
also occur, including misidentifications of the subject's own mirror image 
and of other people. There are however difficulties associated with the 
elucidation of phenomenology in demented patients and many studies have
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relied on reports of symptoms from relatives and caregivers which might 
ideally have been obtained through a direct interview with the patient 
(Rabins et al 1982; Merriam et al 1988; Burns et al 1990a). In future, more 
sensitive instruments might be developed to assess psychotic features in 
the cognitively impaired.
In the final stage of AD, the patient has severe intellectual 
impairment, and often finally becomes bedridden and doubly incontinent. 
Language function declines to a few meaningless utterances and 
comprehension of speech is lost. Neurological disability develops with 
increased tone, myoclonus, Parkinsonian features and extensor plantar 
reflexes. Walking may become increasingly unsteady, until the patient is 
finally bedridden with severe rigidity, muscle wasting and flexor 
contractures. Grand mal seizures also occur in the later stages of AD in 
about 10% of cases. The most frequent final cause of death is registered 
as bronchopneumonia often in bedridden patients. The final period of the 
illness is usually one of inexorable decline.
Thus the course of AD is one of progressive decline, with death 
occurring between two and ten years after onset. Death may occur earlier 
in presenile cases (Seltzer & Sherwin, 1983). The life expectancy of 
Alzheimer patients is reduced compared with age-matched controls (Roth 
1978a, 1978b). There is some evidence that AD patients may be surviving 
longer; in 1955, Roth reported a 55% mortality of demented patients within 6 
months of hospital admission (Roth, 1955), whereas two recent studies 
reported a lower mortality at six months: 32% (Blessed & Wilson, 1982) and 
25% (Christie, 1982).
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1.4 Diagnostic criteria
A variety of criteria have been proposed over the past few years in 
order to improve the clinical diagnosis of AD. This is important for several 
reasons; firstly, accurate diagnosis is a prerequisite for efficient 
management, and although specific treatments for AD are not yet available, 
there are many aspects of management, such as outcome planning that are 
improved by knowing which disease process is present; secondly, clinical 
diagnosis is important for research purposes and in the evaluation of 
putative new treatments. Essentially all the diagnostic schema for AD 
select for cases with the typical insidious onset of memory impairment and 
steady progression of cognitive decline and exclude, through detailed 
clinical assessment and biochemical, and radiological investigation, other 
possible causes of dementia (Glen & Christie, 1979; McKhann et al 1984).
The work group on the diagnosis of AD established by NINCDS and 
ADRDA (see section 1.5) has proposed the following criteria for the clinical 
diagnosis of probable AD (McKhann et al 1984): 1) dementia established 
by clinical examination and documented by the Mini-Mental State 
Examination test (Folstein et al 1975), Blessed Dementia Scale (Blessed et 
al 1968) or similar examination, and confirmed by neuropsychological 
tests; 2) deficits in two or more areas of cognition; 3) progressive 
worsening of memory or other cognitive functions; 4) no disturbance of 
consciousness; 5) onset between the ages of 40 and 90, but more often 
after the age of 65 years; 6) absence of systemic disorders or other brain 
diseases that could result in progressive cognitive decline. A diagnosis of 
probable AD is supported by: progressive deterioration of specific cognitive 
functions such as language (aphasia), visuospatial motor skills (apraxia), 
and perception (agnosia); impaired activities of daily living and altered 
patterns of behaviour; a family history of such disorders, particularly if 
confirmed neuropathologically; and the following laboratory results: normal
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CSF after lumbar puncture, normal pattern or only non-specific changes in 
the EEG, and evidence of cerebral atrophy on X-ray CT neuroimaging with 
progression documented by serial observation. Neuropathological 
confirmation is important for the audit of clinical diagnosis and essential 
before a diagnosis of definite AD can be made. Guidelines for the 
pathological diagnosis of AD have also been suggested by the Medical 
Research Council Working Group on Alzheimer's disease, which are 
consistent with the above NINCDS and ADRDA criteria (Report from the 
Medical Research Council Alzheimer's disease workshop, 1987).
The variable clinical presentations of AD are taken into account by 
the NINCDS-ADRDA criteria, which are a useful guide for correctly 
classifying the probability of making a correct diagnosis of AD. However 
these guidelines are not a means of staging the disease. For example, 
even in the very early stages of AD, a diagnosis of definite AD could be 
established if confirmed by brain biopsy. On the other hand, a patient with 
severe AD may still be classified as possible AD if there are other disorders 
present that might cause the dementia. The variable onset, clinical 
features, disease progression and pattern of cerebral metabolic disturbance 
in AD make diagnosis in the early stages difficult. It is not yet clear how 
best to detect the early signs of AD changes, but most of the available 
cognitive function screening tests are probably inadequate. As improved 
treatment becomes more likely, the importance of early and accurate 
detection of AD will be even more important, therefore more sensitive 
screening tests are clearly required.
1.5 Prevalence and incidence
The prevalence of AD is not known with any precision. Many 
surveys of prevalence have not differentiated between types of dementia
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and estimates vary considerably ranging from 1.5% to 21.9% (Henderson,
1986). These differences are largely accounted for by differences in the 
populations studied, differences in diagnostic and assessment criteria for 
dementia, and the proportion of the very old included. There are no 
reliable estimates of prevalence of dementia, let alone AD, in the under 65 
age group (Mortimer, 1983). Furthermore, most epidemiological studies do 
not differentiate between AD and multi-infarct dementia (MID). The 
prevalence of severe dementia in the over 65 population is between 3% 
and 5%, increasing to greater than 20% in the population aged over 85 
years (Kay & Bergmann 1980; Mortimer et al 1981; Gurland & Cross,
1982).
In chronic disease, such as AD, incidence data are preferable to 
prevalence data which may be confounded by factors associated with 
differential survival. Incidence data however take long periods to collect, as 
they call for examination of the study population at one time and re­
examination after some interval of time to determine who has developed the 
condition. There are very few studies of incidence of AD. In the Swedish 
Lundby Study (Hagnell et al 1983), the incidence of senile dementia, 
presumably of the Alzheimer type, was 0.7% and 0.5% for men and women 
respectively, aged 70-79 years, and 1.9% and 2.5% respectively for men 
and women over 80 years. In the Baltimore Longitudinal Study, the 
incidence rates were similar (Mortimer et al 1981). In a well defined US 
community, Schoenberg et al 1987, found that the annual incidence of AD 
rose with age from 0.004% in the 30-59 age range, to 0.096% in the 
seventh decade, and 1.43% in the ninth decade. With age adjustments 
there were no differences between the sexes.
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1.6 Neuropathological features
Just as normal anatomy and physiology underpins normal brain 
function, neuropathological abnormality underlies abnormal brain function 
and cognitive deficit in AD. Therefore it is essential to review the 
neuropathological features of AD before studying biological and cognitive 
dysfunction. Although brains from AD patients often show fronto-temporal 
atrophy, with enlargement of lateral ventricles (Perry 1984), a pathological 
diagnosis cannot be made on the macroscopic appearances of the brain 
and microscopic examination is necessary. The histopathological 
hallmarks of AD are senile plaques and neurofibrillary tangles (Selkoe, 
1986).
Bloq and Marinesco in 1892, first identified plaques in human brain. 
Plaques are usually associated with AD and the aging human brain, as 
similar structures only rarely occur in other conditions. Plaques are 
extracellular, spherical or ovoid structures of about 15-200/ym in diameter, 
composed of abnormal nerve processes (neurites) containing paired helical 
filaments, glial cells and processes and amyloid fibrils (Tomlinson & 
Corsellis, 1984). In some plaques, but not all, an amyloid core 5-1 O^m 
diameter is present (Wisniewski & Terry, 1973). The amino acid sequence 
of the protein (A4 or beta protein) that constitutes the amyloid core has 
recently been elucidated (Masters et al 1985a). Antibodies have been 
prepared to the A4 protein; such antibodies recognise not only typical, 
neuritic plaques, but also more diffuse plaque-like structures which are not 
stained by the histological stains used to visualise plaques. These plaque­
like structures are widely distributed throughout the central nervous system 
and may represent preliminary amyloid deposits which only develop into 
neuritic plaques in certain areas of the brain, including basal ganglia, 
cerebellum, periaqueductal and periventricular areas, hippocampus and 
spinal cord (Ogomori et al 1989; Bugiani et al 1989).
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The neocortical tangle was described first by Alzheimer in his 
description of the disease (Alzheimer, 1907). In contrast to plaque 
formation, tangles are not found to any significant extent in the neocortex of 
non-demented brains. Tangles are usually intraneuronal, but can be 
extracellular. Chemical analysis of tangles is technically very difficult but 
molecular biological approaches look promising. Recent work suggests 
that the microtubule-associated protein, tau, is likely to be a significant 
component of tangles (Wischik et al 1988), and at least part of the tau 
molecule seems closely bound to paired helical filaments (Kondo et al 
1988). The A4 protein also appears to be a component of tangles (Masters 
et al 1985b; Guiroy et al 1987). Another component of tangles is ubiquitin 
protein (Perry et al 1987), which appears to have a role in the response of 
cells to injury.
Plaques and tangles, however, are not confined to AD. In normal 
aging, plaques are found in the temporal and frontal cortex and 
hippocampus, whilst tangles are usually restricted to the temporal lobe, in 
particular the hippocampus. In AD the number of plaques and tangles in 
these areas is markedly increased compared with controls, and tangles 
appear in cortical areas and the olfactory system which are rarely affected in 
normal aging. Blessed et al (1968) showed that the number of cortical 
plaques in the brains of elderly people correlated with their degree of 
cognitive impairment. However, although the presence of neocortical 
tangles was accepted by the MRC Workshop on Alzheimer’s disease (1987) 
as being essential for a diagnosis of AD, recent work suggests that there are 
elderly cases of AD with large numbers of plaques in temporal and frontal 
cortex but no tangles in frontal cortex (Terry et al 1987; Katzman et al 
1988). There are surprisingly few studies of the relationship of plaque and 
tangle counts to severity of dementia. Tangle density has been reported to
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be directly proportional to degree of dementia (Wilcock et al 1982), but not 
always (Mann et al 1988a).
It appears that over a small range of plaque and tangle numbers, there is a 
positive correlation with degree of dementia, but it is likely that a minimum 
number of plaques and tangles are required before dementia is apparent 
clinically and above a certain number there is no measurable increase in 
dementia (Wilcock et al 1982; Blessed et al 1968). Thus plaque and 
tangle density may not always be useful as a measure of severity of 
dementia. Plaque and tangle formation are probably separate, though 
related, degenerative processes which may occur separately in AD.
Tangles are not confined to cerebral cortex and hippocampus, but 
also occur in subcortical nuclei, such as the basal forebrain nuclei, locus 
coereleus, raphe nuclei and the tuberomamillary nucleus of hypothalamus 
(German et al 1987), which project diffusely to cerebral cortex. The 
association of cortical and subcortical pathology in AD is shown in the 
observation that neuronal loss in a particular part of the basal forebrain 
nucleus is related to the number of plaques in the area of cortex targeted by 
the forebrain nucleus (Arendt et al 1985). The presence of tangles in 
enterorhinal cortical neurones projecting to the hippocampus, and in 
neurones from the hippocampus, may isolate hippocampus from the rest of 
brain and suggests at least one possible mechanism of memory impairment 
(Hyman et al 1984).
1.7 Relationship of early and late forms of Alzheimer’s 
disease
Historically, dementia occurring after the age of 65 years has been 
considered separately from that occurring in younger patients. The 
separate development of clinical services for older patients has reinforced
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this practice and the term ‘senile dementia’ (SD) has tended to acquire a 
separate nosological status through usage, rather than from weight of 
scientific evidence. There are two main problems with this term. Firstly, as 
in younger patients, there are many different types of dementia that can 
occur in older subjects, apart from AD, and diagnosis can only be 
determined with certainty at necropsy. Secondly, the use of the term ‘SD’ 
has obscured the relationship of the commonest form of senile dementia 
with the commonest early dementia, viz Alzheimer's disease. At autopsy of 
elderly patients who have died with a clinical diagnosis of SD, the most 
frequently detected pathology is very similar to, if not quite identical with, 
that of Alzheimer's disease in younger patients. As a result, this clinico- 
pathological condition is now usually referred to as ‘senile dementia of the 
Alzheimer type’ (SDAT) or Alzheimer's disease Type 1 (AD-1), early onset 
AD being referred to as Type 2 (AD-2) (Roth, 1986; Bondareff et al 1987). 
This reflects the current view that both conditions are likely to be similar 
manifestations of a single disease process, and, while age of onset may be 
associated with different clinical and neurochemical characteristics, it is 
nosologically accurate to consider the two types as variants of Alzheimer’s 
disease (Lauter & Meyer, 1968; Terry & Katzman, 1983).
The pathological changes in early onset AD appear to be more 
severe than in SDAT. Detailed comparisons between the pathology of 
younger and older patients, show that reduction in brain weight is greater in 
presenile cases compared with SDAT (Sourander & Sjogren, 1970). In 
studies of cell loss from nucleus locus coeruleus, the distribution of loss of 
cells was bimodal (Bondareff et al 1987; Mann et al 1988b) with less cell 
death in AD-1 (29-30%) compared with AD-2 (70-80%). Further support for 
the subdivision comes from differences in neocortical noradrenaline 
concentrations, choline acetyl transferase activity, plaques and tangles.
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Similarly, neurotransmitter deficits in post-mortem brain are more 
pronounced and more widespread in brains from younger patients with an 
earlier onset who die before the age of 70-80 years, than in brains from 
older, late onset patients who die after the age of 70-80 years (Yates et al 
1983; Rossor et al 1984). Choline acetyl transferase (ChAT) was reduced 
in temporal and frontal cortex in younger cases, but reduced only in 
temporal cortex of older cases. Greater reductions in the concentration of 
noradrenaline (NA), 5-hydroxytryptamine (5-HT), gamma amino butyric acid 
(GABA), somatostatin, and in the number of 5-HT receptors were observed 
in post-mortem brain from cases of Alzheimer disease dying at 70-80 years 
than in older cases dying after 70-80 years (Yates et al 1983; Bowen et al 
1983; Rossor etal 1984; Cross etal 1984; Francis et al 1985; Pierotti,
1986). The neurochemical deficits of earlier onset AD tend to be 
predominantly in fronto-temporal cortex, while in older cases are more 
confined to temporal cortex (Rossor et al 1984). Neurochemical and 
histological differences between AD types 1 and 2 have been used to argue 
for a broad classification of AD into two groups, with the early-onset (AD-2) 
showing the more severe biochemical change ( Bondareff et al 1987).
Thus, the neurochemical evidence tends to support the neuropathological 
evidence that early and late onset cases of AD at least form a continuum.
One explanation of the differences between the two groups may be that
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patients with SDAT (or AD-1) die at an earlier stage in the disease process 
than those with AD-2. Alternatively it could be argued that although the 
pathological process may be the same or similar in AD-1 and AD-2, an 
increased rate of progression in younger patients accounts for the 
increased severity and more widespread involvement. Why the disease 
should progress faster in younger patients is not clear, although there are 
examples of similar phenomena in other disorders. Although there is 
evidence that the clinical course of AD-1 and AD-2 have particular features,
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there has been too little systematic investigation of the progression of 
different AD types to enable firm conclusions to be drawn. In a comparative 
study of early- and late-onset cases, Seltzer & Sherwin (1983) found a 
higher prevalence of speech disorder, gait disturbance, selective 
dysfunction of left hemisphere and shorter life expectancy in the earlier- 
onset cases but no differences in dyspraxia in the two groups.
Longitudinal studies have also been conducted to identify clinical features 
that may predict or influence the course of the disease. In one recent 
study, the rate of progression was found to be greater in patients older than 
65 years at onset, compared with those younger than 65 years (Huff et al
1987). However, Heyman et al (1987) found that young age at onset and 
the presence of aphasia and severity of impairment predicted a rapid 
course. There is clearly a need for further prospective studies to investigate 
and compare the clinical, cognitive, neuropathological and neurochemical 
changes that take place in AD occurring at both younger and older ages.
The experimental studies described in this thesis were carried out on 
AD-2 early-onset patients. The decision to investigate this group was 
based on several considerations. Firstly, younger patients with AD are 
generally in better physical health than the older group, who often have 
other coexistent illness, which may, or may not be detected, and can 
therefore introduce additional variance into the measurements. Secondly, 
age-related complications and pathologies often require medication, with 
further possible confounding effects on brain function, and such patients are 
best excluded if possible. The lack of other pathology in combination with 
detailed supporting history from the patient’s spouse, also helps increase 
diagnostic accuracy. In younger patients, the cognitive and behavioural 
changes resulting from AD are often recognised as abnormal by the patient 
or his family at an earlier stage, and, as a result, AD-2 patients often present 
early and are highly motivated to undergo investigation and co-operate with
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research procedures. This may also have implications for studies of 
therapeutic intervention. There is also a greater likelihood of AD-2 patients 
living at home with their family, rather than in institutions, and all the AD 
patients investigated in this study lived at home.
1.8 Aims of the present study
As the above introduction illustrates, knowledge of the biological 
basis of brain disturbance in Alzheimer’s disease, and how this translates 
into altered mental function, is still at an early stage. Until the development 
of brain imaging techniques, there were only very limited means of 
investigating brain structure and function in vivo, and for most of the 
twentieth century psychiatrists retreated from the brain. There are two 
broad categories of brain imaging: structural techniques and functional 
techniques. Although structural imaging methods, such as x-ray computed 
tomography (CT) or magnetic resonance imaging (MRI), are able to 
visualise in some detail the anatomical structure of brain, they provide little 
information on brain function. The introduction of techniques that permit 
brain activity to be measured in vivo has facilitated the investigation of 
metabolic disturbance in neurodegenerative disorders such as AD. The 
studies discussed in this thesis describe the contribution to understanding 
AD, and other neurodegenerative disorders, from functional brain imaging 
of cerebral blood flow (CBF).
The main aims of the work were as follows:
1. To briefly review the concept of AD, its clinical manifestations and 
underlying neuropathology.
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2. To consider the evidence for a relationship between CBF and brain
metabolism, and review the utility of CBF as a valid and reliable index of 
brain metabolism or function.
3. To review the historical development of the main techniques 
available for measuring CBF in human subjects, and discuss critically their 
contribution to understanding AD.
4. To measure the vascular transit time of pertechnetate in probable 
presenile AD and two control groups: patients with Alcoholic Korsakoff 
Syndrome (KOR), and healthy volunteers. In particular, to assess the utility 
of the method for investigating cortical function in AD, where the recognised 
lesions are predominantly cortical, and in KOR, where the major lesions are 
usually regarded as subcortical. To investigate and describe 
neuropsychological performance in the two disorders, and its relationship to 
cortical transit time.
5. To use single photon emission tomography (SPECT) and the 
radiopharmaceutical, 99mTc-HMPAO, to investigate the pattern of regional 
cerebral blood flow (rCBF) in patients with probable presenile AD and KOR 
and to determine its relation to neuropsychological function in such patients. 
The central questions were:
(a) What is the pattern of perfusion deficit using SPECT in patients with 
AD and KOR, and in particular is there evidence in KOR of cortical 
dysfunction?
(b) Are there relationships between rCBF, a presumptive measure of 
neuronal function, and neuropsychological performance?
6. To use two-dose SPECT imaging techniques to measure the effects 
on rCBF of cholinergic potentiation using the anticholinesterase drug 
physostigmine in presenile AD patients.
7. To develop and describe a method that may allow SPECT imaging 
to be used to investigate the effects of challenge (eg drug or psychological)
on patterns of rCBF during a single imaging session, using a ‘split-dose’ of 
the flow tracer 99mTc-HMPAO. To assess the reproducibility of 99mTC. 
HMPAO uptake measurements using the split-dose paradigm in the 
absence of challenge.
8. To examine the effect of several different sources of reproducibility 
error during repeat SPECT scanning, (a) data acquisition and image 
reconstruction, (b) movement of patient in scanner, (c) patient re-alignment, 
and (d) serial scanning after one week.
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CHAPTER 2
THE MEASUREMENT OF CEREBRAL BLOOD FLOW IN 
ALZHEIMER’S DISEASE: A LITERATURE REVIEW
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2.1 Relationship between CBF and metabolism
In this chapter, the use of cerebral blood flow (CBF) measurements in 
the study of brain abnormality in AD will be reviewed. Before doing this 
however, it is necessary to discuss briefly the rationale of using CBF as an 
index of brain metabolism.
2.1.1 Normal energy sources in brain
In brain, as in any steady-state system, the metabolic rate (ie rate of 
energy production) is closely correlated with physiological function (ie rate of 
energy utilization). Since adenosine triphosphate (ATP) is required as the 
energy source for vital cellular processes, the more functionally active a cell, 
the more ATP it will require. As glucose is the major source of ATP for the 
central nervous system (CNS), the functional activities of the various brain 
regions should be reflected in their rates of regional glucose utilization. Over 
95% of normal energy requirements of cerebral tissue are derived from 
oxidative phosphorylation in mitochondria. Glycolysis in the cytosol 
generates only a small fraction of the total ATP available compared to that for 
complete oxidative metabolism of glucose. While glycolysis is much less 
efficient than oxidative metabolism in terms of ATP yield per molecule of 
glucose, it has the advantage of rapidly producing ATP in the cytosol, which 
may be important during intense short-term stimulation. Glycolysis in the 
presence of adequate oxygen (‘aerobic glycolysis’) has been demonstrated in 
stimulated brain structures (Collins et al 1987; Fox et al 1988; Pulsinelli and 
Kraig 1988; Ueki et al 1988; Blomquist et al 1989), and aerobic glycolysis may 
be the main supplementary ATP source during stimulated conditions.
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2.1.2 Coupling of cerebral blood flow and metabolism
Since the investigations of Roy and Sherrington (1890), it has been 
generally accepted that an intimate coupling between blood flow and tissue 
metabolic rate is dynamically maintained in normal brain (eg Siesjo, 1978). 
Local modulations in neuronal electrical activity are thought to be associated 
with similar modulations in local metabolism, leading in turn, to alterations in 
local blood flow. Blood flow and metabolism have therefore been considered 
to change in unison, with increases in flow reflecting increases in neuronal 
metabolism, and vice versa, both providing indirect indices of brain work (Roy 
and Sherrington 1890; Frackowiak et al 1981). The mechanism by which 
CBF and metabolic rate are coupled remains poorly understood and is outwith 
the scope of this review.
This close relationship between blood flow and metabolic rate seems to 
hold in resting brain, and structures having high blood flow (eg grey matter) 
tend also to have high metabolic rates, while structures having lower blood 
flow (eg white matter) have lower metabolic rates. Thus there are excellent 
regional correlations between CBF and regional cerebral metabolic rate of 
oxygen utilization (rCMR02), (Raichle et al 1976; Baron et al 1984; Fox and 
Raichle 1986) and between CBF and regional cerebral metabolic rate of 
glucose utilization (rCMRglc) (Baron et al 1984; Fox et al 1988). Coupling of 
CBF and rCMR02has also been demonstrated in resting subjects with 
dementia (Frackowiak et al 1981), but in other pathological states the 
relationship between CBF and metabolic rate may be more complex.
2.1.3 Changes In energy demands during stimulation
The coupling of CBF and metabolism (CMRglc and CMRO2) which 
occurs in the 'resting state', is less evident during active brain stimulation.
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For example, the clear correlations between CBF and CMRO2 detected using 
positron emission tomography (PET) in resting healthy human subjects, are 
not found during somatosensory stimulation (Fox and Raichle 1986). Upon 
activation, CBF increased by about 30% while the metabolic increase 
(CMRQ2) was only 5%. In a later study by Fox et al (1988) using PET to 
measure regional cerebral blood flow (rCBF), rCMRglc and rCMR02 in visual 
cortex of healthy volunteers during visual stimulation, there was only a small 
increase in O2 utilization (5%), but glucose uptake and rCBF both increased 
proportionately by much more (51% and 50% respectively). For glucose 
metabolism to rise in excess of oxygen utilization, suggests that glucose is 
metabolised via glycolysis with production of lactate. This has been 
confirmed in two independent studies using animals. Using tissue 
fluoroscopy, Hossman and Linn (1987) noted an increase in tissue lactate in 
rat somatosensory cortex during forepaw stimulation, while Prichard et al 
(1987) used magnetic resonance spectroscopy to show that tissue lactate 
increased in rabbit visual cortex during optic nerve stimulation. In a different 
study, photic stimulation resulted in increased lactate in the superior colliculus 
of rats (Pulsinelli and Kraig ,1988). These results suggest that increased 
transient metabolic needs in the CNS are apparently met with non-oxidative 
glucose metabolism, namely glycolysis, even in the presence of sufficient 
oxygen.
Despite the large increase in glucose uptake observed, the actual 
energy yield in ATP may be much less, even if all the oxygen uptake is 
consumed by glucose oxidation and the remainder of glucose converted by 
glycolysis to lactate. In total this would yield only an increase of about 8% in 
ATP production. However if some of the glucose taken up is converted to 
glycogen, ATP production would be even less.
After neuronal stimulation there may only be a small increase in energy 
requirements above base levels because the additional ion fluxes across the
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cell membrane probably represent only a small fraction of total cellular activity. 
It has been estimated that less than 3% of cortical energy consumption would 
be required for such evoked activity in cortical nerve cells (Creutzfeldt et al 
1975). Membrane bound ion pumps and transmitter release systems may 
depend on ATP generated from aerobic glycolysis. During basal conditions, 
enzymic oxidative capacity of neurones may be functioning near maximal 
capacity, and therefore the additional energy demands imposed by stimulation 
may have to be met by glycolysis (Barrere et al 1989).
2.1.4 Studies using labelled glucose to image stimulation
The deoxyglucose (DG) method of determination of the local cerebral 
glucose metabolic rate (LCMRglc) developed by Sokoloff (1977) has proven 
to be a useful and hence widely employed method for evaluation of cerebral 
function. The use of 14C-DG and 18F-fluorodeoxyglucose (FDG) in 
autoradiographic studies in animals and i8F-FDG in PET studies in humans 
(Phelps et al 1982) have been particularly effective in mapping the effects of 
physiological and pathological stimulation. Pronounced regional increases in 
DG or FDG-based LCMRglc have been found in seizures, pharmacological 
interventions, sensory stimulations and motor activity. DG and FDG have 
become the practical standards of evaluation of cerebral metabolism, despite 
the development of alternative methods. Quantitative methods for the 
measurement of local cerebral oxygen metabolism (LCMRO2) using 1502 and 
positron emission tomography (PET) scanning have also been developed 
(Frackowiak et al 1980). However DG and FDG appear to be more suitable 
than other techniques for imaging increases in brain function associated with 
stimulation. Using an elegant double tracer technique, Ackermann and Lear 
(1989) used the radiolabels 18F-FDG and 14C-6-glucose (GLC) in rats to 
estimate the relative size of contribution to ATP production of the Kreb's Cycle
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and glycolytic pathway. The rationale of this approach is that, while FDG is 
trapped in brain prior to the divergence of oxidative and glycolytic pathways, 
and thus reflects total (ie, oxidative and glycolytic) glucose metabolism, the 
label from 14C-GLC is retained only in oxidative metabolic pools and therefore 
reflects only oxidative metabolism. Via glycolysis, the label, 14C, from GLC 
will proceed to lactate, which will be lost out of the brain. This elegant method 
was used to study oxidative and glycolytic metabolism during Kainic acid- 
induced seizures in rats, demonstrating that glycolysis increases markedly in 
limbic structures during seizures. A similar conclusion can be drawn from 
single label experiments, and Collins et al (1987) found only a 30% increase 
of GLC-based LCMRglc compared to a 200% increase of DG-based LCMRglc 
in superior colliculus after visual stimulation in rats.
2.1.5 CBF and metabolism: conclusions
There is good evidence that under resting conditions CBF and 
metabolic rate are coupled. However, when stimulated, neurones require 
additional supplies of ATP, and this is normally met by a substantial increase 
in glucose utilization but only a small increase in oxidative metabolism. Thus 
it appears likely that additional ATP requirements are met largely from 
glycolysis, rather than oxidative intermediary metabolism, which may in the 
‘resting state’ be operating near maximal levels. In this way, the ATP supply 
may increase during stimulation by about 8%. The work of Fox et al (1988) 
shows that after photic stimulation, rCBF and rCMRglc increased by 50%, 
suggesting that in terms of ATP production, they may overestimate energy 
requirements.
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2.2 Methods of measuring CBF and metabolism and their
application in AD
2.2.1 Methodological problems
The development of methods for measurement of brain perfusion and 
metabolism in vivo have allowed CBF and metabolism to be studied in 
Alzheimer's disease (AD). Although many of the principles for CBF and 
cerebral metabolic rate (CMR) measurement were established some time ago, 
technical sophistication has improved in the last 40 years, with the introduction 
of methods which provide regional information and later, tomographic 
reconstruction. Technical development has been accompanied by improved 
understanding of the nature and concept of AD, and both ante-mortem clinical, 
and post-mortem neuropathological, diagnostic criteria have been established 
(see Chapter 1). Determination of type of dementing illness is now 
recognised as essential but in earlier imaging studies the need for careful 
case definition was poorly appreciated or ignored and resulted in findings that 
are often difficult to evaluate. In many studies, patients were often simply 
described as having ‘dementia’, without description of diagnostic criteria and 
little attempt made to exclude other types of pathological process that could 
confound results. As described in section 1.4, agreed criteria for clinical 
diagnosis of probable AD have only been accepted relatively recently (eg 
McKhann et al 1984; Roth et al 1986; MRC Report from the Alzheimer’s 
Disease Workshop, 1987). While assessment of neuropsychological function 
has improved with the introduction of a number of valid and reliable 
instruments for use in AD (eg Blessed et al 1968; Blackburn & Tyrer, 1985; 
Roth et al 1986), there is still a need to develop more sensitive instruments for 
assessment of cognitive function in dementia. Although the technical
43
sophistication of imaging has improved greatly in the last thirty years, this has 
not been paralleled by similar developments in improved neuropsychological 
assessment.
Throughout the development of techniques for functional brain imaging, 
two broad approaches have been taken; firstly, measurement of CBF and/or 
CMR in demented patients as an index of changed brain function; and 
secondly, attempts have been made to examine the relationship between 
changes in CBF/CMR and impaired neuropsychological performance.
2.2.2 The Kety-Schmidt Technique: inert tracer wash-out
2.2.2.1 Methodology and principles
These early methods are important because they laid the foundations 
for the development of future methods of measurement of CBF and CMR in 
clinical and experimental situations. Kety and Schmidt (1945,1948a, 1948b) 
introduced the inert tracer wash-out method using a non-radioactive tracer, 
nitrous oxide, but subsequent clinical applications used radioactive tracers. 
The method derives from the Fick Principle that, in a system at equilibrium, 
and if the tracer is delivered at a measured rate, flow can be calculated from 
the total quantity of tracer removed from the blood (or ‘washed-out’) divided by 
the net mean concentration difference between arterial and venous blood, 
provided blood flow is constant. In the original Kety-Schmidt method the 
subject inhaled nitrous oxide and the arterio-venous concentration difference 
was determined from samples of arterial and jugular venous blood removed 
over the measurement period.
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Using the Fick Principle, perfusion (P) or flow per unit weight of brain is given 
by:
where Qt is the quantity of nitrous oxide taken up by the whole brain in time t, 
measured from the start of inhalation, and Ca and Cv, the arterial and venous 
concentrations of nitrous oxide respectively, and W the weight of the brain.
An important assumption of the method is that the tracer should be freely 
diffusible in order that its concentration in the venous outflow is in equilibrium 
with that in the brain. A partition coefficient, X, expresses the ratio of solubility 
of tracer in brain to that in blood and can be expressed as,
X = (QtAA/)/Cv(t)
where Qt is the quantity of tracer in the brain at time t, W is the brain weight, 
and CV(t), the venous concentration of tracer at time t. Thus, substituting for Qt 
in equation 1 gives,
Perfusion (P) is thus given by the venous concentration of tracer at time t 
multiplied by the partition coefficient, to take account of differences in 
solubility, and divided by the quantity of tracer extracted from the blood during 
the same time interval.
When a freely diffusible tracer, which does not become bound, is 
introduced as an instantaneous bolus, equilibrium of tracer concentrations 
between blood and brain is soon established and the rate at which the tracer
P = Qt/W j(C a - Cv) dt (equation 1)
o
P = C a - Cv) dt (equation 2)
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is subsequently washed out (dCt/dt) is given by differentiating equation 2 and 
rearranging,
dQ/dt — k (XOg ■ Oy)
Furthermore, if it is assumed that after bolus injection the arterial concentration 
rapidly becomes negligible, then integrating gives,
Ct = C0e-kt
and in the case of a constant infusion of tracer where the arterial concentration 
remains constant,
Ct = XCaO-e-kt)
Thus, there are four parameters which can be measured and from which flow 
can be derived; the rate of wash-in and wash-out of tracer, the total quantity of 
tracer delivered to the region under study, and the change in the concentration 
of tracer with time (Zierler 1965). These principles have been described in 
some detail, because many of the methods for measuring regional cerebral 
blood flow in both experimental animals and man were developed from them.
2.2.2.2 Global CBF in AD
Using the Kety-Schmidt technique (Kety and Schmidt,
1945,1948a, 1948b) described above, measurements of global CBF and 
CMRO2 were undertaken in patients with dementing illness. Initially, the 
inhalation of inert nitrous oxide gas, was used, but this was soon replaced by 
inert radioactive gases in order to take advantage of accurate methods of
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scintillation counting. The Kety-Schmidt method gives absolute mean values 
tor whole brain blood flow per unit weight of tissue, conventionally per 100g of 
tissue. Although non-regional and one-dimensional, it is a valuable reference 
method against which other CBF methods can be compared.
The earliest observation that CBF and CMR02are reduced in senile 
dementia was that of Freyhan et al in 1951. Studies of demented patients 
using the same technique have consistently demonstrated similar reductions 
in CBF and CMRO2 (Lassen et al 1957; Lassen et al 1960). In these early 
studies it was noted that reductions in global cerebral blood flow tended to be 
associated with increasing mental deterioration and Lassen et al (1960) 
reported that this relationship was stronger for CBF in the dominant rather than 
non-dominant hemisphere. The later development of techniques that allowed 
regional brain function to be determined confirmed these early findings.
2.2.3 Measurement of regional CBF using xenon
Ideally, tracers used for the measurement of CBF in vivo should be 
metabolically inert and not undergo chemical alteration in the body. 
Furthermore, in order that equilibrium is rapidly established, the tracer should 
be lipophilic and therefore pass rapidly from blood into brain. A number of 
substances meet these criteria reasonably well and have proved useful in 
clinical practice. Xenon (133Xe) is the isotope most commonly used, but 
unfortunately has a rather low gamma ray energy of 80keV which results in the 
count rate being significantly reduced by intervening tissue. This results in 
measurements that are often biased in reflecting the more superficial parts of 
the cortex rather than deeper structures.
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2.2.3.1 The intra-arterial method
When a bolus of 133Xe dissolved in normal saline is injected into the 
carotid artery, it is largely delivered during the first pass to the ipsilateral 
hemisphere. From the rate of wash-out and the partition coefficient, the 
perfusion of various cortical regions can be determined. The wash-out rate of 
tracer from brain can be measured using a scintillation detector positioned 
over the head and, depending on the number of detectors used, hemispheric 
or regional measures of perfusion can be determined (Lassen & Ingvar 1972).
Regional measurement of CBF using the intra-arterial injection 
technique was introduced to clinical research in 1961 by Lassen and Ingvar in 
a method based on the injection of inert radio-active 85Krypton gas. However 
133Xe soon became the preferred tracer and after intra-carotid injection, the 
instantaneous arrival and subsequent clearance of tracer can be measured by 
multiple external scintillation detectors, each measuring the activity in a 
different brain region. In one analysis, three different flow compartments can 
be recognised from which perfusion in grey and white matter and extra-cranial 
structures can be determined (Obrist et al 1967). In normal subjects the 
distinction between compartments is usually fairly clear with higher flow in 
grey matter (the so-called ‘fast’ component) compared with other 
compartments, but in pathological states, such as dementia, the distinction can 
be much more difficult. The rate of disappearance of 133Xe from each region 
is proportional to the level of perfusion in that region and absolute flow values 
can be calculated from the exponential clearance curves. Thus grey and 
white matter blood flow in a particular brain region can be calculated from the 
fast and slow components of the wash-out curve respectively.
Unfortunately the method has the major drawback of the need for 
carotid arterial puncture and therefore measurements can only be performed 
on one occasion, and on one hemisphere.
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2.2.3.2 The application of intra-arterial methods in AD
Using the above technique, absolute estimates of regional cortical 
perfusion have consistently been shown to be reduced in presenile and senile 
dementia, although type of dementia was often poorly defined, and often 
presumed to be AD without the use of rigorous operational criteria (Ingvar and 
Gustafson, 1970; Gustafson and Risberg, 1974; Hagberg and Ingvar, 1976).
In presenile dementia patients average flow values were found to be 20-25% 
lower than in controls. While a fronto-temporal pattern of CBF reduction was 
reported in patients with ‘senile dementia’, in presenile patients more 
widespread flow reductions involving posterior temporal regions were 
reported (Ingvar & Gustafson, 1970; Obrist et al 1970). Hagberg and Ingvar
(1976) found that the pattern of cognitive deficits in each of four groups of 
increasingly demented patients was associated with reductions in left 
hemisphere CBF, although no perfusion measurements were made on the 
right side.
In that study early cases of dementia with only memory impairment had 
greater flow reductions in anterior temporal regions than elsewhere in left 
cortex. Severely demented patients had more extensive reductions of rCBF 
involving other cortical areas, including posterior temporal and parieto­
occipital cortex. Although these findings were of some interest, uncritical 
patient selection and the limited number of regions of interest in only one 
cortex (left) restricts the conclusions that can be drawn.
A close association between rCBF and cognitive symptoms was found 
in a large study of fifty presenile patients in whom dementia had presumably 
started between the ages of 40 and 65 years (Gustafson and Risberg, 1974).
In the study, psychiatric symptoms were not rated using standardised or 
accepted criteria, but on the basis of ‘clinical impression’ by a trained 
psychiatrist. Ratings for sixty-seven symptoms were factor analysed and the 
fourteen resultant factors correlated with rCBF in eight regions of ‘dominant’
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hemisphere. The results showed an inverse relationship between amnesia, 
apraxia, agraphia and aphasia, and rCBF in posterior temporal and occipito­
parietal regions. This study illustrates several methodological problems that 
occurred in many early imaging studies that make interpretation of findings 
difficult. Although the authors excluded, ‘dementia secondary to psychosis, 
apoplexy, and alcohol abuse’, inclusion criteria were not described and the 
sample may well have been quite heterogeneous. More than half the patients 
were on medication and a few had even received electroconvulsive therapy, 
yet there is no discussion of how these factors may have affected perfusion.
In the study, as in nearly all those using the intra-carotid method, 
measurements were made only in the ‘dominant’ hemisphere, yet no 
information is given on handedness or how the authors determined 
hemispheric dominance. It is also assumed that pathological changes in 
'dementia' are symmetrical, and therefore rCBF measurements need be made 
only in one hemisphere, without considering the influence of type or stage of 
illness. As later studies with PET imaging have shown, there is considerable 
evidence that pathological changes in AD are often asymmetric (see section 
2.2.6.3), indicating the importance of studying both hemispheres.
Some of these methodological problems were addressed by Perez et al
(1977), who used stricter diagnostic criteria and separated patients into three 
groups: AD patients, multi-infarct dementia (MID) patients, and a control group 
with ‘various neurological disorders’ that were not characterised. Using intra- 
arterial 133Xe, rCBF was measured in right sided cortical grey and white 
matter and assessed using a standardized neuropsychological battery, the 
Wechsler Adult Intelligence Scale (WAIS). Significant reduction in mean 
rCBF was found for both AD and MID groups, compared with the control 
group, however no correlation between psychological performance and rCBF 
was detected. Although the study might have been improved by the inclusion
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of a group of healthy control subjects, this was not possible as the intra-arterial 
technique is invasive and potentially hazardous.
2.2.3.3 Inhalational and intra-venous methods
The invasiveness of the intra-arterial injection technique seriously 
limited its usefulness for clinical research and led to the development of 
methods in which 133Xe could be administered intravenously or by inhalation. 
These were first suggested by Conn in 1955, subsequently developed into a 
practical method by Mallett and Veall (1965), and the analysis refined by 
Obrist (Obrist et al 1967,1975).
The technique is carried out using a closed circuit from which the 
subject breathes oxygen, and to which a small quantity of tracer, usually 133Xe 
of activity 20MBq/l, is introduced while the subject continues to breathe 
normally. After rebreathing for a few minutes, equilibrium is established and 
the concentration of 133Xe in brain is constant. The closed circuit is then 
opened and the subject breathes room air normally with the exhaled 133Xe 
collected in a suitable trap. As in the intra-arterial method of measuring rCBF, 
scintillation detectors over the head record the rate of wash-out of 133Xe from 
brain tissue. Corrections are made for scattered radiation from the lungs 
entering the field of the brain detectors, and for recirculation of isotope. The 
number of detectors positioned over each hemisphere is variable, but 
commonly 16 detectors are positioned over each side of the head, allowing 
regional information to be obtained (Obrist et al 1975; Risberg, 1980; Kanno et 
al 1981). Resolution is limited by the radiation dose given to the patient 
(which determines count rates at each detector), the amount of scatter (which 
is relatively high, as pulse height analysers cannot effectively eliminate 
Compton scatter at this energy), and the time available for imaging which is 
limited when dynamic (eg wash-out) methods are used. This is a planar or 2-
51
dimensional technique and therefore cortical perfusion values dominate the 
information obtained.
In order to overcome the major drawbacks of contamination of 
clearance curves from scalp and other extracerebral sources, Obrist et al 
(1967) proposed a three compartment analysis of the wash-out curves. 
Unfortunately, adequate separation of the the cerebral and extracerebral 
components required extended periods of recording, which was not ideal for 
some clinical studies. Later, the same group proposed a two compartment 
model in which a faster clearing component, presumed to be grey matter, is 
identified from the slower white matter and extracerebral component (Obrist et 
al 1975). Although restricted to providing measures of grey matter rCBF, the 
method has the advantage of requiring much shorter periods of data collection 
(about 10 minutes) which make it more suitable for psychiatric research.
Wyper et al (1975) have also described a ‘two-minute slope’ method which 
requires only a brief period for monitoring xenon wash-out and which can be 
used with either single channel detectors or a gamma camera. The method 
has many advantages for the study of uncooperative or restless patients and 
in experiments involving transient physiological stimulation. The intracarotid 
and inhalational methods have been compared in a study of patients 
undergoing cerebral angiography, and there was good correspondence 
between measurements of CBF from both methods (Wyper et al 1975).
Reivich et al (1975) compared the 10 minute, two compartment inhalation 
technique of Obrist et al (1975) with the intra-carotid method and found high 
correlation for grey matter regions.
2.2.3.4 Inhalational methods in AD
The inhalational method found ready acceptance in clinical research as 
no carotid arterial puncture was necessary, and quantitative measurements
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could be made simultaneously in both hemispheres and repeated later if 
necessary. Moreover, healthy subjects could now be ethically investigated as 
a control for patient groups. Despite these advantages however, 
methodological problems related to extracranial contamination and 
recirculation of isotope retarded the usefulness of the technique until improved 
analysis was developed in the mid seventies.
In a study of healthy controls and demented patients, Obrist et al (1975) 
described a new method of estimating the clearance rate and fractional blood 
flow using a 133Xe inhalational method. As explained above, a two- 
compartment model was used, in which a fast (assumed to be grey matter) 
component, was separated from a slower component, assumed to be white 
matter and extracerebral tissue. The chief advantage of the method was that 
only the first 10 minutes of xenon clearance were required for data collection, 
rather the longer periods needed with three compartment models. Using this 
approach, rCBF in frontal and parietal regions was measured in young healthy 
adults and patients with ‘organic dementia’ (sic), and although no diagnostic 
criteria are given, 14 of the group of 20 were considered to have ‘Alzheimer’s 
disease’. Little or no overlap in measures of rCBF occurred between the two 
groups, with demented patients having significantly reduced flow.
Several other studies have reported significant reductions in rCBF in 
demented patients using the xenon inhalation method (Gustafson & 
Risberg,1979; Risberg, 1980; Zemcov et al 1985). Risberg (1985) used the 
method to compare patients with different types of dementia, including a 
group of younger Alzheimer patients, mean age 64 years, and an older 
Alzheimer group, mean age 76 years, many of whom had a pathologically 
confirmed diagnosis. The pattern of flow was similar in both AD groups, with 
apparently ‘characteristic’ low flow areas in posterior temporal and parietal 
cortex. In older AD patients the impairment of flow appeared more 
widespread, but this could reflect increased severity, rather than a different
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pathological process. Yamaguchi et al (1980) has emphasised the need for 
appropriate control groups. Using rigorous diagnostic criteria for probable 
AD, they found bilateral symmetrical reductions in grey matter CBF that 
correlated with degree of atrophy measured using x-ray computed 
tomography. Although handedness was not reported, rCBF in left 
hemisphere appeared more reduced than in the right side. Unfortunately no 
regional CBF data is presented in the paper although the use of 16 
scintillation detectors per hemisphere would have made this possible. In the 
putative AD group, mental functioning was assessed in some patients using 
the WAIS, although this may not be suitable as an instrument for detection of 
cognitive impairment in dementia as it was designed for use in non-demented 
patients. In particular, WAIS scores do not necessarily reflect severity of 
individual impairments in dementia. Unfortunately WAIS scores were not 
presented in the paper, nor regional CBF-cognitive associations, but the 
authors commented that, 'severity of dementia’ correlated with bilateral CBF 
reduction. A more appropriate battery of psychological tests was used in 
conjunction with xenon inhalation in a study of well defined AD and multi­
infarct dementia MID patients matched for age, sex, and degree of impairment 
as judged from neuropsychological performance (Deutsch & Tweedy, 1987). 
Mean hemispheric CBF was reduced in the AD patient group, aged from 52- 
SI yrs, compared with MID and healthy subjects. In AD, CBF tended to be 
reduced bilaterally, in frontal, temporal and parietal areas, with the greatest 
absolute reductions in parietal regions, especially in the left side.
Unfortunately there again was no comment on association of cognitive and 
CBF measures.
A less commonly used variation of the inhalational technique is to 
administer the i 33Xe tracer by intra-venous injection (Lassen & Ingvar, 1972). 
This method may be more convenient for patients who find the inhalational 
technique uncomfortable, or who have limited cooperativity, and it can also be
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used repeatedly, even in normal subjects. Like inhalational methods, two- 
dimensional brain information is obtained that reflects mainly cortical CBF.
The method is of limited value in comparing inter-individual differences, as the 
precise input function of 133Xe to the brain cannot be determined accurately 
(Lassen, 1987).
2.2.4 First pass methods
A number of methods have been developed for examining the first pass 
of a bolus of tracer through an organ. The concept of mean transit time (MTT) 
was proposed by Stewart (1894) who pointed out that the blood flow to any 
organ could be calculated if the volume of blood within it and the mean transit 
time of a tracer through it could be measured. Formal proof of this 
relationship was later provided by Zierler (1962). The vascular mean transit 
time (MTT) is the volume of blood in the organ under investigation divided by 
the rate of blood flow through it.
MTT = BLOOD VOLUME / BLOOD FLOW
The reciprocal ratio Blood Flow / Blood Volume (ie 1/MTT) is also 
referred to as the ‘perfusion reserve’ (Gibbs et al 1984), and may give some 
indication of the extent to which cerebral perfusion is being maintained by 
reflex vasodilatation. The physical meaning of MTT for an intra-vascular 
tracer such as a red blood cell can be expressed as the mean time for that 
particle to pass from arterial to venous side of the organ. It has been argued 
that transit times longer than 10 seconds indicate impending failure of the 
normal compensatory mechanisms (Powers et al 1984).
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The first passage of radioactivity (ie, without recirculation) through a 
blood vessel can be described by a gamma-variate function of the form:
C(t) = k.(t-T)ae-(t-T)/b
where C(t) is the tracer concentration (eg in counts per minute) at time t after 
injection, T is the appearance time (ie the time at which counts are first 
detected over the region of interest) and k, a and b are constants (Merrick et al 
1991). No physiological meaning was ascribed to the parameters a and b, 
until Davenport (1983) proposed a model in which the circulation was 
considered as a series of mixing chambers where a + 1 is the number of 
mixing chambers and b the mean time to empty each chamber. Thus MTT of 
the radioactivity at any particular detection point can be estimated from,
MTT = b (a +1)
in order to measure the MTT of an intravenous bolus as it passes through the 
head and subtract from this the MTT of the bolus entering the head at, for 
example, the aortic arch. Sodium pertechnetate is a reasonably good tracer 
for this purpose as it remains intra-vascular. The practical procedures 
involved in MTT measurement are described in detail in chapter 4 in a study of 
their application to the investigation of presenile AD and Korsakoff’s patients.
First pass methods have a number of disadvantages and limitations. In 
particular the relationship of MTT to CBF is dependant upon the volume into 
which the tracer diffuses and this is discussed in chapter 4 in relation to AD 
and Korsakoff’s patients. Also any condition which tends to prolong the 
central circulation such as a right-to-left or left-to-right shunt, aortic or mitral 
stenosis or incompetence, or low output failure may prolong the first pass over 
such a long period that it cannot be distinguished from recirculation. In such
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circumstances the method is not applicable although in psychiatric practice 
these restrictions are likely to apply to only very few patients.
2.2.5 Tomographic imaging
The term tomography refers to scanning techniques that produce 
images of slices or sections through the body. In tomographic imaging, a 
series of planar projections are acquired at different points around the patient 
from which cross-sectional images are computed. Although originally 
developed using external X-ray sources (transmission computed tomography 
or CT), the principles have been applied in isotope imaging to enable 
sectional images to be constructed (emission computed tomography) and also 
to magnetic resonance signals.
The limitations of the planar scintigraphic methods of imaging 
described above, such as the xenon inhalational technique, were an important 
spur for the development of emission tomographic techniques. In emission 
tomography, cross-sectional images are reconstructed from projections, 
allowing regional CBF data to be obtained from sectional brain images.
Using tomography, better anatomical localisation of cortical regions of interest 
is possible and, for the first time, sub-cortical structures can also be studied. 
Two types of emission tomography are currently available, single photon 
emission tomography (SPECT), using isotopes that emit single photon 
radiation, and positron emission tomography (PET), using positron emitting 
isotopes.
2.2.5.1 Single photon emission computed tomography
Single photon emission computed tomography employs gamma 
emitting radioisotopes such as technetium (99mTc), iodine (123l), and 133Xe.
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The data from the administered isotope can be collected by either a single 
gamma camera or by systems using more than one detector. The realisation 
that improvements in resolution necessitate a loss of sensitivity (i.e. a further 
reduction in the fraction of the emitted gamma rays contributing the image 
process) has led to the development of SPECT systems with more than one 
gamma camera or multiple detectors around the patient’s head. The 
increasing tendency towards the introduction of multidetector systems has 
resulted in improved sensitivity. Several multidetector brain SPECT systems 
are now available. The experimental studies described in chapters 6 and 7 
were undertaken using the Strickman Medical Equipment SME 810, a 
dedicated brain system that scans one slice at a time. The SME 810 has 
twelve detectors 30 degrees apart arranged around a circle. Each detector is 
fitted with a point-focused collimator and during single slice scanning each 
detector moves in a rectiinear course. The reconstructed spatial resolution is 
of the order of 8mm. Although associated with high sensitivity a significant 
fraction of the counts of each measurement originate from slices other that the 
one being scanned and a reconstruction algorithm is necessary to deal with 
this problem. Other multi-detector brain SPECT systems include the GE/CGR 
Neurocam, in which three gamma cameras form a triangular aperture for the 
patient’s head, the Osaka/Hitachi SPECT 2000 utilising four compact gamma 
cameras rigidly fixed in a square arrangement, the Shimadzu Headtome 
SET-031 with three ring detectors, and the Picker PRISM and Triomix TRIAD 
systems each comprising three rectangular detectors arranged as a triangle.
Multidetector SPECT systems offer a substantial increase in sensitivity 
compared with a single rotating gamma camera. Collimator choice is one of 
the most important factors determining image quality. While a compromise is 
necessary between resolution and sensitivity, with multidetector systems, such 
as the SME 810, improvement in resolution can be achieved with acceptable 
loss of sensitivity.
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A number of SPECT techniques have been proposed which are 
analogous to methods of measuring rCBF in animals using injection of 
labelled microspheres. The method employs soluble tracers that can be 
injected intravenously, have almost 100% extraction during first pass, and 
remain trapped in situ long enough for their distribution to be measured 
tomographically. The underlying assumption of these methods is that the 
tracer is retained in the brain in proportion to rCBF. This technique has been 
applied in SPECT and although a number of compounds have been 
developed, two in particular have been widely used: 123l-N-isopropyl- 
amphetamine (IMP) and 99mTc-d,1 hexamethyl propyleneamine oxime 
(HMPAO) (Holman et al 1982; Nowotnik et al 1985; Blau 1985; Neirinckx et al 
1987). An important assumption of the method is that the tracer is trapped in 
tissue, but the mechanism by which this occurs is not established for either 
IMP or HMPAO.
Uptake of IMP is non-saturable and is, therefore, probably not related to 
specific receptors (Winchell et al 1980). Furthermore the rate of wash-out of 
IMP varies for different brain regions (Creutzig et al 1986). Although 
immediately after injection the distribution of IMP is largely a function of blood 
flow and closely resembles the distribution of perfusion as measured by x-ray 
xenon enhanced computed tomography (Heilman et al 1986), at later times 
redistribution of IMP may occur (Royal et al 1985) and the relationship of IMP 
uptake and blood flow is more variable. Images obtained immediately after 
injection of IMP and HMPAO are very similar (Leonard et al 1986; Podreka et 
al 1987). The use of 123l has, however, various drawbacks related to costs, 
delivery timing and dosimetry. The method is non-quantitative and the 
behaviour of IMP is not well understood, such that CBF distribution cannot 
always be imaged reliably (Kuhl et al 1982b; Lassen et al 1983; Creutzig et al
1986).
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A 99mTc-labelled flow tracer, such as HMPAO, has been sought for 
several years because the radiation characteristics of " m jc  have many 
advantages for SPECT imaging. After reconstitution with pertechnetate the 
resultant 99mTc-HMPAO complex is relatively unstable in vitro and therefore 
must be administered to the patient within 30 minutes of preparation. The 
99mTc-HMPAO complex is lipophilic and readily crosses the blood brain 
barrier. The first pass extraction of brain and fatty deposits is close to 100% 
(Ell et al 1987), but that of other tissues is lower and more variable and as a 
result there is some degree of recirculation. The cerebral distribution of 
HMPAO is principally a function of rCBF but other factors such as lipid mass 
and red cell volume may contribute. However, once the 99mTc-HMPAO 
complex has crossed the blood brain barrier, its fate is determined by 
competition between rapid conversion to a non-diffusible form and washout 
into the blood. It is thought that after entry to the cell, 99nnTc-HMPAO is rapidly 
converted to a hydrophilic form, perhaps by reacting with glutathione, and 
consequently cannot readily diffuse out through the cell membrane (Neirinckx 
et al 1988). Thus, HMPAO behaves as a chemical microsphere trapped in the 
brain. However, residue curves obtained after intra-carotid injection studies 
show that steady-state net extraction of HMPAO is reduced in high flow 
regions (Lassen et al 1988). Positron emission tomography has also shown 
that the relationship between HMPAO uptake into brain and rCBF is not 
always linear (Yonekura et al 1988). Over low and middle range CBF values, 
there is reasonable linear correspondence between uptake and flow, 
however, at high flows, HMPAO uptake tends to plateau as flow increases.
The main reason may be that as tracer wash-out is flow-dependent, there may 
be greater wash-out from brain tissue at higher flows. A linearisation 
algorithm has been suggested by Lassen et al (1988) and has been shown 
using PET to provide a better linear relationship between HMPAO uptake and 
rCBF (Inugami et al 1988; Yonekura et al 1988).
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Like SPECT using IMP, the method does not provide absolute measures of 
perfusion as the amount of active 99mTc-HMPAO available to the brain for 
extraction and local extraction efficiencies in brain are not known. 
Consequently only semi-quantitative, relative measures of perfusion are 
available by using indices such as the ratio of 99mTc-HMPAO uptake in the 
region of interest to that in cerebellum or to that in occipital region (Burns et al 
1989; Montaldi et al 1990).
2.2.5.2 Application of SPECT in AD
Kuhl first described a method for the analogue back projection 
technique, leading to the development of emission tomography for brain 
imaging (Kuhl & Edwards, 1963). The i 33Xe inhalation technique was 
modified by Lassen and colleagues (Stokely et al 1980) to enable single 
photon emission tomography of CBF to be carried out. However as xenon 
arrives and washes out in a short time interval, a specialised rapidly rotating 
detector system with high sensitivity was developed, giving a spatial resolution 
of about 1.7cm in the same plane as the image and 2.0cm axially across the 
image. This degree of resolution means that a resolution element is likely to 
contain a mixture of tissue types. Moreover, Compton scatter from other parts 
of the brain unavoidably influences the counting rate from a given resolution 
element. Thus i33Xe, a soft gamma emitter, with radiation of only 81 keV is 
not particularly well suited for SPECT imaging when resolution is important, as 
in dementia. Furthermore, the need for rapidly rotating detectors, limits the 
number of centres able to use the method. However, i33Xe inhalation 
SPECT has proved useful as a quantitative reference method against which 
other qualitative SPECT methods, such as 123lodine-isopropyl- 
iodoamphetamine, can be compared (Lassen et al 1983). Using the xenon 
SPECT method, nineteen patients with probable AD, diagnosed according to 
the NINCDS-ADRDA criteria (McKhann et al 1984), were studied by Bonte et
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al (1986). Compared with age and sex matched control subjects, AD patients 
showed reduced rCBF in bilateral temporal regions, and in some this was 
more marked on the left side. In more severely affected patients, left frontal, 
and bilateral parietal and occipital reductions in flow were also detected.
In order to overcome the problems discussed above with xenon 
SPECT, radioligands such as the lipophilic amine, i 23lodine-isopropyl- 
iodoamphetamine (IMP), were developed. As explained above, IMP behaves 
as a ‘chemical microsphere’, with high first pass extraction by brain (about 
90%) and slow wash-out, resulting in an initial distribution that correlates well 
with rCBF distribution (Holman et al 1982). One particular advantage of IMP, 
compared to the inhalational methods described above, is its ease of 
administration as a single intravenous injection. The utility of IMP for SPECT 
in dementia was assessed in a small study of five patients with probable AD 
(pAD) and diffuse symmetrical reductions in relative 123I-IMP uptake, 
particularly in parieto-occipital areas, were demonstrated (Cohen et al 1986). 
In a larger study in Aberdeen (Sharp et al 1986a) that included fourteen senile 
patients with pAD, SPECT scanning was used to determine relative 123I-IMP 
uptake in ten symmetrical regions. In all the pAD patients there was bilateral 
reduction of uptake in temporo-parieto-occipital regions and in many patients 
posterior frontal flow deficits were also detected. Interestingly, in 64% of the 
pAD group, magnetic resonance imaging (MRI) was normal in posterior 
regions, suggesting that SPECT provides different information from MRI.
Using the McKhann et al (1984) standardised diagnostic criteria, fifteen 
patients with pAD were compared with a group of nine, age matched controls 
using 123I-IMP and a rotating gamma camera SPECT system (Johnson et al 
1987). The patient group consisted of mixed presenile and senile pAD types 
with onset of illness after 65 years in eight patients, and before 65 years in the 
remainder. Marked reductions in cortical / cerebellum ratios of tracer uptake 
occurred in all cortical areas of the AD group compared with controls, but were
62
most marked (20-30% decrease) in posterior parietal, posterior temporal and 
frontal areas. Overall, no asymmetries were detected, but marked side to side 
differences did occur in individual cases. In a different study (Jagust et al
1987), nine patients with pAD were compared with five non-matched control 
subjects using 123I-IMP SPECT, including neuropsychological testing. In all 
pAD patients there was marked reduction in relative IMP uptake in bilateral 
temporo-parietal cortex and this was significantly associated with severity of 
dementia, as measured by Mini-Mental State Examination score. Rather 
ambitiously, on the basis of this study, Jagust et al (1987) concluded that the 
IMP SPECT method was able to distinguish AD from control subjects, even in 
very early stages of the disease. The authors also emphasised the 
importance of impaired temporo-parietal rCBF and speculated about its 
significance in the pathogenesis of AD, and possible utility for staging the 
progression of the disease.
Experience with 123l-labelled amines, and in particular IMP, showed 
that microsphere analogue techniques for SPECT imaging of rCBF in humans 
had many advantages. It was recognised, however, that both 123l and IMP 
have a number of features that limit their usefulness for SPECT. Iodine-123 is 
a cyclotron-produced radionuclide, with a short half-life of thirteen hours and 
as a result, is not readily available, is expensive, and deliveries must be 
carefully timed to coincide with imaging. As described above in section 
2.2.5.1, the behaviour of IMP is poorly understood and is not consistently 
reliable for imaging CBF distribution. On the other hand, a microsphere 
analogue flow marker, based on technetium (99mTc), has several advantages 
that it make it more suitable for SPECT.
Technetium has better imaging and dosimetry characteristics than 123l, 
and, as it is routinely used for isotopic imaging, it is widely available at low 
cost. Therefore the development in 1986 of a hexamethyl derivative of 
propylene amine oxime (HMPAO), that readily complexed with " mTc,
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facilitated the use of SPECT for investigation of rCBF distribution (Neirinckx et 
al 1987). There is high correlation between relative rCBF, measured using 
" mTc-HMPAO SPECT, and corresponding absolute rCBF values, measured 
with 133Xe inhalation, in both normal subjects and pAD patients (Andersen et 
al 1988b). Furthermore, in dementia and other neuropsychiatric disorders, 
"m jc-HMPAO SPECT has an advantage in that the tracer is administered 
intravenously and has a distribution in brain that is relatively stable, thus 
allowing sufficient time for imaging and patient cooperation.
In a qualitative study using " mTc-HMPAO, Neary et al (1987) 
examined 21 patients with presumed AD and 9 others with ‘frontal lobe 
dementia’, which the authors believe may be distinct from AD. The 
tomograms were evaluated by inspection, and classified according to whether 
they had anterior or posterior areas of reduced uptake. In the pAD group, 
33% had a posterior deficit, a similar percentage a mixed anterior and 
posterior deficit, and the remainder had either reduced anterior uptake or no 
detectable abnormality. In two thirds of the pAD patients, visuo-spatial 
impairment was associated with reduced posterior flow. In patients classified 
as having ‘frontal dementia’ on the basis of clinical features, 80% had, not 
unexpectedly, reduced frontal flow. In a comparable qualitative study of 17 
pAD patients, and 10 MID patients, Gemmell et al (1987) used 99mTc-HMPAO 
SPECT to investigate whether groups could be distinguished by pattern of 
uptake. Tomograms were divided into ten regions and their degree of 
abnormality scored from one to three. All patients also had magnetic 
resonance imaging, and no focal abnormalities were detected in the pAD 
patients. Reduced HMPAO uptake was more common in the AD group than 
the MID group, especially in bilateral temporo-parieto-occipital regions. In 
both studies it was suggested that inspection of SPECT images may permit 
better diagnosis of dementia type and that pAD patients tended to have 
bilateral posterior deficits. Reduced flow in bilateral temporal and posterior
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parietal regions was also found in older pAD patients with aphasia and 
apraxia, and associations found between memory loss and temporal lobe 
activity, and between language and left sided tracer uptake (Burns et al 1989). 
In another SPECT study of 26 older pAD patients, there was reduced rCBF in 
cortical regions, particularly in bilateral posterior temporal, but also in left 
temporal, left parietal and bilateral frontal regions, with relative sparing of 
occipital regions (Montaldi et al 1990). Numerous associations between 
cognitive performance and rCBF were found, which may reflect the severity of 
patient group or the non-specificity of the cognitive battery. The fact that no 
associations between memory and rCBF were detected is not surprising, in 
view of the pronounced floor effects that occur in pAD with most simple tests of 
memory. The correspondence between neuropsychological deficits and 
SPECT in AD, was investigated by Goldenberg et al (1989), and the results 
interpreted in terms of two dimensions of organisation, along which rCBF 
measures and cognitive test scores co-varied in a systematic fashion. The 
first dimension was said to correspond to the fronto-temporo-parietal axis, with 
naming, constructional praxis and visual recognition memory associated with 
parieto-temporal regions, and semantic memory and behaviour more 
associated with frontal areas. In a second left-right axis of organisation, the 
ordering of test results was partly consistent with what is known about the 
lateralization of neuropsychological deficits from studies of localised lesions.
2.2.6 Positron emission tomography
Positron emission tomography is the most sophisticated technique for 
the study of brain function. Any review of functional brain imaging in 
dementia would be incomplete without at least some discussion of the 
principles of PET and the results obtained from its use. In PET, positron 
emitting isotopes are used to construct 3-dimensional functional brain images. 
Positrons are p-particles which carry a positive rather than a negative charge,
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and which, on collision with an electron, emit a pair of y-ray photons at 
approximately 180 degrees (a ‘coincidence-pair’ ), each of 511KeV energy. 
These photons can be detected by positioning a pair of detectors on either 
side of the patient and selectively only detecting those y-rays which are 
simultaneously counted by both detectors. Such simultaneous detection 
allows the anatomical origin of the positron to be determined and thus 
eliminates the need for the lead grid collimators which are required with all 
SPECT instruments, and which reduce sensitivity by 1-2 orders of magnitude. 
Unlike the microsphere analogue tracers used in SPECT (eg HMPAO), true 
quantification is also possible using PET. However, PET cameras have the 
disadvantage that many accidental coincidences cannot be eliminated, and 
consequently PET images contain considerable background noise which 
reduces the accuracy of measurements.
The use of a labelled ligand to measure a physiological process 
depends on an understanding of the fate of the injected molecule and a 
description of the whole process in mathematical terms. The versatility of PET 
is shown by the wide range of variables that have been measured in humans 
including local tissue perfusion, blood volume, glucose and oxygen 
consumption, as well as the fractional extraction of various metabolites which 
have been accurately imaged quantitatively (Phelps et al 1986; Frackowiak
1988). Positron emitting forms of the ‘physiological’ elements carbon (11C), 
oxygen (150), and nitrogen (13N) can be substituted for the same stable 
elements in molecules to be studied, thus avoiding the conformational 
alterations of normal metabolites that can result when other isotopes, such as 
i23l, are used to label molecules. As the brain uses oxygen and glucose 
almost exclusively as the substrates for metabolic energy, PET measurements 
of oxygen and glucose consumption accurately reflect neuronal metabolism. 
Apart from metabolic and transmitter studies, PET can be used to measure
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tissue concentrations of any labelled substance or drug and its rate of change 
with time (Baron et al 1983).
The short half-life of PET radioligands requires considerable on-site 
technical expertise including a cyclotron for their manufacture. For example, 
the half-life of 150  is 2.1 minutes and that of 11C, 20 minutes, therefore the 
newly generated isotopes have to be used quickly. Fluorine-18 (18F) has 
been used in many PET studies and can be readily incorporated into small 
molecules (eg as 18F-fluorodeoxyglucose) behaving as a proton and therefore 
it can be used as a hydrogen substitute. Furthermore, it has a comparatively 
longer half-life of 110 minutes, making it potentially transportable from site of 
production to PET facility. After generation in a cyclotron, the radioisotopes 
are incorporated into the pharmaceutical or ligand and only then is the 
resulting radio-pharmaceutical administered to the subject. Thus, it is 
necessary to have a skilled chemistry laboratory on site in order that the short 
half-life PET isotopes can be quickly incorporated into the ligand of interest.
2.2.6.1 PET measurements of CBFf CMROaand CMRglc
There are several ways in which PET has been used to measure 
cerebral blood flow. The inert gas wash-out method, described earlier, can 
be used with several positron emitters including 77Kr, n c , 18F (eg Yamamoto 
et al 1980). The method was further developed using continuous inhalation 
by Jones et al (1976), in which the patient inhales air containing carbon 
dioxide (CO2) labelled with 150. In the lungs, C1502 is rapidly converted by 
carbonic anhydrase to carbonic acid and H2150. Thus 150-Iabelled water, 
assumed to be freely diffusible between blood and brain, is used as the tracer. 
After about 7 minutes, (or about three half-lives of 150), a steady state is 
established with the rate of arrival of labelled water in brain equal to the rate of 
loss by wash-out and radioactive decay. Thereafter the concentration and 
distribution of radioactivity in the brain remains constant for imaging. Thus, if
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in the steady-state the arterial (delivery) concentration and tissue 
concentration can be measured, CBF can be calculated from the following 
equation (Frackowiak et al 1980), where perfusion (P) is given by,
P = ____________ K____________
[(H 20)a /(H 20 )b] - 1
and K is the radioactive decay constant for oxygen, (H20)a the arterial 
concentration of H2 150  in an arterial blood sample and (H2 0 )b the 
concentration of H2150  in brain as measured by PET. There is a reasonably 
good correlation between CBF measured using this technique and that 
obtained with intra-arterial microspheres in baboons for perfusion in the range 
10-100ml/100mg/min (Steinling et al 1985). The method is more accurate for 
measuring low or normal flow (eg patients with dementia, Frackowiak et al 
1981) but may be misleading in situations where flow is greater than 
100ml/100mg/min. However, such situations are quite unusual eg ictal 
epilepsy or encephalitis and the errors involved may not be crucial. If the 
subject is made to breath labelled molecular oxygen (150 2 ), 150-Iabelled 
oxyhaemoglobin is synthesized in lung and, after arterial distribution, 150  is 
available for tissue oxidative metabolism. This results in the tissue synthesis 
of H2150, which can be measured, and the oxygen extraction ratio (OER) can 
be calculated. After corrections are made for blood volume and the 
recirculating H2150  component, the product of CBF, OER and stable arterial 
oxygen content is the CMRO2, the rate of oxygen utilization by the brain.
Thus, one label (150), and essentially one tracer (H2150), though generated 
in two ways, can be used to measure three variables, CBF, OER, and CMRO2 .
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The advantages of this method are that it is conceptually and mathematical 
simple and highly reproducible in practice.
A second and entirely different strategy is used to measure cerebral 
glucose consumption (CMRglc). This is an extension of the techniques 
originally developed for use with autoradiographic measurements in animals. 
When glucose is taken up into brain and enters the glycolytic pathway at 
hexokinase, the vast majority passes into the Kreb’s cycle for production of 
ATP. The product of this pathway is CO2 which is rapidly cleared from tissue. 
This explains why 11C-labelled glucose is difficult to use.
An alternative approach is to use an analogue of glucose to study 
glycolytic flux. Deoxyglucose (DG) can be used as a glucose analogue as it 
uses the same blood brain barrier uptake system and acts as a substrate for 
hexokinase. The product of this reaction is deoxyglucose 6-phosphate which 
cannot be metabolised further and is therefore trapped in the cerebral tissues. 
Thus measurement of DG consumption can be used as a measure of CMRglc. 
The relationship between DG handling and glucose metabolism is termed the 
lumped constant because it incorporates terms relating the different rates of 
transport and phosphorylation of the analogue and glucose. The technique is 
practical and straightforward and, because 18F can be used to label DG, it has 
been widely used.
2.2.6.2 The effect of aging measured by PET
Positron emission tomography (PET), is probably the most elegant 
technique for imaging in vivo brain function. Although several PET studies 
have confirmed that rCBF, rCMRglc and rCMR02 are reduced in cortical brain 
regions in AD compared with age-matched healthy controls, there have been 
conflicting results regarding the effects of age on normal cerebral metabolism. 
Kuhl et al (1982a) studied 17 men and 23 women between the ages of 18 and 
78 years and found a small but significant decrease in regional glucose
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consumption with age. However Duara et al (1984) repeated the study in a 
more detailed way in 40 healthy men aged from 21 to 83 years, and the mean 
cerebral metabolic rate did not change significantly with increasing age, 
although there was a minor trend towards lower values in older men. Several 
smaller studies also failed to demonstrate significant changes in brain glucose 
metabolism with advancing age. For example de Leon et al (1983a), used the 
tracer 18F-2-deoxy-2-fluoro-D-glucose (18F-FDG) with PET to compare 
glucose metabolism in 15 young and 22 elderly normal subjects. No 
significant differences in CMRglc were detected between the two groups.
There have been fewer studies of rCMR02 in humans that addressed 
this question. Frackowiak et al (1980), using continuous inhalation of 150- 
labelled CO2 and O2, showed a decrease in rCBF and rCMR02 with 
increasing age in grey but not white matter in normal volunteers aged from 26 
to 74 years. Lebrun-Grandie et al (1983) confirmed this finding with a similar 
technique in three regions of cortex in a group of 19 normal subjects.
However Frackowiak et al (1983) subsequently reanalysed their PET data and 
concluded that CBF, but not CMRO2 was age related, due to increases in the 
oxygen extraction ratio.
it is difficult to reconcile these findings, especially in view of the 
apparent coupling of CBF, CMRO2 and CMRglc in resting subjects. Some of 
the observed differences are probably due to variations in methodology eg in 
Kuhl et al (1982a) subjects were examined with eyes open, while Duara et al 
(1984) examined subjects with eyes closed and ears plugged in conditions of 
minimal sensory input. As it is likely that any age-related effect is probably 
small, the standardization of experimental conditions is essential before 
studies can be meaningfully compared. Furthermore the putative age-related 
changes in brain function may only become apparent if subjects are examined 
under conditions of activation, rather than in the ‘resting state’. In reviewing 
the contribution of PET to the study of the effect of age on normal brain
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metabolism, Dastur (1985) concludes that most evidence suggests that CBF 
and metabolism are not changed, except for a small but significant decrease 
in glucose utilization.
If age-related changes in CBF and metabolism are important, there is clearly a 
need for careful age-matching of control subjects and patients.
2.2.6.3 Glucose and oxygen metabolism in AD
Several studies have confirmed that rCMRglc is reduced in cortical 
areas in senile dementia, compared with age-matched controls. Ferris et al 
(1980) were the first to report preliminary PET findings in 7 patients with senile 
AD and 3 normal controls. These authors found significantly reduced 
rCMRglc in bilateral frontal and temporal cortex and in bilateral caudate and 
thalamus, but reported the results cautiously because of concerns about the 
poor resolution of the PET imager. Later, studies with larger series of patients 
and better instrumentation confirmed this general finding (Farkas et al 1982; 
Foster et al 1983; Friedland et al 1983; and Cutler et al 1984). Measurements 
of rCMR02 and rCBF in dementia were also consistent with these reductions 
in glucose metabolism (Frackowiak et al 1981).
As the quality of imaging investigation improved, a number of focal 
patterns of regional metabolism in AD were demonstrated, rather than the 
generalised reductions noted in earlier studies. Reductions in rCMRglc 
appeared to be smaller in perirolandic and occipital areas than in association 
cortices (Benson et al 1983; Haxby et al 1985), while temporo-parietal 
association areas showed the greatest reductions in mild to moderate AD, with 
comparatively less reduction in frontal metabolism (Frackowiak et al 1981; 
Foster et al 1983; Friedland et al 1983). In severe AD however, marked 
involvement of bilateral frontal cortex was also observed (Frackowiak et al 
1981; Benson et al 1983; Duara et al 1986). It is likely that as Alzheimer’s 
disease progresses, other brain regions become involved, and therefore the
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pattern of metabolic impairment observed is closely related to the disease 
stage. As might be expected, patients with mild or early dementia have 
metabolic rates that overlap with those of controls, but as severity increases 
there is clear distinction from healthy controls (Duara et al 1986). One 
common pattern of progression appears to be initial involvement of temporo­
parietal regions, with subsequent involvement of frontal regions (Friedland et 
al 1983; Kuhl et al 1985; Benson, 1988). However, atrophy of frontal and 
temporal lobes is often a distinctive macroscopic feature of AD pathology 
(Tomlinson & Corsellis, 1984), and frontal decrements in metabolism and CBF 
have been found in AD patients of all grades of severity (Duara et al 1986).
Studies of the relation of cerebral metabolic rates to severity of 
dementia in AD have yielded less consistent results. Earlier studies, found 
that rCMR0 2  was lower in more severely demented patients than in 
moderately demented patients (Frackowiak et al 1981), and Ferris et al (1983) 
found significant correlations between rCMRglc and measures of global 
impairment and memory. On the other hand, in a report by Foster et al (1983) 
there was no relation between rCMRglc and global severity, but in 13 AD 
patients there was a postive association with reaction time. In an increased 
sample, Foster et al (1984) found that rCMRglc values in mild and severe AD 
were not significantly different from each other. One reason for such 
inconsistencies may be the large variation in normal values of rCMRglc in 
healthy adults. Thus, any relation between severity and glucose metabolism 
may be masked by the variation in premorbid levels of rCMRglc. In order to 
reduce variance that is not disease related, indices of rCMRglc pattern, such 
as the ratio of, or difference between, regional values and whole brain 
rCMRglc, have been used. Only when this analysis was used to compare 
matched AD and healthy controls, were differences in rCMRglc between 
groups detected (Haxby et al 1985).
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Cerebral atrophy complicates the interpretation of PET (and SPECT) 
images in two respects. Firstly, the measuring instruments suffer from partial 
volume effects, that is their spatial resolution is inadequate to resolve cortical 
structures. Thus measurements from cortical regions will include data from 
cortex, white matter and cerebrospinal fluid spaces. In addition, 
interpretational problems also result from the significant cell loss in AD. For 
example in advanced cases there may as much as 46% neuronal loss in 
temporal, and 40% loss in frontal cortex (Terry et al 1981) leading to 
uncertainty about whether estimates of reduced CBF or metabolism reflect 
neuronal cell death, reduced functional activity of preserved tissue, or, as 
seems likely, some combination of both. The spatial resolution of PET, 
typically of the order of 1 cm, may be at the limit of some anatomical 
examination. Functional imaging of medial temporal structures such as 
hippocampus that are usually, perhaps always, involved in AD (section 1.6) 
may potentially help in early AD case detection.
Initial studies of inter-regional metabolic differences suggested that 
antero-posterior changes were more prominent than left-right hemispheric 
differences. Friedland et al (1983), for example, reported that frontal to 
temporo-parietal ratios of CMRglc were greater than right to left ratios in 10 
patients with mild to moderate pAD reflecting reduced CMRglc in temporo­
parietal regions. However in this study, right to left frontal ratios were strongly 
correlated with severity of dementia and verbal IQ, and right to left temporo­
parietal ratios with performance IQ. Increased right-left asymmetry of rCMRglc 
has been found in mild to severe AD cases (Foster et al 1983; Friedland et al 
1985; Haxby et al 1985; Duara et al 1986), but with no characteristic direction 
to the asymmetry, ie in some patients there were greater reductions in left 
rather than right side, but other patients showed the opposite pattern. In mild 
to moderately severe AD, measurements of rCMRglc in frontal, temporal and 
parietal association cortices were significantly more laterally asymmetrical
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than healthy controls (Haxby et al 1985). Furthermore in this study, lateral 
asymmetry of rCMRglc in AD correlated with impaired language and visuo- 
spatial function, in that greater impairment of left sided rCMRglc was 
associated with relatively greater impairment of language, and right-sided 
rCMRglc impairments with increased visuo-spatial dysfunction. In a study of 
12 AD patients, of whom 4 could be classed as severe, Duara et al (1986) 
concluded that right to left asymmetry occurs early in the course of AD, and 
becomes more prominent as the disease progresses. It has also been 
suggested that metabolic and neuropsychological asymmetries persist at least 
until the disease becomes very severe (Grady et al 1986).
The nature of the association between mental function and regional 
metabolism in AD has been addressed in a number of studies. In mild and 
moderate cases of probable AD, metabolism in specific brain regions has 
been correlated with some cognitive measures (Foster et al 1983; Haxby et al 
1985; Riege et al 1985). Not all studies however used homogeneous patient 
populations, or adjusted significance levels to take account of multiple 
correlations. With absolute measures of rCMRglc correlations were not 
always detected (Cutler et al 1984), and patterns of association have been 
more often detected between regional CMRglc corrected for whole brain 
CMRglc or left-right asymmetry, and specific cognitive deficits (Riege et al 
1985). Foster et al (1983,1986) and Chase et al (1987) studied clinically 
diagnosed pAD patients who were selected as having disproportionate 
language or visuoconstructive impairments. Those with disproportionate 
language deficits tended to have relatively lower left hemisphere rCMRglc, 
whereas patients with predominantly visuospatial deficits had relatively lower 
right hemisphere metabolism. Furthermore, language performance 
correlated highly with left perisylvian rCMRglc, and performance with 
visuospatial consructional tests correlated with posterior parietal rCMRglc. 
However, as patients were preselected for the presence of particular
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neuropsychological deficits, the generality of the conclusions may be 
uncertain.
All the PET studies reviewed above were carried out under basal or 
‘resting conditions’ and at a different time from assessment of 
neuropsychological function. The criticism could be made that brain energy 
demands during ‘resting’ conditions might not be expected to be closely 
correlated with mental task performance. It could be argued that more 
meaningful relationships might exist between task performance and brain 
metabolism during the task. There are practical difficulties in undertaking 
such studies but investigation of how brain metabolism changes during 
psychological activation will be an important direction for this work in future 
studies.
2.3 Conclusions from literature review on functional imaging in 
Alzheimer’s disease
In summary, the literature reviewed above illustrates the following:
1. A close relationship exists between CBF and metabolism, during both 
‘basal’ and activated conditions of brain function. This is important support for 
the use of CBF as an index of brain function in the study of AD.
2. Since the introduction of techniques for the measurement of CBF in the 
1940s, sophistication has improved from the early estimates of global CBF 
provided by the Kety-Schmidt method to the tomographic regional values of 
CBF and metabolism available from PET.
3. Early studies demonstrated reductions in global CBF that were significantly 
correlated with cognitive impairment. Later, these findings were confirmed by 
intra-arterial techniques that permitted different cortical regions in one 
hemisphere to be studied. These studies indicated hypoperfusion of temporal 
regions in AD, with more widespread cortical perfusion deficits as severity 
increases.
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4. The introduction in the 1960s of the more acceptable inhalational methods 
of measuring CBF enabled quantitative regional measurements to be made 
on both hemispheres, and suggested that impaired cortical perfusion in AD is 
often bilateral.
5. The advantage of tomographic imaging methods, such as SPECT and 
PET, is that they allow subcortical and cortical regions to be studied and 
patterns of functional deficit to be identified. Severity of dementia appears to 
be a major determinant of severity of metabolic impairment and pattern of 
reduced cerebral function. Several patterns of functional deficit have been 
recognised using PET and SPECT, suggesting that AD may be more 
heterogeneous than indicated by the early techniques. Although many, and 
perhaps most, patients with AD show characteristic metabolic reductions in 
temporo-parietal regions, other patients show marked frontal deficits, and 
often not necessarily as a concomitant of severe dementia.
6. As with earlier two-dimensional measurements of CBF, there are often 
difficulties in the interpretation of SPECT and PET data in patients with 
significant cortical atrophy. This is mainly the result of partial volume effects 
due to limited resolution and consequent uncertainty about whether reduced 
CBF or metabolism results from reduced function or reduced tissue mass.
7. Although PET provides estimates of several metabolic parameters in 
addition to CBF, there are some advantages associated with SPECT.
These include readily available radiopharmaceuticals, low cost isotopes, 
comparatively lower cost SPECT imagers, and limited technical support 
required. These factors suggest that SPECT imaging may be performed on 
large numbers of patients at reasonable cost. Moreover moderate resolution 
SPECT is potentially available to many researchers and clinicians.
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CHAPTER 3 
GENERAL METHODS
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3.1 Introduction
This chapter describes the main methods used in the experimental 
sections. Two control groups were studied for comparison with AD patients: 
matched healthy control subjects and patients with chronic Korsakoff’s 
syndrome. There are several reasons why the study of patients with 
Korsakoff’s syndrome is appropriate and relevant to an investigation of AD. 
Firstly in Korsakoff’s syndrome memory impairment over-shadows other 
aspects of cognitive failure, in contrast to AD where, although dysmnesia may 
be an initial feature, other cognitive deficits are usually also prominent. This 
provides an important opportunity to examine the changes in brain function 
associated with the two different patterns of cognitive impairment. Secondly, 
while in AD it is not disputed that cortical pathology makes a significant 
contribution to the pattern of cognitive deficit, in Korsakoff’s syndrome the main 
lesions have traditionally been considered to be subcortical, and attention at 
autopsy focussed on basal brain regions. This has continued despite 
accumulating neuropathological and encephalographic evidence that 
prolonged alcohol abuse can result in diffuse brain damage (Ron, 1977).
Thus the inclusion in the study of a control group with chronic cognitive 
impairment, possibly attributable to subcortical pathology, was an appealing 
idea. More important, however, was the opportunity to investigate the 
functional integrity of cortical regions in Korsakoff patients who had abstained 
from alcohol for some time in order to assess the contribution of cortical 
dysfunction to the syndrome. Finally, there is another reason for interest here 
in Korsakoff syndrome. In a detailed comparison of the memory problems of 
AD and Korsakoff’s syndrome, Kopelman (1985) concluded that they have 
many deficits in common, with particular difficulty in getting information into 
long-term storage. There is evidence that damage to a number of 
neurotransmitter systems, including cholinergic and noradrenergic, are 
implicated in both disorders (Hardy et al 1985; Kopelman & Corn, 1988;
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McEntee et al 1984). In many ways Korsakoff’s syndrome may prove to be a 
useful ‘model’ system in which to study the way in which neurotransmitter 
failure produces cognitive failure.
Studies of isotope imaging necessarily involve exposure to ionising 
radiation. In general, different patient and control groups were recruited for 
the studies described in chapters 4, 5 and 6, in order to limit the exposure of 
patients and control subjects to radiation. No control subject was imaged 
more than once, as it was considered unethical to expose them to this amount 
of additional radiation. Imaging facilities for measuring MTT were located at 
the Western General Hospital, Edinburgh, and for SPECT at the Institute of 
Neurological Sciences, Glasgow. Patients were transported to the two sites 
using a comfortable car, in the company of the investigator (RH), and often the 
patient’s relative. At both sites patients were given time to relax after the 
journey, before the experimental session.
3.2 Patient selection
3.2.1 Alzheimer’s dementia
Patients with AD were recruited for the studies described in this thesis 
from clinical referrals to the MRC Brain Metabolism Unit of patients thought to 
have pre-senile dementia. In the main, referrals were from consultant 
colleagues in neurology and psychiatry in Lothian, although a few patients 
were referred to the Unit directly by their general practitioner. From such 
referrals only those patients meeting recently agreed criteria for probable 
Alzheimer's disease, as laid down by National Institute of Neurological and 
Communicative Disorders Stroke (NINCDS ) and Alzheimer's Disease and 
Related Disorders Association ( ADRDA) (McKhann et al 1984), were recruited 
for study. The cardinal features of these criteria, which were satisfied for all 
AD patients studied, include:
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a) onset of symptoms before the age of 65 years of age, with dysmnesia as 
the initial presenting feature.
b) clinical course characterised by steadily progressing dementia.
c) absence of a history suggestive of an another type of dementia.
d) absence of focal neurological signs.
e) no evidence of hypertension or other cardio-vascular abnormalities and 
normal electrocardiogram.
f) X-ray computed tomography (CT) scan normal or showing only 
generalised cortical atrophy and no additional pathology.
g) no focal abnormalities on the electroencephalogram (EEG).
h) all patients had a comprehensive range of blood investigations, including 
full blood count, erythrocyte sedimentation rate, urea, creatinine and 
electrolytes, liver function tests, thyroid function tests, serum vitamin B12 
and folic acid, and VDRL (Venereal Disease Research Laboratory) and 
TPA (Treponema Pallidum Agglutination test).
i) all patients had lumbar puncture performed as part of their diagnostic 
assessment and were not included in the study unless cerebrospinal fluid 
(CSF) investigations were within normal limits.
These criteria form part of the Cambridge Diagnostic Examination for 
the Elderly (CAMDEX), developed by Roth et al (1986), which was completed 
for all patients studied and was used to exclude other psychiatric disorders, 
such as alcohol abuse or major depressive disorder, or physical illness such 
as malignancy, diabetes or other major systemic illness, and hence improve 
the quality of the probable diagnosis of AD.
Figure 3.1 The CAMDEX schedule
Section A Structured psychiatric interview.
Information about present mental and physical state, in 
particular symptoms suggestive of organic psychoses, 
depression and functional paranoid psychoses. Past medical 
and family history.
Section B CAMCOG - the cognitive examination.
Section C Interviewer’s observations.
Observations of present mental state, including 
appearance, behaviour, mood, speech, mental slowing, 
thought processes and level of consciousness.
Section D Physical examination.
Section E Results of laboratory and radiological investigations.
Section F Current medication.
Section G Additional information.
Section H Structured interview with informant.
Incorporates items on personality change, difficulties in 
everyday functioning, signs of impaired cognition, evidence of 
depressive or paranoid phenomenology. Corroboration and 
elaboration of past medical and family history.
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3.2.2 Alcoholic Korsakoff syndrome
Patients with alcoholic Korsakoff Syndrome (KOR) were recruited from 
the long-stay wards or nursing-supervised hostel accommodation of the Royal 
Edinburgh Hospital, and in a few cases from other psychiatric hospitals in 
Lothian. All met DSM-III-R (Diagnostic and Statistical Manual, third edition, 
revised) criteria for Korsakoff syndrome. The chief criteria used to select 
Korsakoff patients were as follows:
a) Definite history of prolonged alcohol abuse, usually in excess of 20 years.
b) Severe anterograde memory deficit, out of all proportion to other 
disturbances of intellect and behaviour.
c) No history of progressive dementia.
d) Definite history of past episodes of either acute confusion or Wernicke's 
encephalopathy (with or without peripheral neuropathy).
e) No documented history of ‘significant’ head injury.
f) EEG normal or showing no focal activity.
g) Normal haemotological and biochemical tests as outlined in 3.2.1(h) 
above.
h) No alcoholic beverage taken for at least 6 months.
Recruitment of KOR patients according to the above criteria presented 
several difficulties. Firstly, patients with a ‘case notes’ diagnosis of 
‘Korsakoff's psychosis, alcoholic’ based on the International Classification of 
Diseases, Ninth Revision (ICD-9, World Health Organisation, 1978), did not 
always satisfy the above operational criteria, and were therefore not included 
in the studies. One reason for this is that the diagnostic label ‘Korsakoff’s 
psychosis', (ICD-9 category 291.1) has tended in the past to be applied rather 
widely by some clinicians to incorrectly include any patient with a history of 
prolonged heavy alcohol intake and signs of dementia. Many patients 
labelled as ‘alcoholic dements’ (ICD-9 category 291.2) are in fact suffering 
from Korsakoff’s psychosis, while others may be merely displaying the
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profound social and mental disorganisation due to continued heavy drinking, 
or have coincidental Alzheimer’s disease or multi-infarct dementia. However, 
there is evidence that prolonged ingestion of alcohol can give rise to varying 
degrees of cognitive impairment and, in some patients, dementia 
characterised by progressive memory failure and deterioration of personality 
and intellect (Wilkinson et al 1971). Another difficulty for researchers trying to 
define a homogeneous group of KOR patients is that many patients who have 
a long history of alcohol abuse have also sustained head injuries which could 
also contribute to organic brain damage. Establishing whether or not a 
patient has such a history is often very difficult but attempts were made to 
discover a history of head trauma using case notes, informants and by 
interviewing the patient. No patient with a documented history of significant 
head injury was included in the KOR group studied.
3.2.3 Healthy control subjects
Healthy control subjects were recruited from local voluntary 
organisations in Edinburgh including the Hospital League of Friends and the 
Womens Royal Voluntary Service, and in some cases the patient’s spouse 
also volunteered. All volunteers were carefully interviewed and examined to 
exclude physical or psychiatric illness. The CAMDEX schedule was also 
used to detect past or present mental or physical disorder in controls.
Although this use of CAMDEX can be questioned, the chief aim was to ensure 
that significant illness was not present in subjects recruited for the control 
group. For this limited purpose, CAMDEX formed the basis of a reasonable 
screening instrument. All subjects had blood taken for full blood count, 
erythrocyte sedimentation rate, urea, creatinine and electrolytes, liver function 
tests, thyroid function tests, serum vitamin B12 and folic acid, and VDRL 
(Venereal Disease Research Laboratory) and TPA (Treponema Pallidum
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Agglutination test), and were only included in the study if values were within 
normal laboratory limits.
3.2.4 Handedness
Handedness may affect the regional localisation of function in brain and 
hence rCBF. In order to control for the possible confounding effect of 
handedness, only patients and control subjects who fulfilled criteria for right- 
handedness were included in the studies. The Edinburgh Inventory for 
determining handedness was used (Oldfield, 1971).
3.2.5 Age and sex
As discussed in chapter 2 there appears to be a small, but significant 
reduction in glucose metabolism and probably CBF with aging (eg see Cutler 
et al 1984). Similarly, it is likely that sex may also affect rCBF. Little is known 
about the magnitude of such effects but in order to reduce possible 
confounding age or sex effects, attempts were made to match healthy control 
subjects for age and sex with AD patients. Efforts to do the same for the 
Korsakoff group were less successful, mainly because Korsakoff’s psychosis 
is not a common condition, and most sufferers are male with a greater age 
range than for AD. Recruiting healthy males of late middle age to act as 
controls proved more difficult than recruiting healthy females. Hence the 
matching of controls to AD patients was more satisfactory than the matching to 
KOR patients.
3.2.6 Concomitant medication
None of the patients or control subjects had taken psychotropic 
medication for at least six months before the study. As all AD patients lived at 
home under the care of their spouse, and all KOR patients lived in supervised
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hospital accomodation, it was possible to be reasonably sure that no 
unreported medication was taken during the study.
3.3 Consent
Patients and control subjects gave informed consent to take part in the 
studies and where there was doubt about a patient's understanding of what 
was entailed, the agreement of a close relative, or independent nurse, who 
could act as an advocate for the patient, was consulted before the patient was 
included. The studies were all approved by the Ethics of Medical Research 
Sub-Committee for Psychiatry and Psychology of the Lothian Health Board 
and in the case of the SPECT project, consent was also obtained from the 
Ethics of Medical Research Committee of the Institute of Neurological 
Sciences, Southern General Hospital, Glasgow. The use of sodium 
pertechnetate and " mTc-hexarnethyl propyleneamine oxime (99mTc-HMPAO) 
was approved by the Administration of Radioactive Substances Advisory 
Committee (ARSAC) of the Department of Health.
3.4 Neuropsychological assessment
The CAMDEX was developed for the diagnosis and measurement of 
dementia (Roth et al 1986) and was completed for all patients in the study.
The interval between cognitive assessment and imaging was never more than 
one week. The CAMDEX provides a useful instrument for assembling 
information on patients suspected of having a dementing illness and contains 
the following sections: 1) a structured psychiatric interview with the 
respondent, incorporating questions regarding the present mental disorder, 
the past history and family history; 2) the objective evaluation of a broad 
range of neuropsychological functions; 3) a standardised schedule for 
recording observations of the present mental state together with appearance 
and demeanour; 4) physical examination including neurological
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examination; 5) a structured interview with a relative or other informant able 
to provide independent information regarding the respondent's present state, 
changes in personality and activities of daily living, and to corroborate or 
complete, the past medical, personal and family history; 6) investigation 
results and drug history where applicable. The CAMDEX schedule is shown 
in more detail in Figure 3.1. The CAMDEX section for neuropsychological 
assessment is the CAMCOG, which has subtests for orientation, 
comprehension, expression, language, memory (remote, recent, learned and 
total), attention, praxis, calculation, abstraction and perception. The 19 items 
which comprise the Mini Mental State Examination (MMSE) of Folstein et al 
(1975) are incorporated into CAMCOG, allowing MMSE scores to be 
calculated, however, 43 additional items make the CAMCOG more 
comprehensive than the MMSE and allow different subtests to be assessed. 
The total CAMCOG score (maximum 106) and MMSE (maximum score 30) 
can be used as a measure of overall cognitive function. Administration of 
CAMCOG takes about 45 minutes, depending on the degree of impairment of 
the patient.
3.5 Measurement of vascular transit time
The principles of MTT have been summarised in section 2.2.4. 
Measurements of MTT for cortical blood flow in resting conditions were 
undertaken in the Department of Nuclear Medicine, Western General Hospital, 
Edinburgh. The patient was asked to lie supine on a high couch with their 
head extended over a small field of view (FOV) gamma camera with very high 
sensitivity collimator. The camera was postioned to exclude the trunk from the 
FOV and the patient’s skull oriented with both orbito-meatal lines parallel to 
and equidistant from the face of the collimator, which was in contact with the 
vertex. An 18G Venflow cannula attached to a short length of wide-bore
Figure 3.2
The time-activity curve (TAC) obtained from detector placed over the 
aortic arch in a normal subject (red line).
The first peak is activity passing through the superior vena cara and the 
second, through the aortic arch. The third ill-defined peak of the red line 
is due to recirculation. By fitting a gamma variate to the aortic curve, the 
MTT from arm to the aortic arch (MTT s-a) can be calculated as described 
in the text (section 3.5). By subtracting MTT s-a from the MTTs calculated 
at each pixel of the head measured with a gamma camera (MTT from 
arm to internal jugular vein) net MTT through the cerebral circulation can 
be calculated for each pixel.
Figure 3.3 The transit of isotope tracer through the brain
A series of vertex images showing (from left to right, and top row down), 
the passage of pertechnetate (99mTc) through the brain. Each image 
has a frame duration of 1.5 seconds, and the activity increases to a 
maximum (at image number 8, from top left), then decreases as the 
activity is washed out. For each pixel in the image the MTT from arm to 
internal jugular vein can be calculated as described in the text.
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tubing and 3-way tap was inserted into an antecubital vein. The radioactivity 
(700MBq sodium pertechnetate, "m Tc) in volume of less than 1.5 ml was 
introduced through the side port of the tap without spilling into the vein. A 
1cm diameter scintillation detector fitted with a simple cylindrical collimator 
was placed 2cm distal to the sterno-manubrial joint, directed dorsally at right 
angles to the sternum to view the aortic arch. The computer was started and 
the injection flushed in by the rapid hand injection of 10ml of normal saline. 
Camera images (eg Figure 3.3) and the probe time-activity curve (TAC; eg see 
Figure 3.2) were collected simultaneously at a rate of 3 frames per second for 
60 seconds, using a 32x32 matrix (pixel area approximately 80mm2). The 
first peak of the probe TAC (Figure 3.2), due to activity tranversing the superior 
vena cava (SVC), was fitted by a gamma variate function (Thomson et al 
1964), the start and end points for fitting being set manually on the computer 
display and the fitted curve subtracted from the raw data to reveal the aortic 
curve, which was then fitted similarly to exclude recirculation and obtain the 
MTT from the arm to the aortic arch (MTTs-a).
The frames corresponding to the first pass through the head were 
identified on a TAC of total count rate. To improve the statistical quality, this 
part of the study was summed to produce a 20 frame condensed view of the 
first pass and smoothed. In normal adults the usual frame length was 0.9 
seconds, but the optimum probably lies between 0.3 and 2.1 seconds. This 
produces a 3-dimensional matrix of 32x32 x approximately 20 pixels. Pixels 
lying outside an elliptical region of interest that defined the outline of the 
cortical area were set to zero, the matrix rotated and each pixel TAC dead-time 
corrected. Data points between the first rising and seventieth falling fractile 
were identified and MTT from the arm to internal jugular vein (MTT s-j) 
calculated for each pixel by the same method as described above for MTTs-a. 
The MTT through the cerebral circulation (net MTT) at each pixel can be 
calculated from the difference between the MTT s-j values and MTT s-a. The
Figure 3.4 Net MTT regions of interest
Diagram showing the position of the regions of interest in relation 
to the cortical image. On the left side, the regions LA, LB, LC and 
LD are shown, and on the right side, the hemi-cortical region, R 
Cx.
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matrix of net MTTs can be used to construct a cerebral transit time image (eg 
Figures 4.2, 4.3, 4.4). A second matrix can be produced of the reciprocal of 
net MTT at each pixel (the cerebral vascular reserve (CVR) or so-called 
‘fractional flow’).
The data from this image can be examined as net MTT for right (RCx) 
and left (LCx) sides of the midline, or by subdividing each side of the image 
into four equal regions of interest, A, B, C, and D (see Figure 3.4). It is 
important to emphasise again however, that a planar imaging system, like the 
MTT method, does not allow tomographic or anatomical identification of 
regions. In the study described in Chapter 4, regions of interest A, B, and C 
are emphasised, as MTT values for posterior region D are likely to be 
contaminated by neck blood flow. All patients and controls were given a 
unique code number, and calculation of cerebral net MTT values and regional 
analysis of the image, was carried out blind to the identity or diagnosis of the 
subject.
3.6 Single photon emission computed tomography measurements
Single photon emission computed tomography ( SPECT ) using the 
flow tracer " mTc-hexarnethyl propyleneamine oxime (99mTc-HMPAO) was 
carried out at the Institute of Neurological Sciences, Southern General 
Hospital, Glasgow . HMPAO is well suited for SPECT because it shows high 
fractional uptake into brain with a distribution that reflects regional cerebral 
blood flow (Neirinckx et al 1987). As it is retained in the brain for many hours 
without apparent redistribution, there is adequate time for SPECT to be carried 
out. This has been discussed in section 2.2.5.1 .
HMPAO ( Exametazime or ‘Ceretec’, Amersham International pic, UK 
Product Licence No. PL0221/0-091) was supplied as a freeze-dried 
formulation and reconstituted with sodium pertechnetate solution. Within 15
Figure 3.5 The Novo 810 dedicated tomographic brain 
imager
Figure 3.6 The Novo 810 SPECT imager with covers 
removed to show the Harvard multi-detector scanning 
system with 12 sets of scintillation detectors and 
focussing collimators
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minutes of preparation, subjects were administered 2.5ml (500 MBq) of 99nrrc. 
HMPAO complex as a single intravenous bolus via a right antecubital vein.
The injection was administered in a quiet room with subjects resting, eyes 
closed and ears unplugged. Imaging was carried out within 30-90 minutes 
using the Novo 810 (Strichman Medical Equipment Inc.), a dedicated brain 
SPECT system (Figure 3.5). The Novo 810 imager uses the Harvard multi­
detector scanning system with 12 sets of scintillation detectors, each with 
focussing collimator, arranged at 30 degrees around the field of view (Figure 
3.6). Each detector scans both tangentially and radially to the field of view 
resulting in relatively uniform spatial resolution, sensitivity and slice thickness 
throughout each slice.
For imaging, subjects were positioned supine on a comfortable 
tomography table and a light source used to align the scanner parallel to the 
orbitocanthal meatal (OM). Head support was obtained using polystyrene 
wedges to ensure that the head remained in the standard configuration during 
imaging. Transverse sectional images at +30, +40, +50, +60 and +70mm 
superior to the OM line were constructed. A brain atlas was used to assign 
the five transverse slice images to particular anatomical levels and to define 
brain regions. SPECT images of severely demented patients are less 
anatomically distinct than those of controls, and care must be taken in 
assigning slice levels and defining anatomical regions. Definition of ROI 
and/or slice location is a potential error source.
Two slices were used to define particular regions of interest. The lower 
of the two slices (the ‘low’ slice), usually at +30 to 40mm above the OM line 
was identified by the presence of putamen, thalamus and occipital cortex and 
the absence of cerebellum. The second (or ‘high’) slice of interest (usually at 
OM +70mm), was positioned immediately above the corpus callosum. Using 
the computing system of the Novo 810 a total of 14 regions of interest (ROI), 
were defined by drawing on the image with a light pen. In this way 5 pairs of
Figure 3.7 SPECT regions of interest
Transverse cross-sectional SPECT images at +30mm superior to 
the orbito-meatal (OM) line (‘low’ slices, A to E) showing how the 
regions of interest were defined on left and right sides for 
quantification, showing frontal (A), temporal (B), posterior temporal 
(C), occipital (D), and basal ganglia (E) regions. A transverse 
sectional image in the same plane at OM +70mm (‘high’ slice, F) is 
also illustrated and shows high frontal and parietal regions of 
interest on left and right sides.
J f l r P~CV
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left and right ROIs in the low slice, and 2 pairs of left and right ROIs in the high 
slice were demarcated. Corresponding right and left regions were 
symmetrical. In the low slice the following symmetrical regions of interest 
(ROI) were defined (Figure 3.7): right and left frontal (RF, LF), right and left 
temporal (RT, LT), right and left posterior temporal (RPT, LPT), right and left 
occipital (RO, LO), and right and left basal ganglia (RBG, LBG). From the high 
slice at 70mm above the OM line symmetrical right and left high frontal (RHF, 
LHF), and right and left parietal (RP, LP) ROIs were also defined (Figure 3.7).
Neuroimages can show substantial variability in global metabolic 
activity, reflecting unknown combinations of various measurement problems 
including ROI identification, head movement, head positioning and 
reconstruction algorithm. As a crude adjustment for these effects some for of 
normalisation is sometimes useful. Normalisation usually takes the form of 
the division of the regional values by a measure of global activity or by the 
activity in a specific region. It is important that interpretation and statistical 
analyses should be in terms of the ‘new’ normalised variables and not in terms 
of the unadjusted measures. However the normalisation process itself can 
induce spurious patterns in the data and this must also be borne in mind 
(Ford, 1986: Ford et al 1991).
Right and left occipital regions were used as reference areas (see 
below) as these regions are relatively spared in Alzheimer's disease (Rogers 
& Morrison, 1985; Pearson et al 1985). In other studies the cerebellum has 
been used as a reference region (eg Burns et al 1989), but this was not used 
in the present work for two main reasons. Firstly, with a dedicated brain 
section imager, such as the Novo 810, a single slice image can be obtained in 
only 3 minutes. This facility for rapid data collection helps ensure a high level 
of patient cooperation. As measurement of uptake in cerebellum would 
require a different set of slices, and consequently longer periods of imaging 
time, with perhaps reduced patient cooperation, it appeared unjustifiable.
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The second reason for not adopting the cerebellum for normalisation is that 
cerebellar blood flow may be affected by crossed cerebellar diaschisis 
resulting from damage to the cortico-ponto-cerebellar system (Baron et al 
1980).
The analysis of sectional images to define ROIs was undertaken 
according to standardised criteria by the same medical physics technician 
who was blind to the diagnostic category. Raw data for each ROI was 
background corrected, typically by subtracting 15%. For each ROI and 
transverse sectional image, the area (in pixels) and background corrected 
uptake of 99mTc-HMPAO (in counts per pixel) were determined, and from 
these, mean uptake for each ROI relative to the occipital region was calculated 
as follows:
RELATIVE MEAN UPTAKE FOR ROI =
MEAN UPTAKE OF""hc-HMPAO IN ROI / MEAN UPTAKE OF ""hc-HMPAO IN 
OCCIPITAL REGIONS.
For each region this measure of relative rCBF was calculated and used 
in the analysis of results.
3.7 Statistical analysis
The main data analysis was carried out using the Statistical Package 
for the Social Sciences (SPSS-X) available via the EMAS (Edinburgh Multi 
Access System) mainframe computer of the Edinburgh University Computing 
Service. Smaller data analyses were carried out using the Stat View 512+ 
package for the Apple Macintosh computer.
In order to avoid assumptions about the distribution of MTT, blood flow 
and neuropsychological measures in the population being sampled, non-
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parametric tests were preferred to parametric tests. Although, in general, non- 
parametric tests are not as powerful as parametric tests, they are often more 
appropriate and valid than parametric equivalents when sample sizes are not 
large. Where it was thought statistically appropriate parametric tests were 
occasionally used, as in chapter 6. The statistical methods used are 
described more fully by Cohen and Holliday, 1982.
In Chapters 4 and 5 the median was used as a measure of central 
tendency and the range as a measure of variability. One point should be 
clarified; the median values in Chapter 4 for each group were calculated from 
the raw data values of net mean transit times for each subject.
Kruskal-Wallis one-way analysis of variance (K-W ANOVA) was used to 
test the differences in blood flow parameters (either MTT or relative mean 
uptake of 99mTc-HMPAO) and the differences in psychological parameters 
between the three subject groups, and post hoc Mann-Whitney U tests were 
used to locate significant differences between pairs of groups. The 
relationship between blood flow parameters and neuropsychological scores 
was examined using Spearman's rank correlation coefficients with an 
adjusted significance level of p < 0.01 to take account of multiple comparisons.
In the physostigmine study described in section 6.1 and the 
reproducibility studies described in section 6.2, measures of relative rCBF 
were approximately normally distributed, and therefore Student’s paired t-test 
(two-tailed) was used to test the significance of differences between pairs of 
values.
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CHAPTER 4
CEREBRAL VASCULAR TRANSIT TIME IN ALZHEIMER’S 
DISEASE AND KORSAKOFF’S PSYCHOSIS AND ITS RELATION
TO COGNITIVE FUNCTION
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4.1 Introduction
The rationale for interest in cerebral haemodynamics in dementia is that 
under resting circumstances CBF and cerebral metabolism are coupled 
(section 2.1). Gustafson and Risberg (1974) used the 133 Xenon intra-carotid 
injection technique to measure rCBF in patients with pre-senile dementia, and 
concluded that there was an approximate relationship between cognitive 
impairment and decreased perfusion, especially in grey matter regions. 
Abnormalities of regional perfusion were associated with specific cognitive 
functions in a way that was also found after focal brain lesions in hemispheric 
perfusion. However, the intra-carotid injection method was of limited clinical 
applicability, especially in routine diagnosis and follow-up of patients suffering 
from dementia. Intravenous (Lassen & Ingvar, 1972) or inhalational 
techniques (Mallett & Veall, 1965) for administration of inert gaseous tracers 
were more acceptable and have been used to investigate dementia (Ingvar, 
1982). However, these approaches still require the head to be kept immobile 
for a considerable period of time which, in demented patients or others with 
psychiatric illness, can present difficulties. More recently PET has provided 
regional 3-dimensional CBF measurements but it is not widely available in the 
United Kingdom.
For routine clinical studies there is a need for simpler methods of 
evaluating cerebral haemodynamics in dementia and other brain diseases. 
One such approach is based on the measurement of vascular transit time in 
cortex. Transit time methods were originally developed by cardiologists to 
measure cardiac output (Thomson et al 1964) but can, in principle, be applied 
to any determination of tracer dynamics (Davenport, 1983; Merrick, 1984). 
Recent work using PET has suggested that a useful indicator of the extent to 
which CBF is maintained by vasodilatation is the ratio of CBF to cerebral blood
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volume. This is the reciprocal of mean cerebral transit time (Gibbs et al 1984). 
The theoretical basis and practical details of the use of transit time methods to 
study cerebral vascular reserves (or the ratio of rCBF to volume) has been 
described by Merrick et al 1991. Naylor et al (1991) using the same 
methodology as that employed in the present study, have shown that within 
the range of end-tidal CO2 which could be achieved in conscious subjects 
breathing spontaneously, hemisperic net MTT showed a linear relationship 
with end-tidal CO2. Furthermore at a standardised end-tidal CO2 good 
reproducibility of hemispheric net MTT was demonstrated (coefficient of 
variation 5.7%). In the following study cerebral haemodynamics in demented 
patients were investigated using the net MTT method. As net MTT and end- 
tidal CO2 values are inversely related (Naylor et al 1991), interpretation of net 
MTT must be made in the context of the dynamic equilibrium between cerebral 
blood flow and blood volume.
4.2 Aims
The aims of the present study were as follows:
1) To measure cortical mean transit times of pertechnetate in three distinct 
clinical groups: pre-senile AD patients who have a predominantly cortical 
dementia, KOR patients where the significant pathology is reputed to be sub- 
cortical and healthy controls.
2) To consider whether transit times provide clinically useful information in 
these disorders, where perfusion abnormalities are known to exist.
3) To investigate the relationship between transit time measurements and 
cognitive impairment in such patients.
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Figure 4.1
The net mean transit times for left and right sides of the cortical 
image, and for regions of interest A, B, and C on left and right 
sides in all subjects studied: controls (•), Alzheimer patients(A), 
and Korsakoff patients(>).
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Figure 4.2 Net MTT: Alzheimer’s disease
Representative planar images of net MTT and fractional turnover 
rate (1/net MTT or cerebral vascular reserve) in cortex for two 
patients with presenile Alzheimer’s disease. Values given are 
mean +/- standard deviation for left and right sides of the image.
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Figure 4.3 Net MTT: Korsakoff’s psychosis
Representative planar images of net MTT and fractional turnover 
rate (1/net MTT or cerebral vascular reserve) in cortex for two 
patients with Korsakoff’s psychosis. Values given are mean +/- 
standard deviation for left and right sides of the image.
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Figure 4.4 Net MTT: healthy control subjects
Representative planar images of net MTT and fractional turnover 
rate (1/net MTT or cerebral vascular reserve) in cortex for two 
healthy control subjects. Values given are mean +/- standard 
deviation for left and right sides of the image.
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4.3 Methods
Seventeen patients with probable pre-senile AD, nine patients with 
KOR and ten healthy controls were studied. All fulfilled the selection criteria 
outlined in section 3.2 and the study population is described in Table 4.1.
The CAMDEX schedule was used to assess all subjects (see section 3.4) and 
mean vascular transit time (MTT) was measured at the Department of Nuclear 
Medicine, Western General Hospital, Edinburgh as described in section 3.5.
4.4 Results
4.4.1 Net mean transit times
The mean transit time of the input bolus from the arm to aortic arch 
(MTTs-a Input or Function (IF) of the radioactivity, which is thought to be 
principally a function of cardiac output, was similar in all three groups (Table 
4.2). All patients and controls had comparable cardiac function; thus a similar 
isotope profile was presented to the cerebral circulation in each group, at least 
as measured at the level of the aorta where the input function was determined.
Values for net mean transit times (net MTT) for each subject in each of 
the three groups over each cerebral hemisphere (left and right cortex) is 
shown in figure 4.1 . Both AD and KOR patients showed net MTT in left and 
right cortex that were prolonged by about 50% (Table 4.2). Thus, if the 
assumption that transit time and flow are inversely related (section 2.2.4), is 
justified, then flow in left and right cortex in the patient groups appears to be 
appreciably reduced compared to normal controls (Table 4.2).
Individual values of net MTT in the individual cortical regions of interest 
A, B, and C, showed symmetrical prolongation of net MTT on left and right 
sides in AD and KOR groups compared to normal controls(Figure 4.1). The 
magnitude of this effect is again of the order of 50% (Table 4.2). As explained
95
in section 3.5, the distribution of net MTT (or 1/MTT, so-called fractional 
turnover rate or cerebral vascular reserve) for all cortical pixels, can be used to 
construct a cortical image. Representative examples of cortical images for 
AD, KOR and an age-matched healthy control are shown in Figures 4.2, 4.3, 
and 4.4 respectively.
4.4.2 Positive predictive value of net MTT measurements
The ideal clinical test is one in which there is no overlap in the range of 
results among subjects with and without the disease in question. As can be 
seen in figure 4.1 of net MTT measurements for individual patients, there is 
some overlap between healthy normal subjects and those with AD or KOR. In 
determining the clinical utility of a test, it is customary to define a ‘normal 
range’ as two standard deviations from the mean value of the normal group 
(Griner et al 1981). Such a range encompasses approximately 95% of the 
results of subjects without the disease.
Using this method cut-off points were calculated, above which net MTT 
values were defined as abnormal. Table 4.6 shows the upper cut-off point of 
normal for each ROI and the number of AD and KOR patients with MTT 
measurements above this ‘normal’ cut-off. Positive predictive values (Griner 
et al 1981), namely the probability that disease is present (either AD or KOR) 
when the test result is positive (net MTT above the cut-off), are shown in Table 
4.6 for each ROI of the two patient groups.
4.4.3 CAMCOG neuropsychological scores and net MTT
Orientation and total memory scores were impaired in both AD and 
KOR patients compared with control subjects (Table 4.3). Language function 
was also reduced in AD patients compared with controls; KOR patients were 
less impaired. Scores for praxis were clearly reduced in AD patients but not
w
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in KOR patients (Table 4.3). Measures of attention were markedly reduced in 
AD, but much less impaired in the KOR group. Overall cognitive function, as 
measured by total CAMCOG score (CAMTOTAL), or MMSE was lowest in the 
AD group compared with controls, but also significantly reduced in the KOR 
patients (Table 4.3).
The correlation matrix of net MTT and cognitive function scores is 
shown for AD subjects in Table 4.4. Negative association at the p < 0.01 
level was detected only between orientation scores and right frontal cortex, 
although there is a trend for low cognitive scores to be associated with 
prolonged net MTT. This relationship is most apparent between hemispheric 
net MTT (left and right cortex) and CAMTOTAL, orientation, language, and to a 
lesser extent, memory function. By comparison, no association is observed 
between cognitive function scores and the input function.
The association between net MTT and psychological measures in KOR 
patients is shown in Table 4.5. No association was detected in the KOR 
group between net MTT and CAMTOTAL, language and praxis. As in the AD 
group there was an apparent trend for memory and orientation subscores to 
show a negative association with net MTT values in both sides of cortex.
None of these correlation coefficients however was statistically significant. A 
positive association between net MTT and attention was detected in both 
sides of cortex in KOR patients (Table 4.5)
4.5 Discussion
Intravenously injected radioactive tracers allowing external monitoring 
of the transit over the head have been used for some years to study cerebral 
circulation. Although it might appear that transit times give information about 
local blood flow, without an estimate of local blood volume, MTT values cannot
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be interpreted physiologically. Thus the trend in this study for net MTTs to be 
prolonged in AD and KOR patient groups, compared with healthy controls, 
might reflect reduced cortical blood flow, but without estimates of blood 
volume, no such inference can be made. At any given flow rate, MTT will 
depend on the volume into which the tracer diffuses - the volume of 
distribution. Vascular MTTs therefore require a tracer that is confined to the 
vascular compartment such as labelled human serum albumin. In normal 
brain pertechnetate appears to remain almost wholly intravascular during the 
first pass (Bartolini et al 1983) and is therefore acceptable as a blood marker. 
However in pathological states, where the blood brain barrier is substantially 
disrupted, e.g. in major head trauma, pertechnetate tends to diffuse out of the 
vascular bed into a larger volume of distribution, resulting in MTT 
prolongation. Although there is evidence that the integrity of the blood brain 
barrier is damaged in AD (e.g. Selkoe 1989), it is unlikely that, during the short 
time interval that transit time is measured, pertechnetate would be 
extravasated to any significant extent. Although MTT cannot be used as an 
index of blood flow without information on blood volume, transit time may 
however provide an index of cerebral haemodynamics or ‘brain function’ in 
situations where volume of distribution varies much less than blood flow and 
as such could have clinical utility. The normal range of values for net MTT 
observed in this study are not significantly different from those reported with 
PET (Gibbs et al 1984; Powers et al 1984) obtained by separately measuring 
blood flow and volume or following intra-arterial injection (Nylin et al 1960). It 
has been shown that there is a linear relationship between net MTT and end- 
tidal CO2 (Naylor et al 1991). In comparing different groups of subjects it has 
been assumed that end-tidal CO2 values are not significantly different between 
the groups. It is also assumed that during the net MTT examination, end-tidal 
CO2 remains constant as the examination time of 1 minute is relatively short.
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There was a trend for transit times to be prolonged in both AD and KOR 
groups, and on a group basis, significant differences in net MTT were detected 
between these groups and healthy controls, but not between AD and KOR 
groups. However there is overlap of individual net MTT values for all three 
groups in all regions of interest (individual MTT values shown in Figure 4.1).
In order to determine accurately the clinical utility of test data such as net MTT, 
both sensitivity (the true positive rate) and specificity (the true negative rate) 
are required. It is not possible to calculate sensitivity and specificity from the 
net MTT data in this study because in the study design only patients satisfying 
clinical criteria for AD or KOR were recruited. In order to calculate sensitivity 
and specificity a different epidemiological study design would be necessary, 
with measurements of net MTT being made in a group of patients with 
dementia, not carefully selected AD or KOR patient groups. The present 
design does however allow positive predictive values to be calculated - i.e. the 
likelihood of the disease being present when net MTT is abnormal (Griner et al 
1981).
In the AD group the positive predictive values (PPV) varied between 
regions of interest, with lowest values in frontal regions (Left A and Right A) 
and highest in more posterior regions (Left C and Right C). This is consistent 
with neuropathological and imaging evidence (see section 2.2) that posterior 
cortical areas are more often affected in AD. The PPV of greater than 70% for 
net MTT in posterior regions of AD patients suggests that further study with 
larger numbers of subjects may be worthwhile in establishing the clinical utility 
of net MTT. One reason why PPV of the transit time method may not be 
higher is that the clinical criteria used to select AD cases are themselves 
imperfect. When similar clinical criteria for AD case selections were 
compared with neuropathological diagnosis, estimates of their PPV vary from 
46% (Kellet et al 1988), to 84% (Burns et al 1990 a). This issue is further
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complicated by differences between laboratories of pathological diagnostic 
criteria for AD (Wisniewski et al 1988).
As might be expected from examination of individual net MTT data 
points in figure 4.1, positive predictive values of net MTT for the KOR group are 
less satisfactory. This may partly reflect the small group size, but is also likely 
to be attributable to difficulties in clinically defining cases of KOR (discussed in 
section 3.2.2).
Neuropathological studies of patients with moderate to severe AD show 
temporal, parietal and frontal lobes affected by neurofibrillary tangles, plaques 
and neuronal degeneration (Pearson et al 1985). These lesions result in 
widespread impairment of cerebral metabolism with consequent focal and 
global cognitive deficits. In this study net MTT was prolonged in all cortical 
areas in AD patients. There was also a trend for cognitive scores to be 
inversely associated with net MTT, as would be expected if transit time 
reflected function. However in both AD and KOR groups the association of 
net MTT and cognitive scores was not marked and rarely reached 
significance. This lack of association casts doubt on the usefulness of net 
MTT as an index of brain function, as does the paradoxically significant 
association between increased net MTT and improved attention scores in KOR 
patients.
In the KOR group, transit times were prolonged compared with healthy 
controls, but similar to those of AD patients. The finding of prolonged net MTT 
in stable abstinent subjects is unexpected as KOR patients are generally 
believed to have a relatively localised macroscopic neuropathological lesion 
in the diencephalon or hippocampal formation and an associated discrete 
impairment of memory without necessarily more global cognitive impairment 
(Victor et al 1971; Blackburn & Tyrer 1985). This is consistent with the 
neuropsychological data from this study, which separated the KOR patients 
from the more globally impaired AD group, especially with respect to
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language, attention, praxis and total score, and suggests that the KOR group 
were not globally demented. However there is evidence that the brain 
dysfunction in KOR is more extensive than former neuropathological and 
clinical findings have suggested, even in reasonably well defined KOR 
populations. Magnetic resonance imaging has shown that a significant 
proportion of KOR patients, who do not appear to have a generalised alcoholic 
dementia have high proton spin-lattice relaxation time (T1 values) for both 
frontal and parietal white and grey matter (Christie et al 1988). Hata et al 
(1987) have shown that KOR patients have widespread reduction in rCBF 
throughout cortical and subcortical structures. Using i33Xenon contrast 
computed tomography they have demonstrated reduced rCBF in 
hippocampus, nucleus basalis of Meynert and frontal white matter, as well as 
throughout cortical grey matter. Similar abnormalities in KOR patients include 
reduced mean hemispheric grey matter CBF using i33Xe inhalation (Rogers 
et al 1983), and reduced whole brain CBF, CMRO2 and CMR glc (Kruger et al 
1980) using the Kety-Schmidt technique.
Lishman (1986) has recently suggested a unifying hypothesis to 
account for the symptoms common to AD and KOR patients. He suggests that 
in Korsakoff’s psychosis patients, alcohol exerts toxic effects on the basal 
forebrain nuclei, causing damage to cholinergic projections to cortex with 
resultant cognitive impairment. Such a pathological process might be 
expected to result in a diffuse and variable reduction in cortical metabolism 
and blood flow.
4.6 Conclusion
This study was undertaken because transit time methods appeared to 
offer a number of attractions for the investigation of cerebral haemodynamics 
in dementia. Although measurement of net MTT is rapid, non-invasive and
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inexpensive, the present investigation illustrates a number of serious 
shortcomings with the method. Lack of definition of tracer volume of 
distribution results in difficulties in the interpretation of MTT prolongation. 
Without distribution volume information it is not possible to make any 
interpretation about the relationship of MTT to blood flow. This limitation 
could perhaps be accepted if net MTT provided some clinical utility. Despite 
the overlap in individual net MTT values in regions of interest for the three 
patient groups, calculation of positive predictive values suggest that in 
comparing AD and healthy controls, posterior cerebral regions may have 
some clinical utility. These results suggest that it would be worthwhile 
embarking on an assessment of diagnostic accuracy of net MTT in posterior 
cortex in order to determine the sensitivity and specificity of the method in 
separating AD patients from controls. In KOR patients positive predictive 
values were lower, but the prolongation of net MTT in cortical regions supports 
other evidence for cortical dysfunction in this condition previously considered 
subcortical. There was no clear association between net MTT and 
neuropsychological test scores, although there was a trend towards negative 
correlation in AD and KOR, as might be expected if net MTT provides an index 
of cortical function in dementia.
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CHAPTER 5
STUDIES OF BASAL BRAIN FUNCTION USING 
SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY
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5.1 Basal patterns of rCBF investigated by single photon 
emission computed tomography with 99mTc-HMPAO in 
presenile Alzheimer's Disease and Korsakoff's Psychosis
5.1.1 Introduction
Techniques for the tomographic reconstruction of signals from 
radioactive tracers in different brain regions may change our understanding of 
brain function. Positron emission tomography (PET) has attracted attention 
but in practice, it is operationally complex and a limited resource. Alternative 
tomographic imaging techniques such as SPECT may allow advances from 
PET to be translated into more general clinical use and may push studies of 
brain function into new clinical areas where access to PET is and may remain 
limited. Single photon emission computed tomography (SPECT) with 
administration of intravenous radioligands promises to be an important 
technique to complement PET in this way.
Initial applications of PET have centered on estimation of regional 
cerebral metabolism and cerebral blood flow. The results suggest that 
cerebral blood flow is, under most circumstances, tightly coupled to local 
neuronal demand for glucose (section 2.1). Interest in SPECT proceeds in 
the first instance from the wish to investigate patterns of regional blood flow in 
the neocortex as a potential measure of neuronal function.
Radionuclides based on 99mjc are optimal for clinical SPECT imaging 
because the radio-isotope is inexpensive and has favourable properties for 
clinical use such as stability and relatively pure emission of 140KeV 
Y-radiation. The recent introduction of hexamethyl propyleneamine oxime 
(Exametazime or d,1 HMPAO, Amersham Intl. pic) thus offers considerable 
potential for imaging of brain perfusion patterns using SPECT. It complexes 
readily with 99m-rc and its distribution following intravenous injection conforms
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closely to that of an ideal ‘first pass’, high clearance, marker of brain blood 
flow (Neirinckx et al 1987; Costa et al 1986; Sharp et al 1986b).
The aims of this study were to use 99mTc-HMPAO SPECT to investigate 
the pattern of regional cerebral blood flow (rCBF) in patients with probable 
presenile Alzheimer's disease and Korsakoff's psychosis and to determine its 
relation to neuropsychological function in such patients. The central 
questions were:
(a) What is the pattern of perfusion deficits using SPECT in patients with 
presenile Alzheimer’s disease and Korsakoff psychosis?
(b) Is there evidence of cortical dysfunction using SPECT in Korsakoff 
patients?
(c) Can we demonstrate meaningful relationships between rCBF patterns as 
measured by SPECT, and neuropsychological performance?
5.1.2 Methods
5.1.2.1 Patients and control subjects
Twelve patients with pre-senile Alzheimer’s disease (AD) were studied 
and are described in Table 5.1. All met the agreed consensus criteria for 
probable Alzheimer's disease described in section 3.2.1.
Ten patients with Alcoholic Korsakoff Syndrome (KOR) were also studied 
and are described in Table 5.1. All KOR patients were resident in a 
psychiatric hospital ward or supervised hostel accommodation and all met the 
operational criteria for KOR described in section 3.2.2.
Twelve control subjects (Table 5.1) were recruited from local voluntary 
groups and the spouses of patients. All volunteers were in good physical and 
psychiatric health as described in section 3.2.3.
All patients and healthy volunteers gave informed consent to take part in 
the study (section 3.2.7) and only patients and subjects who met criteria for
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right-handedness were admitted to the study (section 3.2.4). The study was 
approved by the Ethics of Medical Research Sub-Committee for Psychiatry 
and Psychology of the Lothian Health Board and the use of 99mTc-HMPAO 
approved by the Administration of Radioactive Substances Advisory 
Committee of the Department of Health (ARSAC).
5.1.2.2 Psychological assessment
The Cambridge Mental Disorders of the Elderly Examination (CAMDEX) 
was used for diagnosis and assessment of dementia (Roth et al 1986) and 
was completed for all subjects in the study. The CAMCOG protocol (of 
CAMDEX) and MMSE (Folstein et al 1975) were used to assess cognitive 
function (see section 3.3) in patients and to screen healthy control subjects.
All control subjects obtained maximal or near maximal scores, providing 
evidence of normal cognitive function.
5.1.2.3 Measurement of regional cerebral blood flow
Regional CBF was measured at the Institute of Neurological Sciences, 
Glasgow using single photon emission tomography (SPECT) and the tracer 
" mTc-hexarnethyl propyleneamine oxime (99mTc-HMPAO), as described in 
section 3.6.
5.1.2.4 Statistical analysis
Measures of relative rCBF and CAMCOG scores are presented as 
median and range. Kruskal-Wallis one-way analysis of variance (K-W 
ANOVA) was used to test the differences in blood flow between the three 
groups and post-hoc Mann-Whitney U tests were used to locate significant 
differences. The relationship between relative mean uptake of 99mTc-HMPAO 
and cognitive scores was examined using Spearman's rank correlation
to
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Figure 5.1
Uptake of 99mTc-HMPAO in posterior temporal and parietal 
regions is shown for the three subject groups, (AD, Alzheimer’s 
disease; KOR, Korsakoff’s psychosis; CONTROL, healthy controls) 
as the mean percentage difference in uptake between the region 
of interest (ROI) and the reference area (occipital region). Vertical 
bars show SEM. Right sided regions are shown as white, and left 
sided regions are hatched in dark.
| POSTERIOR TEMPORAL
CONTROL
PARIETAL
CONTROL
Figure 5.4 SPECT: healthy control subject
Representative transverse sectional SPECT images at +30mm 
(lower image) and +70mm (top image) superior to the orbito- 
meatal line for a normal control subject. Orientation of images: 
frontal region to top of page; right side of image to left of page.
\

Figure 5.5 SPECT: Alzheimer's disease
Representative transverse sectional SPECT images at +30mm 
(lower image) and +70mm (top image) superior to the orbito- 
meatal line for a patient with Alzheimer's disease. Orientation of 
images: frontal region to top of page; right side of image to left of 
page.
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in section 3.5, the distribution of net MTT (or 1/MTT, so-called fractional 
turnover rate or cerebral vascular reserve) for all cortical pixels, can be used to 
construct a cortical image. Representative examples of cortical images for 
AD, KOR and an age-matched healthy control are shown in Figures 4.2, 4.3, 
and 4.4 respectively.
4.4.2 Positive predictive value of net MTT measurements
The ideal clinical test is one in which there is no overlap in the range of 
results among subjects with and without the disease in question. As can be 
seen in figure 4.1 of net MTT measurements for individual patients, there is 
some overlap between healthy normal subjects and those with AD or KOR. In 
determining the clinical utility of a test, it is customary to define a ‘normal 
range’ as two standard deviations from the mean value of the normal group 
(Griner et al 1981). Such a range encompasses approximately 95% of the 
results of subjects without the disease.
Using this method cut-off points were calculated, above which net MTT 
values were defined as abnormal. Table 4.6 shows the upper cut-off point of 
normal for each ROI and the number of AD and KOR patients with MTT 
measurements above this ‘normal’ cut-off. Positive predictive values (Griner 
et al 1981), namely the probability that disease is present (either AD or KOR) 
when the test result is positive (net MTT above the cut-off), are shown in Table
4.6 for each ROI of the two patient groups.
4.4.3 CAMCOG neuropsychological scores and net MTT
Orientation and total memory scores were impaired in both AD and 
KOR patients compared with control subjects (Table 4.3). Language function 
was also reduced in AD patients compared with controls; KOR patients were 
less impaired. Scores for praxis were clearly reduced in AD patients but not
to
ok.**coo
CB
(0 Q)
c E0)
■ -  o >
iM+*
rt .t;£  to
» § 
2 £  
o O)
w.E _  to
CB 3
B'S
PfO » 
>»
COQ.O
k _
3
0)
CO
Lil-I
OQ
<h-
= j£
is
2 |
D g 
g §
cc o>
p  1^  c
a
<
g o
O C O
in in in in in m ino o o o o o oo o o o o o oo o o o o o o
o o o o o o o
V V V V V V V
Q. Q. Q. Q. CL Q. Q.
« «* 6) * oT oT♦ CM CM CO CM6)i 100 CMi r-a ■ ICO 1CM CO, N- in T"“
in CO CM in f— in OCM T~ r^ - CM
* « * *It * « « « * ** R in * 1“ CMa> CM i— CO T“ 00 CMIo o Io 1o 1o . o o
o h- T- ho r- CMCM in
in,_„ oo CO t- oCO CM lo CO
o 100 1CO 1^-1 CM o 1oCM CM in T- T— CM<s—
o o> r- CM CM O1— CM CM T“ O CO
<
i i
UJ
cc
O
LU
o
<3
o
>
DC
O
LU
Zo
LU
s
co
X
<
ccQ_ <O
LU
CO
Re
su
lts
 
ex
pr
es
se
d 
as 
me
dia
n 
an
d 
ra
ng
e.
 
Al
l 
po
st-
ho
c 
co
m
pa
ris
on
s 
we
re 
ma
de
 
be
tw
ee
n 
pa
tie
nt
 
gr
ou
ps
 
an
d 
co
nt
ro
l s
ub
jec
ts 
us
ing
 
M
an
n-
W
hit
ne
y 
U 
te
st;
 
*p 
< 
0.
00
5;
 
**p
 
< 
0.
00
1.
TA
BL
E 
4.
4
co4*c
.2
COa
<D
E
0£
<
C
aoo
2
<O
TJ
C
CO
0
E
c0
c0
0
E
0c
c
0
0
5
0n
0co
**
0
0cc
LL
Q
CC
O
CC
o
CD
CC
CO
<
cc
<3
CC
a
o
■M-
O
CO
o
CO CD
O
i
o
o
o• o• o+
o
+ o+ oi
CO■M- COin COCO CO o oCO
o• o• o• oi oi o•
in
inCO inCO o> ■M-CO
o• o• o• o■ oi o•
CM COin inCM COCM CO CMCM
o• o• o• o1 o• o•
CMCO COCO in^ r CM CMO CM
o■ o• o• o1 oi d1
CO
M-
h -in in
inCO GO 00CM
o
•
o
■
o
•
o
■
o1 o1
- CO CO 00
o
CO
o
o• o• o■ o• o• o■
in
*
CO
CO in
T”
Tf- COCM 00CO
o■ o■ o■ o■ o1 o■
COCO GO■M" COCO inCO 1^CM M-CO
o• o• o• o• o1 o•
o
CO
*
CO
CO
CO
CO
00
in 00
COCO
o■ oi oi o• o• o•
COCO GOCO COin COCO o inT“
oi o1 o• o■ o+ o■
CA
M
TO
TA
L
O
RI
EN
TA
TI
O
N
LA
NG
UA
G
E
M
EM
O
RY
AT
TE
NT
IO
N
PR
AX
IS
*
0■0-^
0
00
20
o
'■co0
O
E
0
Eo
o
co
o
c
•4—
sQ.c
0
0
o
o
v
0 ■4—>c
0
g
oo
co
0
0k_I.oo
XL
c
2
0
“c
0
Ek_
0
0Q.
CO
TA
BL
E 
4.
5
Po
si
tiv
e 
pr
ed
ic
tiv
e 
va
lue
 
of 
ne
t 
MT
T 
in 
re
gi
on
s 
of 
in
te
re
st
 
fo
r 
AD
 
an
d 
KO
R 
pa
tie
nt
s
o
JOD>
be
CO
CD CO C D CD
1^
CD
O
<1>
CO
CD
CM in CDin
CQ ■«—> .c
g>
be
o>
in
co
*
00
in inCD in CDin
sz
g>
be CD o> s CO
CO
CO
% CD CO
CO
CO
Xo
D)
be
CM
CD
CO CD1^ CD 1^CD
XO
s
CM
CD
in
CD in CDin
CO
111-I
CQ
<H
c/> •o 
_  c  
CO o
E o 0
o  ®
f  ®o 3
^  CO
1 t
1 ?3  c
0) •*—« 
c  
0
"co
Q.
Q<
0
.Q
E13
03
CO>
»=
o
•«—>3O
0
Ek_
o
c
0>
o_o0
0> ^^
b 0^T30 a
k_
CL <
0 o>
V-• 
CD
03o 0Q_ >
0 
3
0 >
0 ? 
Q. £
ce o
9  0 
;  e
0 b
0 c _Q 0
1 5
Z  0
c  
0
0.>
o _  
T3 £0 O*- V Q. *
0 O > H“'■t5 0
CO 3
£  5 To
ta
l n
um
be
r 
of 
AD 
pa
tie
nts
 
stu
die
d 
wa
s 
17 
an
d 
KO
R 
pa
tie
nts
 
9.
Po
sit
ive
 
pr
ed
ict
ive
 
va
lue
 
(%
) 
is 
nu
m
be
r 
of 
pa
tie
nts
 
wit
h 
ne
t 
MT
T 
va
lue
 
ab
ov
e 
cu
t-o
ff 
va
lue
 
div
ide
d 
by 
to
ta
l 
nu
m
be
r 
of 
pa
tie
nt
s.
 
Ab
br
ev
ia
tio
ns
 
ex
pla
ine
d 
in 
te
xt
.
96
in KOR patients (Table 4.3). Measures of attention were markedly reduced in 
AD, but much less impaired in the KOR group. Overall cognitive function, as 
measured by total CAMCOG score (CAMTOTAL), or MMSE was lowest in the 
AD group compared with controls, but also significantly reduced in the KOR 
patients (Table 4.3).
The correlation matrix of net MTT and cognitive function scores is 
shown for AD subjects in Table 4.4. Negative association at the p < 0.01 
level was detected only between orientation scores and right frontal cortex, 
although there is a trend for low cognitive scores to be associated with 
prolonged net MTT. This relationship is most apparent between hemispheric 
net MTT (left and right cortex) and CAMTOTAL, orientation, language, and to a 
lesser extent, memory function. By comparison, no association is observed 
between cognitive function scores and the input function.
The association between net MTT and psychological measures in KOR 
patients is shown in Table 4.5. No association was detected in the KOR 
group between net MTT and CAMTOTAL, language and praxis. As in the AD 
group there was an apparent trend for memory and orientation subscores to 
show a negative association with net MTT values in both sides of cortex.
None of these correlation coefficients however was statistically significant. A 
positive association between net MTT and attention was detected in both 
sides of cortex in KOR patients (Table 4.5)
4.5 Discussion
Intravenously injected radioactive tracers allowing external monitoring 
of the transit over the head have been used for some years to study cerebral 
circulation. Although it might appear that transit times give information about 
local blood flow, without an estimate of local blood volume, MTT values cannot
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be interpreted physiologically. Thus the trend in this study for net MTTs to be 
prolonged in AD and KOR patient groups, compared with healthy controls, 
might reflect reduced cortical blood flow, but without estimates of blood 
volume, no such inference can be made. At any given flow rate, MTT will 
depend on the volume into which the tracer diffuses - the volume of 
distribution. Vascular MTTs therefore require a tracer that is confined to the 
vascular compartment such as labelled human serum albumin. In normal 
brain pertechnetate appears to remain almost wholly intravascular during the 
first pass (Bartolini et al 1983) and is therefore acceptable as a blood marker. 
However in pathological states, where the blood brain barrier is substantially 
disrupted, e.g. in major head trauma, pertechnetate tends to diffuse out of the 
vascular bed into a larger volume of distribution, resulting in MTT 
prolongation. Although there is evidence that the integrity of the blood brain 
barrier is damaged in AD (e.g. Selkoe 1989), it is unlikely that, during the short 
time interval that transit time is measured, pertechnetate would be 
extravasated to any significant extent. Although MTT cannot be used as an 
index of blood flow without information on blood volume, transit time may 
however provide an index of cerebral haemodynamics or ‘brain function’ in 
situations where volume of distribution varies much less than blood flow and 
as such could have clinical utility. The normal range of values for net MTT 
observed in this study are not significantly different from those reported with 
PET (Gibbs et al 1984; Powers et al 1984) obtained by separately measuring 
blood flow and volume or following intra-arterial injection (Nylin et al 1960). It 
has been shown that there is a linear relationship between net MTT and end- 
tidal CO2 (Naylor et al 1991). In comparing different groups of subjects it has 
been assumed that end-tidal CO2 values are not significantly different between 
the groups. It is also assumed that during the net MTT examination, end-tidal 
CO2 remains constant as the examination time of 1 minute is relatively short.
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There was a trend for transit times to be prolonged in both AD and KOR 
groups, and on a group basis, significant differences in net MTT were detected 
between these groups and healthy controls, but not between AD and KOR 
groups. However there is overlap of individual net MTT values for all three 
groups in all regions of interest (individual MTT values shown in Figure 4.1).
In order to determine accurately the clinical utility of test data such as net MTT, 
both sensitivity (the true positive rate) and specificity (the true negative rate) 
are required. It is not possible to calculate sensitivity and specificity from the 
net MTT data in this study because in the study design only patients satisfying 
clinical criteria for AD or KOR were recruited. In order to calculate sensitivity 
and specificity a different epidemiological study design would be necessary, 
with measurements of net MTT being made in a group of patients with 
dementia, not carefully selected AD or KOR patient groups. The present 
design does however allow positive predictive values to be calculated - i.e. the 
likelihood of the disease being present when net MTT is abnormal (Griner et al 
1981).
In the AD group the positive predictive values (PPV) varied between 
regions of interest, with lowest values in frontal regions (Left A and Right A) 
and highest in more posterior regions (Left C and Right C). This is consistent 
with neuropathological and imaging evidence (see section 2.2) that posterior 
cortical areas are more often affected in AD. The PPV of greater than 70% for 
net MTT in posterior regions of AD patients suggests that further study with 
larger numbers of subjects may be worthwhile in establishing the clinical utility 
of net MTT. One reason why PPV of the transit time method may not be 
higher is that the clinical criteria used to select AD cases are themselves 
imperfect. When similar clinical criteria for AD case selections were 
compared with neuropathological diagnosis, estimates of their PPV vary from 
46% (Kellet et al 1988), to 84% (Burns et al 1990 a). This issue is further
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complicated by differences between laboratories of pathological diagnostic 
criteria for AD (Wisniewski et al 1988).
As might be expected from examination of individual net MTT data 
points in figure 4.1, positive predictive values of net MTT for the KOR group are 
less satisfactory. This may partly reflect the small group size, but is also likely 
to be attributable to difficulties in clinically defining cases of KOR (discussed in 
section 3.2.2).
Neuropathological studies of patients with moderate to severe AD show 
temporal, parietal and frontal lobes affected by neurofibrillary tangles, plaques 
and neuronal degeneration (Pearson et al 1985). These lesions result in 
widespread impairment of cerebral metabolism with consequent focal and 
global cognitive deficits. In this study net MTT was prolonged in all cortical 
areas in AD patients. There was also a trend for cognitive scores to be 
inversely associated with net MTT, as would be expected if transit time 
reflected function. However in both AD and KOR groups the association of 
net MTT and cognitive scores was not marked and rarely reached 
significance. This lack of association casts doubt on the usefulness of net 
MTT as an index of brain function, as does the paradoxically significant 
association between increased net MTT and improved attention scores in KOR 
patients.
In the KOR group, transit times were prolonged compared with healthy 
controls, but similar to those of AD patients. The finding of prolonged net MTT 
in stable abstinent subjects is unexpected as KOR patients are generally 
believed to have a relatively localised macroscopic neuropathological lesion 
in the diencephalon or hippocampal formation and an associated discrete 
impairment of memory without necessarily more global cognitive impairment 
(Victor et al 1971; Blackburn & Tyrer 1985). This is consistent with the 
neuropsychological data from this study, which separated the KOR patients 
from the more globally impaired AD group, especially with respect to
1 0 0
language, attention, praxis and total score, and suggests that the KOR group 
were not globally demented. However there is evidence that the brain 
dysfunction in KOR is more extensive than former neuropathological and 
clinical findings have suggested, even in reasonably well defined KOR 
populations. Magnetic resonance imaging has shown that a significant 
proportion of KOR patients, who do not appear to have a generalised alcoholic 
dementia have high proton spin-lattice relaxation time (T1 values) for both 
frontal and parietal white and grey matter (Christie et al 1988). Hata et al 
(1987) have shown that KOR patients have widespread reduction in rCBF 
throughout cortical and subcortical structures. Using 133Xenon contrast 
computed tomography they have demonstrated reduced rCBF in 
hippocampus, nucleus basalis of Meynert and frontal white matter, as well as 
throughout cortical grey matter. Similar abnormalities in KOR patients include 
reduced mean hemispheric grey matter CBF using 133Xe inhalation (Rogers 
et al 1983), and reduced whole brain CBF, CMRO2 and CMR glc (Kruger et al 
1980) using the Kety-Schmidt technique.
Lishman (1986) has recently suggested a unifying hypothesis to 
account for the symptoms common to AD and KOR patients. He suggests that 
in Korsakoff’s psychosis patients, alcohol exerts toxic effects on the basal 
forebrain nuclei, causing damage to cholinergic projections to cortex with 
resultant cognitive impairment. Such a pathological process might be 
expected to result in a diffuse and variable reduction in cortical metabolism 
and blood flow.
4.6  Conclusion
This study was undertaken because transit time methods appeared to 
offer a number of attractions for the investigation of cerebral haemodynamics 
in dementia. Although measurement of net MTT is rapid, non-invasive and
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inexpensive, the present investigation illustrates a number of serious 
shortcomings with the method. Lack of definition of tracer volume of 
distribution results in difficulties in the interpretation of MTT prolongation. 
Without distribution volume information it is not possible to make any 
interpretation about the relationship of MTT to blood flow. This limitation 
could perhaps be accepted if net MTT provided some clinical utility. Despite 
the overlap in individual net MTT values in regions of interest for the three 
patient groups, calculation of positive predictive values suggest that in 
comparing AD and healthy controls, posterior cerebral regions may have 
some clinical utility. These results suggest that it would be worthwhile 
embarking on an assessment of diagnostic accuracy of net MTT in posterior 
cortex in order to determine the sensitivity and specificity of the method in 
separating AD patients from controls. In KOR patients positive predictive 
values were lower, but the prolongation of net MTT in cortical regions supports 
other evidence for cortical dysfunction in this condition previously considered 
subcortical. There was no clear association between net MTT and 
neuropsychological test scores, although there was a trend towards negative 
correlation in AD and KOR, as might be expected if net MTT provides an index 
of cortical function in dementia.
1 0 2
CHAPTER 5
STUDIES OF BASAL BRAIN FUNCTION USING 
SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY
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5.1 Basal patterns of rCBF investigated by single photon 
emission computed tomography with " mTc-HMPAO in 
presenile Alzheimer's Disease and Korsakoff's Psychosis
5.1.1 Introduction
Techniques for the tomographic reconstruction of signals from 
radioactive tracers in different brain regions may change our understanding of 
brain function. Positron emission tomography (PET) has attracted attention 
but in practice, it is operationally complex and a limited resource. Alternative 
tomographic imaging techniques such as SPECT may allow advances from 
PET to be translated into more general clinical use and may push studies of 
brain function into new clinical areas where access to PET is and may remain 
limited. Single photon emission computed tomography (SPECT) with 
administration of intravenous radioligands promises to be an important 
technique to complement PET in this way.
Initial applications of PET have centered on estimation of regional 
cerebral metabolism and cerebral blood flow. The results suggest that 
cerebral blood flow is, under most circumstances, tightly coupled to local 
neuronal demand for glucose (section 2.1). Interest in SPECT proceeds in 
the first instance from the wish to investigate patterns of regional blood flow in 
the neocortex as a potential measure of neuronal function.
Radionuclides based on 99mTC are optimal for clinical SPECT imaging 
because the radio-isotope is inexpensive and has favourable properties for 
clinical use such as stability and relatively pure emission of 140KeV 
Y-radiation. The recent introduction of hexamethyl propyleneamine oxime 
(Exametazime or d,1 HMPAO, Amersham Intl. pic) thus offers considerable 
potential for imaging of brain perfusion patterns using SPECT. It complexes 
readily with 99mjc ancj \\s distribution following intravenous injection conforms
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closely to that of an ideal ‘first pass’, high clearance, marker of brain blood 
flow (Neirinckx et al 1987; Costa et al 1986; Sharp et al 1986b).
The aims of this study were to use 99mTc-HMPAO SPECT to investigate 
the pattern of regional cerebral blood flow (rCBF) in patients with probable 
presenile Alzheimer's disease and Korsakoff's psychosis and to determine its 
relation to neuropsychological function in such patients. The central 
questions were:
(a) What is the pattern of perfusion deficits using SPECT in patients with 
presenile Alzheimer’s disease and Korsakoff psychosis?
(b) Is there evidence of cortical dysfunction using SPECT in Korsakoff 
patients?
(c) Can we demonstrate meaningful relationships between rCBF patterns as 
measured by SPECT, and neuropsychological performance?
5.1.2 Methods
5.1.2.1 Patients and control subjects
Twelve patients with pre-senile Alzheimer’s disease (AD) were studied 
and are described in Table 5.1. All met the agreed consensus criteria for 
probable Alzheimer's disease described in section 3.2.1.
Ten patients with Alcoholic Korsakoff Syndrome (KOR) were also studied 
and are described in Table 5.1. All KOR patients were resident in a 
psychiatric hospital ward or supervised hostel accommodation and all met the 
operational criteria for KOR described in section 3.2.2.
Twelve control subjects (Table 5.1) were recruited from local voluntary 
groups and the spouses of patients. All volunteers were in good physical and 
psychiatric health as described in section 3.2.3.
All patients and healthy volunteers gave informed consent to take part in 
the study (section 3.2.7) and only patients and subjects who met criteria for
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right-handedness were admitted to the study (section 3.2.4). The study was 
approved by the Ethics of Medical Research Sub-Committee for Psychiatry 
and Psychology of the Lothian Health Board and the use of 99mTc-HMPAO 
approved by the Administration of Radioactive Substances Advisory 
Committee of the Department of Health (ARSAC).
5.1.2.2 Psychological assessment
The Cambridge Mental Disorders of the Elderly Examination (CAMDEX) 
was used for diagnosis and assessment of dementia (Roth et al 1986) and 
was completed for all subjects in the study. The CAMCOG protocol (of 
CAMDEX) and MMSE (Folstein et al 1975) were used to assess cognitive 
function (see section 3.3) in patients and to screen healthy control subjects.
All control subjects obtained maximal or near maximal scores, providing 
evidence of normal cognitive function.
5.1.2.3 Measurement of regional cerebral blood flow
Regional CBF was measured at the Institute of Neurological Sciences, 
Glasgow using single photon emission tomography (SPECT) and the tracer 
99mTC-hexamethyl propyleneamine oxime (99mTc-HMPAO), as described in 
section 3.6.
5.1.2.4 Statistical analysis
Measures of relative rCBF and CAMCOG scores are presented as 
median and range. Kruskal-Wallis one-way analysis of variance (K-W 
ANOVA) was used to test the differences in blood flow between the three 
groups and post-hoc Mann-Whitney U tests were used to locate significant 
differences. The relationship between relative mean uptake of 99mTc-HMPAO 
and cognitive scores was examined using Spearman's rank correlation
in
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Figure 5.1
Uptake of 99mTc-HMPAO in posterior temporal and parietal 
regions is shown for the three subject groups, (AD, Alzheimer’s 
disease; KOR, Korsakoff’s psychosis; CONTROL, healthy controls) 
as the mean percentage difference in uptake between the region 
of interest (ROI) and the reference area (occipital region). Vertical 
bars show SEM. Right sided regions are shown as white, and left 
sided regions are hatched in dark.
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Figure 5.2
Uptake of 99mTc-HMPAO in temporal and basal ganglia regions is 
shown for the three subject groups, (AD, Alzheimer’s disease; 
KOR, Korsakoff’s psychosis; CONTROL, healthy controls) as the 
mean percentage difference in uptake between the region of 
interest (ROI) and the reference area (occipital region). Vertical 
bars show SEM. Right sided regions are shown as white, and left 
sided regions are hatched in dark.
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Figure 5.3
Uptake of 99mTc-HMPAO in frontal and high frontal regions is 
shown for the three subject groups, (AD, Alzheimer’s disease; 
KOR, Korsakoff’s psychosis; CONTROL, healthy controls) as the 
mean percentage difference in uptake between the region of 
interest (ROI) and the reference area (occipital region). Vertical 
bars show SEM. Right sided regions are shown as white, and left 
sided regions are hatched in dark.
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Figure 5.4 SPECT: healthy control subject
Representative transverse sectional SPECT images at +30mm 
(lower image) and +70mm (top image) superior to the orbito- 
meatal line for a normal control subject. Orientation of images: 
frontal region to top of page; right side of image to left of page.
a
Figure 5.5 SPECT: Alzheimer's disease
Representative transverse sectional SPECT images at +30mm 
(lower image) and +70mm (top image) superior to the orbito- 
meatal line for a patient with Alzheimer's disease. Orientation of 
images: frontal region to top of page; right side of image to left of 
page.

Figure 5.6 SPECT: Korsakoff's psychosis
Representative transverse sectional SPECT images at +30mm 
(lower image) and +70mm (top image) superior to the orbito- 
meatal line for a patient with Korsakoff's psychosis. Orientation of 
images: frontal region to top of page; right side of image to left of 
page.
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coefficients. Significance levels were adjusted to take account of multiple 
comparisons as described previously.
5.1.3 Results 
5.1.3.1 Regional CBF measurements
In patients with AD, relative rCBF was reduced in posterior temporal 
areas compared with controls; posterior temporal rCBF was maintained in 
KOR patients (Figure 5.1, Table 5.2). In AD, rCBF was also reduced in 
parietal (Figure 5.1, Table 5.2) and left temporal regions (Figure 5.2, Table 
5.2). In other individual cortical areas for AD, and in all areas for KOR, 
differences between patient groups and normal controls were not statistically 
discernible (Table 5.2). However, there was a tendency for median values for 
all cortical areas to be lower in both the patient groups (Figures 5.1, 5.2, 5.3 
and legend to Table 5.2). In the representative subcortical area studied 
(basal ganglia), rCBF was the same in all groups (Figure 5.2).
Representative examples of SPECT images at ‘high’ and ‘low’ levels, 
(OM +70mm and OM +30mm), obtained using the technique are shown for a 
healthy control subject (Figure 5.4), Alzheimer patient (Figure 5.5) and 
Korsakoff patient (Figure 5.6). In the Alzheimer patient, reduction in relative 
flow can be seen in fronto-temporal and parietal areas, while in the Korsakoff 
patient flow is reduced in frontal regions.
5.1.3.2 Positive predictive value of relative rCBF measurements
As explained in section 4.4.2, in order to determine the clinical utility of 
an investigative test, it is useful to define a ‘normal range’ of values. This can 
be established by defining ‘normal’ cut-off values as two standard deviations 
from the mean value of the healthy subjects; if normally distributed, such a 
range will encompass 95% of the individual subjects without disease. Using
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this method lower ‘normal’ cut-off values were calculated for each ROI below 
which relative rCBF values were defined as abnormal. Table 5.6 shows the 
lower cut-off value of relative rCBF for each ROI and the number of AD and 
KOR patients below this cut-off. The extent of overlap of individual results 
between the AD group and healthy controls is reflected in the small numbers 
of AD patients below the cut-off. Only in the right and left posterior temporal 
groups are there 50% or more patients with values outwith the normal range. 
For the KOR group, most patients have relative rCBF values within the range 
of normal values for every ROI.
Positive predictive values (Griner et al 1981), or the probability that the 
disease is present (viz AD or KOR) when the relative rCBF value is below the 
cut-off are shown in Table 5.6 for each ROI in AD and KOR. Due to the 
degree of overlap of individual patient values with those of the ‘normal range’, 
the positive predictive values are only greater than 50% in posterior temporal 
regions of AD patients.
5.1.3.3 Neuropsychological scores
Total CAMCOG and MMSE scores were reduced in both AD and KOR 
patient groups (Table 5.3), although the pattern of subtests affected was 
different in AD and KOR, reflecting the more limited cognitive deficit associated 
with KOR, compared to AD. In all areas of cognitive function, CAMCOG 
subscores were reduced in AD patients compared with controls, reflecting 
their more global impairment (Table 5.3). Korsakoff patients also had 
impaired scores in many cognitive subtests in particular, orientation, recent 
memory and memory for newly learned information (‘memory-learned’), but 
had better preserved function in many areas, including comprehension, 
expression, attention, praxis and calculation where scores were similar to 
controls (Table 5.3).
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5.1.3.4 Association of HMPAO uptake and cognitive function
The correlation matrix of relative 99mTc-HMPAO uptake and cognitive 
scores for AD is shown in Table 5.4. Because of the large number of multiple 
comparisons, only correlations where p < 0.01 are highlighted. There are 
sixteen correlations at p < 0.01 where only two would be expected by chance. 
However, in addition, positive correlations showed patterning to particular 
cortical areas. For example clustering of positive correlations occurred for 
tracer uptake into left parietal (LP) cortex, where all values of the correlation 
coefficient, r, were positive (Table 5.4).
There were also significant associations between reduced LP flow and 
language function (including expression and comprehension), remote and 
total memory scores, attention and praxis. Association with right parietal 
tracer uptake, although showing positive correlates, were much less striking 
(Table 5.4).
Left posterior temporal cortex showed a similar pattern of associations to 
LP, confirming a general tendency for impairment of left lateral hemispheric 
function to be associated with reduced cognitive performance. Uptake in 
frontal areas (RF, LF, RHF, LHF) and basal ganglia did not show statistically 
significant correlations with performance for AD patients.
In the correlation matrix of relative uptake and cognitive scores for KOR 
patients there were six correlations at p < 0.01 (Table 5.5). Again, there were 
apparent patterns of positive correlation. In common with AD, uptake of tracer 
in left parietal cortex again tended to be correlated with scores for language 
and memory function. There was, however, no clear discrepancy between LP 
and RP. Furthermore, but again unlike AD, there was a cluster of r values 
apparently associating reduced flow in high frontal areas with impaired 
memory and orientation. Other areas showed little evidence of association 
between performance and rCBF.
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5.1.4 Discussion
This study presents quantitative estimates of relative rCBF in presenile 
AD, Korsakoff's psychosis and controls using the intravenous ligand 99mjc- 
HMPAO. In summary the following conclusions can be drawn from this work; 
first, relative rCBF was bilaterally reduced in posterior temporal and parietal 
cortical areas in presenile Alzheimer's disease but not in Korsakoff's 
psychosis; second, apparently meaningful correlations exist between 
cognitive function in AD and relative rCBF in the cortical areas most affected; 
third, in KOR, the prominent impairments of orientation and memory that 
characterise the disease were correlated with impaired relative rCBF in frontal 
regions.
The aim of the present investigation was not to determine the accuracy of 
the diagnostic usefulness of SPECT imaging. To do this a different study 
design would be required where all patients with dementia were investigated, 
not just two carefully selected groups, and from which sensitivity and 
specificity could be calculated. Although the present study design does not 
allow sensitivity or specificity to be calculated, it does yield positive predictive 
values (PPV) - i.e. the likelihood of the disease (AD or KOR) being present 
when relative rCBF is low. As table 5.6 shows, PPVs are low for all brain 
regions studied with the exception of the posterior temporal regions in AD.
The numbers of subjects investigated in this study were small and results 
need to be treated with caution. In a larger study the 'normal range’ could be 
defined with greater accuracy and PPVs confirmed. Nevertheless the overlap 
of individual test results between groups was marked casting considerable 
doubt over the diagnositc utility of SPECT in dementia. This does not mean 
that SPECT may have no clinical utility. There may be value in knowing the 
pattern of perfusion deficit in individual patients, not with a view to diagnosis, 
but in providing information on which brain areas are likely to be 
dysfunctional. This is supported by the association of specific cognitive 
impairments and particular brain regions (discussed below).
1 1 0
In conclusion the findings suggest that SPECT may have limited potential 
in the clinical assessment of dementia. However they do support the view that 
SPECT can provide measures of brain function that may allow its further 
experimental application in organic brain disease and possibly also in the 
so-called ‘functional’ psychiatric disorders.
5.1.4.1 Alzheimer’s Disease
There have been previous reports of non-quantitative application of 
SPECT in AD (see section 2.2.5.2), but not in KOR. Intravenous ligands 
including N-isopropyl-p-iodoamphetamine (IMP) labelled with 123I (Jagust et 
al 1987; Johnson et al 1987) and 99mTc-HMPAO (Gemmell et al 1987; Neary 
et al 1987) have shown qualitative defects in posterior temporal blood flow. In 
a SPECT study of senile AD patients using 99mTc-HMPAO, significant 
reductions in rCBF were found in left and right posterior temporal regions, and 
left temporal and left parietal regions (Montaldi et al 1990). As in the present 
study of younger AD patients, these authors noted that in senile AD patients, 
rCBF was often also reduced in frontal regions. These results are consistent 
with earlier studies and suggest that Alzheimer’s disease pathology may affect 
frontal lobes, although some authors have preferred to consider 'frontal 
dementias’ as a separate nosological entity from AD (Neary et al 1988). 
Prospective studies in which the progression of the brain dysfunction in 
probable AD patients is followed using SPECT or PET, with neuropathological 
examination after death is required to resolve these difficulties.
Quantitative PET studies have shown reduced regional cerebral 
metabolic rates for glucose (rCMRglc), oxygen (rCMR02) and rCBF in 
temporo-parietal cortex in AD of mild-moderate severity (eg Frackowiak et al 
1981; Duara et al 1986). In more severe cases, frontal regions were also 
significantly affected (Friedland et al 1983; Duara et al 1986). The 
percentage changes in regional metabolism revealed by PET in such studies
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are of the same order as the relative changes documented in the present 
study using SPECT. Neuropathological studies of patients with moderate to 
severe AD (section 1.6) show that temporal, parietal and frontal lobes are the 
areas of neocortex most severely affected by neurofibrillary tangles, plaques 
and neuronal degeneration (Pearson et al 1985). This corresponds with the 
effects on CBF seen here and in previous studies.
5.1.4.2 Korsakoff’s Psychosis
There have been few imaging studies of Korsakoff's psychosis. This is, 
to the knowledge of the author, the first employing SPECT and 99mTc-HMPAO. 
The patients in the present study were selected on the basis of operationally 
defined psychopathological features and abstinence from alcohol. There are 
difficulties in ensuring a reasonably homogeneous KOR group (see section 
3.2.2), yet few other studies have attempted to address this problem.
The results of this study show that, unlike in the AD group, relative rCBF 
in posterior temporal areas was maintained in the KOR group. There was 
also little reduction in rCBF in parietal and temporal regions compared with 
healthy controls, and normal flow in basal ganglia. However there was a 
tendency for other areas to show reduced blood flow compared with controls 
with the most marked local trend in higher frontal areas. The probable 
functional significance of reduction in relative flow in this region may be 
supported by its apparent correlation with impairment of cognitive function. 
Victor et al (1971) has reported, that the microscopic pathological lesions in 
KOR are subcortical, with the amnesic syndrome particularly associated with 
lesions of the medial dorsal nucleus and pulvinar of thalamus and mamillary 
bodies. However, in the Victor study some generalised cortical atrophy was 
also noted in 25% of cases and recent studies using x-ray CT imaging also 
suggest that cortical atrophy occurs in KOR (Cala & Mastaglia, 1980; Carlen 
et al 1981). As will be discussed below, cortical atrophy can confuse the
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interpretation of rCBF measures especially if atrophy is regionally selective.
In one autopsy study of alcoholic patients, selective frontal atrophy was 
present in 33% of cases (Harper, 1983). The same author subsequently 
reported marked reduction in frontal white matter and ventricular enlargement 
of approximately 50% (Harper et al 1985), a finding consistent with that from 
the CT studies. Using quantitative counting techniques, Harper et al 1987, 
has also shown a 22% reduction in the number of neurones in the superior 
frontal cortex of alcoholics. In confirmation of these findings, magnetic 
resonance imaging (MRI) studies have demonstrated increased proton spin- 
lattice relaxation time (T1 values) for frontal and parietal white and grey matter 
in KOR patients (Christie et al 1988), a finding which may reflect increased 
tissue water. One hypothesis that links the subcortical and cortical lesions of 
KOR patients is that deafferentation may occur secondary to the destruction of 
sub-cortical projection nuclei. Thus, it is possible that white matter changes 
and/or cortical atrophy, may account for the regional frontal impairment of CBF 
detected in the KOR patients. The ability to align accurately corresponding 
CT or MR images with SPECT should help to resolve the issue of atrophy.
Several studies suggest that cortical rCBF is globally reduced in patients 
who have taken excessive quantities of alcohol over long periods (eg 
Berglund, 1981), and Xe contrast computed tomography (Hata et al 1987) has 
suggested that alcoholic patients have widespread reduction in rCBF 
throughout cortical and subcortical structures. Such flow changes, may in 
part, reflect metabolism, for in a small preliminary study of KOR patients using 
PET, absolute rates of regional cerebral glucose metabolism were reduced in 
cortical and subcortical regions (Kessler et al 1984).
The findings from this, and the other imaging studies described above 
suggest strongly that in KOR, there is not only subcortical damage, but frontal 
pathology also. This is not unexpected when clinical information is 
considered; Korsakoff patients show not only memory impairment but usually
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also changes in behaviour (e.g. apathy, inertia, loss of insight) indicative of 
frontal dysfunction. The frontal changes may also contribute to the amnesic 
syndrome (Moscovitch, 1982), as well as to other cognitive changes. In 
cognitive tests sensitive to frontal lobe lesions, such as verbal fluency and 
category sorting tasks, patients with KOR performed less well than other 
alcoholics and this was related to radiological measures of frontal atrophy 
(Jacobson, 1989).
5.1.4.3 Relationship between patterns of rCBF and
neurpsychological function
The biological measurement, relative rCBF, (similarly net MTT in chapter 
4) is confounded by counting variability, head positioning, head movement, 
ROI identification and the reconstruction algorithm used. Similarly cognitive 
subtest scores are influenced by patient and tester variability on the day when 
the test was administered. Although CAMCOG subtests are designed to 
assess particular areas of cognitive function, it should be recognised that any 
single subtest performance is also influenced by other cognitive functions.
This is a complication of most neuropsychological test batteries and is not 
unique to CAMCOG. Therefore as both the biological and psychological 
measures are imprecise, it was not thought meaningful to test specific 
relationship hypotheses a priori. Examination of general relationships 
between biological function in particular brain areas and cognition offers a 
more cautious approach. This approach to the analysis, together with an 
adjusted significance level to account for multiple comparisons, may generate 
more specific hypotheses to test in future studies.
In both AD and KOR, correlations between neuropsychological function 
and relative rCBF could be demonstrated. In AD, left parietal and left 
posterior temporal regions were correlated with scores on a range of sub-tests 
of CAMCOG. These effects may reflect language dysfunction due to reduced
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rCBF in dominant hemisphere association areas. While previous PET 
studies have shown an association between regional cortical metabolism and 
neuropsychological performance in AD patients, in many studies only 
Alzheimer patients with specific cognitive deficits were selected for inclusion 
(Foster et al 1983, 1986; Chase et al 1987; Martin et al 1986). This 
approach is quite different from that employed in this study, where unselected 
presenile probable Alzheimer patients fulfilling strict clinical diagnostic criteria 
were studied. In other PET studies the association between cognition and 
cerebral blood flow has been examined; eg Frackowiak et al (1981) found an 
association between severity of dementia and flow but did not report regional 
association between neuropsychological function and perfusion. Similarly, 
Ferris et al (1983) also found an association between severity and rCMRglc.
In the present study, associations between specific aspects of cognitive 
performance and rCBF patterns in unselected cases of presenile AD were 
detected. Previous work with PET in presenile patients has produced similar 
evidence of association. Friedland et al (1983) reported that the ratio 
between right frontal and right temporo-parietal glucose uptake in 10 
Alzheimer-type dementia patients was negatively correlated with performance 
subtests on the WAIS. However, this, and their other significant correlations 
were quoted in isolation without the number of correlations performed. In this 
study no left sided associations with language impairment were reported. 
Haxby et al (1985) used right/left asymmetry ratios for 10 early probable AD 
patients and demonstrated poorer language performance in patients with 
relatively decreased left hemisphere function. Preliminary data has also 
appeared on the association between parietal hypometabolism and visual 
memory deficits (Riege et al 1985). It should be noted that PET studies with 
18F-2DG require a much longer duration of cooperation between subjects and 
experimenter than do SPECT studies of the type described here. Thus, 
patients must remain in a constant basal state for up to 45 minutes while the
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label accumulates in the brain, and then remain still for a further variable 
interval while the data continues to be acquired by the camera. Such 
requirements may be difficult to attain in many, if not most, demented patients. 
The findings support the earlier work of Gustafson and Risberg (1974), who 
showed, using intracarotid 133Xe injection, that in dementia organic symptoms 
correlated with estimates of cerebral perfusion in the dominant hemisphere.
5.1.4.4 Effects of atrophy
The finding of regional reductions in tracer uptake could mean that 
normal tissue mass has reduced neuronal activity or that reduced tissue mass 
has normal levels of activity or some mixture of the two. This difficulty arises 
both for absolute estimates of tracer uptake and, as here, for relative estimates 
also. It is by no means established that efforts to measure cortical atrophy 
independently with x-ray CT or MR I are satisfactory; however, when such 
estimates have been made to correct for lobar atrophy, PET studies still 
showed significant impairment of rCBF in temporal lobes in AD (Herscovitch et 
al 1986; Chawluk et al 1987). Nevertheless, it is likely that reduced rCBF in, 
for example, posterior temporal cortex does reflect reduced structure as well 
as reduced function at least at the microscopic level of selective cell loss. In 
KOR, as already described, the evidence suggests that both frontal white and 
grey matter are affected by chronic alcoholism. Therefore, the finding of 
reduced tracer uptake using SPECT in frontal regions could reflect structural 
and/or functional impairment. However, the correlation between impaired 
cognitive performance and tracer uptake into frontal cortex in KOR may be 
more likely to reflect impaired function than simply reduced tissue mass.
There is a need for studies using structural and functional imaging techniques 
to study the contribution of atrophy to functional image impairment. There are 
technical difficulties however in ensuring that scan images from the two
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imaging types are comparable and represent the same brain region or same 
anatomical plane.
5.1.4.5 Conclusion
Although there is no support from this study for the diagnostic utility of 
SPECT, the present results indicate the potential for detecting and following 
the course of differential regional cerebral involvement in AD and KOR, and 
this may have clinical, as well as, experimental utility. The associations 
demonstrated between tracer uptake and cognitive function suggest the 
prospect of investigation of cerebral function in other major psychiatric 
disorders. The potential of SPECT may have to await the development of 
selective ligands either to label receptors or to allow more flexible dynamic 
studies of blood flow and metabolism. The present findings set the scene for 
more dynamic studies of the relationship between performance and neuronal 
activity in the dementias using SPECT or similar techniques. In Chapter 6 this 
approach is further discussed and a number of experiments described that 
demonstrate the potential of 99mTc-HMPAO SPECT for imaging the effects of 
perturbation of basal brain function.
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5.2 Regional cerebral hypofunction In the presence of 'normal'
structure in Creutzfeldt-Jacob Disease
5.2.1 Introduction
It is crucial to progress in the investigation of brain disease that changes 
in brain function can be distinguished from changes in brain mass.
Estimation of functional activity in the brain can be continuously made by 
measuring regional brain metabolism (Sokoloff, 1981). Furthermore, recent 
work has proved that a close relationship exists between regional glucose 
metabolism and regional cortical blood flow (rCBF) under both resting and 
stimulated conditions in the human brain (section 2.1). In other words, rCBF 
is function related and patterns of rCBF can be estimated economically with 
SPECT using the ligand 99mTc-HMPAO (Neirinckx et al 1987). However, 
SPECT, like PET, is subject to partial volume artefacts such that loss of brain 
tissue may result in reduced apparent rCBF or metabolism in affected brain 
regions. This problem may be marked for changes measured in Alzheimer’s 
disease (AD) and has cast doubt on the reliability of metabolic or rCBF 
measurements for estimating regional brain function (Herscovitch et al 1986; 
Chawluk et al 1987).
Creutzfeldt-Jacob disease (CJD) is a rare transmissable dementia that 
can be diagnosed with certainty only at post mortem by histological 
identification of characteristic spongiform degeneration of brain. 
Investigations, and in particular the electroencephalogram (EEG) and x-ray 
computed tomography (CT) are often normal until late in the course of the 
disease (Kuritzky et al 1980; Galvez & Cartier, 1984; Keshaven et al 1987). 
This structural preservation alongside gross functional impairment suggests 
that imaging of rCBF with SPECT in CJD may offer an unusual opportunity to 
highlight the utility of SPECT to distinguish between loss of structure and loss 
of function in the brain.
5.2.2 Case history
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5.2.2.1 Clinical findings
A 66 years old retired electronics worker was referred by his GP for 
investigation of increasing forgetfulness which had become noticeable over 
six months. When first seen in December 1986, he complained of episodes of 
memory loss when he would forget what he was talking about. He was fully 
orientated but unable to recall the name of the Prime Minister or US President. 
He could not give his date of birth or the dates of World War 2, but did 
remember that he had served in the Army Dental Corps where he had worked 
as a dental mechanic. He showed moderate nominal dysphasia and poor 
memory for recent events. There was no left-right disorientation and he 
satisfactorily drew a complex geometric shape. He scored 21 out of a 
possible score of 30 in the Mini-Mental State Examination (MMSE) (Folstein et 
al 1975).
He had no other complaints and was leading a fairly normal retired life. 
Two years previously he had undergone prostatectomy for benign prostatic 
hypertrophy and recovered satisfactorily. He had been treated by his GP for 
mild angina pectoris for ten years, but there was no history of myocardial 
infarction or cerebrovascular disease. His only medication was propranolol 
20mg and isosorbide dinitrate 30mg per day.
Physical examination was normal and in particular there were no focal 
neurological signs or evidence of hypertension or other cardiovascular 
abnormality. The following investigations were all normal: full blood count, 
ESR, serum electrolytes, renal, thyroid and liver function tests, blood glucose, 
syphillis serology, serum B12 and folate. Electrocardiogram, chest and skull 
radiology and EEG were within normal limits for his age. X-ray computed 
tomography (CT) in February 1987 showed that the ventricular system was 
normal with no evidence of cerebral atrophy (Figure 5.7). The most likely
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diagnosis on this evidence was dementia of presenile onset probably of 
Alzheimer type.
He was reviewed in March 1987 when further significant deterioration 
was noted; he was now perseverative in answering questions, had great 
difficulty in remembering his home address and could not name simple 
objects or describe their use. There was evidence of right-left disorientation 
and he was unable to draw simple objects, such as a house. MMSE score 
was 9/30. One month later he was assessed at home where he needed 
continual help with bathing, toileting, feeding and dressing. Although still fully 
mobile he was noted to have a shuffling gait and difficulty climbing stairs.
In May 1987 he was admitted to the Brain Metabolism Unit for further 
investigation. He was agitated and unable to cooperate with even simple 
forms of psychological testing. It was difficult to follow his speech as he now 
had marked expressive and receptive dysphasia. His behavioural disability 
in the ward was assessed daily using the Behavioural Rating Scale of the 
Clifton Assessment Procedures for the Elderly (CAPE) (Pattie & Gilleard,
1979). Whereas an independent, fit elderly person would be expected to 
score 0-3, our patient had daily scores ranging from 17-23 consistent with 
severe impairment and maximum dependence.
Single photon emission computed tomography (SPECT) was carried out 
using 99mTc-HMPAO in early May 1987, and showed marked reduction in the 
tracer uptake throughout the grey matter of the cerebral cortex especially in 
frontal regions (Figure 5.8). This was qualitatively obvious but was also 
confirmed quantitatively by determining count density relative to occipital 
cortex. Quantitative estimates of relative flow in frontal regions were 
calculated and compared to that of age matched controls (eg see Table 5.2), 
showing marked reduction: right high frontal 0.55 (normal range 0.88-1.40); 
left high frontal 0.51 (normal range 0.91-1.46). These images of function are 
in striking contrast to the normal x-ray CT images (Figure 5.7). Over the next
Figure 5.7 CT images of patient with Creutzfeldt-Jacob
disease
X-ray computed tomography scans, in a plane +40mm (lower 
image), and +80mm (upper image) above the orbito-meatal line, 
showing details of brain structure in patient with Creutzfeldt-Jacob 
disease.
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Figure 5.8 SPECT images of patient with Creutzfeldt-
Jacob disease
Transverse sectional SPECT images at +30mm (first image) and 
+70mm (second image) superior to the orbito-meatal line for 
patient with Creutzfeldt-Jacob disease
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few months the patient deteriorated further and he died at home in October 
1987, ten months after initial presentation. As the course of the illness had 
been rapid, a diagnosis other than AD was anticipated and post mortem brain 
examination was performed.
5.2.2.2 Neuropathological findings at necropsy
The brain weighed 1320 grams at macroscopic examination, and was 
remarkably normal in appearance. No abnormality of dura or leptomeninges 
was noted and the superior longitudinal sinus was patent. The arterial system 
was also normal apart from patchy atheroma. The cerebral hemispheres 
externally and on coronal sectioning showed only mild generalised atrophy 
and the lateral ventricles slight dilatation. There were no focal abnormalities 
in cortex, white matter or basal ganglia and brain stem, cerebellum and spinal 
cord were all normal in appearance.
After fixation, blocks from every brain region were examined 
microscopically. Widespread, severe neuronal depletion and vacuolation 
with rod cell infiltration and astrocytic gliosis was noted throughout the 
cerebral cortex. Spongiform degeneration was most striking in the supra- 
medial border of the frontal lobes bilaterally. The basal ganglia, particularly 
putamen and caudate, were also affected but the hypothalamus was relatively 
normal. The cortico-spinal tracts were also severely affected but mid-brain 
showed no evidence of involvement.
In summary, the neuropathological findings were consistent with a 
diagnosis of Creutzfeldt-Jacob Disease and excluded other causes of 
dementia.
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5.2.3 Discussion
Since most investigations in this patient were normal, the rapidity of 
deterioration was the only real clinical clue to diagnosis. Even in advanced 
CJD, x-ray CT imaging is often normal and poorly correlated with clinical 
condition (Galvez & Cartier, 1984). In this case the CT appearances were 
entirely consistent with the normal macroscopic appearance of the brain at 
post mortem. On the other hand, the cross-sectional SPECT images, at 
comparable levels, were grossly abnormal and quite atypical of other 
dementias such as Alzheimer's or Korsakoff's disease (eg Figures 5.5 and 
5.6). Unlike the EEG or CT findings, SPECT imaging suggested a severe and 
widespread disorder of brain function.
The reduced rCBF in frontal cortex detected by SPECT in this patient is 
likely to reflect reduced neuronal metabolism because the histological findings 
at post mortem demonstrated widespread microscopic evidence of CJD 
pathology, especially in frontal lobes, but there was no important change in 
tissue mass. It has been suggested that functional imaging techniques such 
as SPECT and PET merely reflect cortical atrophy (Herscovitch et al 1986), 
and at least in Alzheimer's disease, reduced function and atrophy may often 
be co-localised. However, this case illustrates that estimation of regional 
brain function with SPECT can provide additional information when structural 
brain imaging is apparently normal or at least not grossly abnormal and 
macroscopic brain structure apparently preserved.
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CHAPTER 6
USING SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY 
TO STUDY THE EFFECTS OF INTERVENTION ON CEREBRAL
FUNCTION
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6.1 Cerebral pharmacodynamics of physostigmine in
Alzheimer's Disease investigated using 99mTc-HMPAO
SPECT imaging 
6.1.1 Introduction
There is compelling evidence from many different studies (Perry, 1986; 
Rossor et al 1984; Sims et ai 1983) linking cholinergic neuronal function and 
memory. Thus, the cholinergic hypothesis of dementia attributes cognitive 
impairment to defects in the synthesis of acetylcholine (ACh) in central 
cholinergic neurones (Davies & Maloney, 1976; Davies, 1979). Support for 
this hypothesis comes from post-mortem neurochemical studies of Alzheimer's 
disease (AD) which have shown a marked reduction in choline acetyl 
transferase (ChAT), the rate limiting enzymic step for the synthesis of ACh 
(Bowen et al 1983), and also confirmed the reduced production of ACh in 
such patients (Richter et al 1980). Accordingly there has been considerable 
interest in pharmacological treatment strategies aimed at facilitating 
cholinergic function. Although three types of strategy are possible, 
(precursor-loading, inhibition of ACh catabolism, and the use of cholinergic 
receptor agonists), the more successful results have been obtained using 
cholinesterase inhibitors to enhance central cholinergic function, and there 
have been several reports of improved memory/cognition following 
administration of the anticholinesterase physostigmine (Christie et al 1981; 
Davis & Mohs, 1982). Another anticholinesterase drug, 
tetrahydroaminoacridine (THA), which may act in a similar way to 
physostigmine, also appears to improve memory/cognition in Alzheimer's 
disease, (Summers et al 1986; Byrne & Arie, 1989) and has renewed interest 
in the use of pharmacological strategies to improve cognitive function in 
Alzheimer patients (Whalley, 1989).
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Unfortunately, psychological assessment of improvement in demented 
patients is difficult because exhaustive batteries take so long to administer 
while short tests, for example of memory function, may show prominent floor or 
ceiling effects. Hence there can be many reasons for the failure of such tests 
to show an improvement, apart from simply lack of drug efficacy. In part, this 
must contribute to the inconsistent results reported from drug studies (Stern et 
al 1987). There is, therefore, a need for methods of assessing drug action 
which are more biologically based and hence less susceptible to the 
difficulties associated with current psychological test batteries.
Single photon emission tomography using the blood flow marker, 
HMPAO, permits regional patterns of cerebral blood flow (rCBF) to be 
measured in vivo. In chapters 2 and 5 evidence is presented suggesting that 
the reductions in rCBF in dementia are quantitatively related to deficits in 
neuropsychological function, therefore SPECT, by evaluating functional 
effects in brain, may provide a useful quantitative adjunctive measure of drug 
action. The aim of this study was to use SPECT imaging to examine the 
effects of administration of physostigmine in demented patients. In particular 
five specific hypotheses were investigated in the study:
1) As rCBF usually reflects underlying neuronal metabolism, the effect of 
physostigmine will be to increase cerebral uptake of 99mTc-HMPAO.
2) As the pattern of functional impairment in AD is focal, the effects of 
physostigmine may be regional.
3) Furthermore as cognitive functions tend to be lateralised, 
physostigmine may change left / right asymmetry patterns.
4) Physostigmine requires an intact cholinergic system, pre and post- 
synaptic for drug action; accordingly there will be a consistent 
relationship between change in relative 99mTc-HMPAO uptake after 
physostigmine and basal uptake patterns.
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5) An association may exist between cognitive impairment and the pattern 
of relative uptake after physostigmine, such that less impaired patients and/or 
those with short illness duration will show larger increases in relative uptake.
6.1.2 Methods
6.1.2.1 Study design
The study had two complementary phases:
(1 ) Preliminary Dose-Finding Phase.
In the first phase, patients' cognitive performance was assessed double 
blind on three separate test occasions, with a different physostigmine dose 
(0.5mg, 0.375mg and placebo) on each occasion. Before and after each test 
infusion a short battery of tests, designed for assessing the psychological 
effects of drugs, was administered to each subject (Wesnes et al 1987). To 
avoid practice effects parallel forms of this test battery were used. Each 
patient had one practice session and was then tested before and after each 
infusion. Using this phase of the study, that dose which produced the 
maximum increase in cognitive performance was determined and used in the 
second phase. Where no change could be detected the higher dose (0.5mg) 
of the drug was employed.
(2 ) Single photon emission tomography after drug infusion
In the second phase which was single-blind, patients had SPECT brain 
imaging on two separate occasions, once after a saline infusion containing 
that dose of physostigmine chosen from preliminary testing, and on a different 
occasion (one week interval), with a saline infusion containing no drug. In the 
test retest SPECT reliability study, described in section 6.2 (see Table 6.7), no 
significant change in " mTc-HMPAO uptake was found when patients had a 
repeat scan after one week. Apart from the presence or absence of active 
drug, test conditions were identical on each of the two SPECT test occasions.
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The order in which patients received physostigmine and placebo infusions 
was randomised between patients. On both test days, patients were pre­
treated with methylscopolamine to prevent the peripheral actions of the 
anticholinesterase.
6.1.2.2 Patient selection
Seven patients with a diagnosis of probable pre-senile Alzheimer's 
disease were recruited into the study and are described in the Table 6.1. All 
patients met agreed criteria for probable Alzheimer's disease as laid down by 
National Institute of Neurological and Communicative Disorders Stroke 
(NINCDS) and Alzheimer's Disease and Related Disorders Association 
(ADRDA) (section 3.2.1). All patients met criteria for right handedness 
(section 3.2.4). The Cambridge Mental Disorders of the Elderly Examination 
(CAMDEX) was completed for all patients in the study (section 3.4).
6.1.2.3 Single photon emission computed tomography
All subjects were studied at the Institute of Neurological Sciences, 
Southern General Hospital, Glasgow using single photon emission 
tomography (SPECT) and the tracer 99mTc-HMPAO. This agent shows high 
fractional uptake into brain and its distribution reflects regional cerebral blood 
flow (section 2.2.5.1; Neirinckx et al 1987). Its retention in brain without 
apparent redistribution for many hours, allows a ‘snap-shot’ image of cerebral 
blood flow pattern to be determined at a particular interval in time such as 
during drug infusion.
HMPAO was used as described in section 3.6. Injection of HMPAO 
was administered 20 minutes after the start of drug infusion, in a quiet room 
with subjects resting, eyes closed and ears unplugged. Imaging was carried 
out within 30-60 minutes using the Novo 810 brain SPECT system. Internal 
landmarks were used in the final definition of the ‘low’ (usually at +30mm
TABLE 6.1
Description of Alzheimer patients imaged after physostigmine
Patient Age Sex Duration CAMTOTAL Physostigmine 
No. (years) Dose (mg)
1 65 F 6.0 39 0.375
2 57 M 1.5 66 0.375
3 55 F 2.5 58 0.375
4 62 F 6.0 40 0.500
5 58 M 6.5 40 0.375
6 60 F 1.5 77 0.375
7 58 F 3.0 55 0.500
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above the OM line) and ‘high’ (usually at +70mm above OM line) slices. 
Symmetrical paired regions of interest (ROIs) were defined, representing 
frontal, temporal, posterior temporal, occipital and basal ganglia on the low 
slice, and high frontal and parietal on the high slice. These are illustrated in 
Figure 3.7.
6.1.2.4 Comparison of amount of HMPAO within ROIs
The technique of SPECT imaging with HMPAO provides measurements 
of the pattern of CBF distribution and not absolute values of CBF. Data 
normalisation is therefore necessary when making comparisons within 
groups. Two methods were used in this study: 1) adopting white matter 
(WM) as a control region and calculating the ratio of mean counts within 
cortical regions to mean counts within the WM region and 2) using an 
asymmetry index (Al), which is defined as the ratio of counts in each left sided 
ROI divided by the counts in the corresponding right sided ROI.
Method 1 The cortical/WM ratios
The amount of 99mTc-HMPAO in grey matter (GM) and white matter 
(WM) ROIs was determined as described above in 6.1.2.3. A special colour 
scale was developed to highlight contrast in low count regions, such as WM, 
and this was used consistently throughout the study. The WM ROI was 
outlined medial to high frontal cortex. A fronto-parietal GM ROI was also 
examined that encompassed both the high frontal and parietal ROIs of the 
high slice, as shown in Figure 3.7. The ROIs were outlined blind as to 
whether placebo or physostigmine images were being analysed and the order 
of analysis of images was random. The mean count density within the WM 
ROI was measured and then corrected using the equation,
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W* = W - C/3
where W  = true count density of HMPAO in WM
W = measured count density of HMPAO in WM (which is 
affected by scatter) 
and C = measured count density of HMPAO in adjacent high
frontal cortex.
This equation was derived empirically using a physiologically realistic 
phantom which was filled with known concentrations of radioisotope (Wyper et 
al 1988). This procedure was used in order to give more accurate 
cortical/WM ratios, but the data was also analysed with no correction factor 
applied and the significance levels for change in this ratio during placebo and 
physostigmine conditions remained valid. Cortical/WM ratios during placebo 
and physostigmine infusions were approximately normally distributed and 
were therefore compared using Student's paired t-test (two-tailed).
Hypotheses were also investigated using Pearson’s product moment 
correlational method.
Method 2 The asymmetry index (Al)
The Al was used because it is a robust measure of asymmetrical 
change in pattern, and therefore suited for the detection of such changes after 
physostigmine. In order to ensure that both left and right ROIs had the same 
area for analysis of counts, the ROI drawn on one side of the brain image was 
automatically mirrored on to the other side. The Al was defined as the ratio of 
counts in each left sided ROI to the counts in the corresponding right ROI. 
Asymmetry indices during placebo and physostigmine infusions were 
approximately normally distributed and were compared using Student's 
paired t-test (two-tailed).
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6.1.2.5 Physostigmine infusion
All patients were given 0.2mg of methylscopolamine subcutaneously 20 
minutes before the start of the infusion in order to antagonise peripheral 
muscarinic receptors, as methylscopolamine does not cross the blood brain 
barrier. The order in which patients received physostigmine and placebo, 
was randomised between subjects. Both the placebo and physostigmine 
infusions were administered intravenously via a forearm cannula and the rate 
of flow controlled using an I VAC volumetric control pump to ensure delivery of 
the 100ml volume over 30 minutes. The dose of physostigmine (Table 6.1) 
was administered in a volume of 100ml of normal saline, and prepared by the 
Pharmacy Department of the Royal Infirmary of Edinburgh such that the 
investigator was blind to whether physostigmine had been added to or omitted 
from the infusion on each of the two test occasions. Electrocardiographic and 
blood pressure measurements were monitored throughout the test 
procedures.
6.1.3 Results
Physostigmine infusions were well tolerated by all patients. The only 
detected side effect was dry mouth, which probably reflects effective 
peripheral muscarinic blockade by methylscopolamine. Measurements of 
heart rate and blood pressure remained constant throughout infusions of 
saline or physostigmine and for all patients recordings were similar in both 
conditions.
Table 6.1 shows the age and sex characteristics of the group. Also 
shown in Table 6.1 is the estimated duration of dementia for each patient 
(mean duration 3.9, range 1.5 to 6.5 years) and total CAMCOG (CAMTOTAL) 
score (mean 54, range 39 to 77).
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Table 6.2 shows the mean uptake of 99mTc-HMPAO in bilateral frontal, 
temporal, posterior temporal, high frontal, parietal, occipital and basal ganglia 
regions expressed relative to uptake in white matter, for placebo and 
physostigmine conditions. There were significant increases in relative 
HMPAO uptake in the physostigmine condition compared with placebo in left 
frontal (t = - 3.76, P <0.01), left temporal (t = - 3.86, P = 0.01), left high frontal 
(t = 3.85, P < 0.01) and left basal ganglia regions (t = -3.72, P = 0.01).
Although in all other ROI’s there was a consistent trend for more uptake in the 
physostigmine condition, this did not reach significance at the P = 0.01 level.
Table 6.3 compares the left / right ratio of HMPAO uptake (asymmetry 
index, Al) in placebo and physostigmine conditions in frontal, temporal, 
posterior temporal, basal ganglia, high frontal, parietal and occipital regions. 
Significant increases in Al occurred in frontal (t = -4.95, P < 0.004), high frontal 
(t = -4.29, P = 0.005) and basal ganglia (t = -4.12, P = 0.006). Increases in Al 
may represent increased HMPAO uptake on left side or decreased uptake on 
the right side. However the increase in cortical / white matter uptake ratios 
after physostigmine (Table 6.2) suggests that increases in Al are due to 
increased perfusion in left sided regions.
The hypothesis that change in relative HMPAO uptake after 
physostigmine may be a function of basal relative uptake was tested using 
Pearson’s correlation coefficients; the correlations are shown in Table 6.4. 
There were no significant associations at P < 0.01. In addition the absence of 
a clear correlation trend provides little support for the hypothesis. CAMTOTAL 
score and illness duration were significantly negatively associated (Pearson’s 
r = - 0.952, P < 0.001). There were no significant associations between 
change in relative HMPAO uptake after physostigmine for any ROI, and 
CAMTOTAL score or duration of illness (Table 6.5). Similarly there were no 
significant associations between Al in either placebo or physostigmine 
conditions and CAMTOTAL or ilness duration (Table 6.6)
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6.1.4 Discussion
The results of this study suggest that changes in brain function, 
produced using specific cholinergic stimulation can be localised in vivo using 
SPECT functional imaging. However as the number of patients studied in this 
experiment was small, results should be interpreted with caution.
6.1.4.1 Effects of physostigmine
It is unlikely that the changes in rCBF pattern observed in this study 
were simply due to non-specific vasodilation by physostigmine for, in a study 
in which CO2 was used to produce vasodilation of central vessels, blood flow 
to cortex and white matter increased (Davis et al 1983). As Table 6.2 shows, 
cortical/white matter ratios increased after physostigmine, significantly in left 
frontal/temporal regions, supporting the view that the observed increases in 
flow were due to a specific effect in grey matter.
There was no support from the results for the hypothesis that change in 
HMPAO uptake after physostigmine may be a function of basal uptake 
patterns (Table 6.4). In order to have a pharmacodynamic effect, 
physostigmine requires that acetylcholine is synthesised and released from 
the presynaptic terminal and has available postsynaptic receptor and 
catabolism system. Histochemical studies suggest that the presynaptic 
synthesis and release of acetylcholine is reduced in AD (Richter et al 1980; 
Bowen et al 1983). In such conditions where the intact metabolic substrate 
does not exist, it is perhaps not too surprising that no clear association exists 
between basal function and physostigmine-related function. However the 
number of subjects studied was small and larger numbers are needed to 
confirm this finding.
A related hypothesis that an association would exist between degree of 
cognitive impairment, as indicated by CAMTOTAL or duration of illness, and
Ii
j
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HMPAO uptake after physostigmine was also investigated. Consequent upon 
the assumption that an intact metabolic substrate is required, it might be 
expected that less cognitively impaired patients, with higher CAMTOTAL 
scores or shorter durations of illness might show relatively greater increases in 
uptake. However no such association was detected for either CAMTOTAL or 
duration (Table 6.5), although there was a trend for longer illness durations to 
be associated with greater increases in HMPAO uptake after physostigmine. 
Support for this finding comes from a similar study where physostigmine had 
no effect on HMPAO uptake in brain regions in eight healthy controls 
(Geaney et al 1990). In this study there was also a trend for the more 
cognitively impaired patients to show the greatest increase after 
physostigmine. These findings challenge the hypothesis that AD patients 
who are less cognitively impaired may show greater relative rCBF changes 
after physostigmine. However as the numbers in the present study (n = 7) 
and the Geaney et al study (n = 8) are small, all such conclusions must be 
tentative. Nevertheless the results suggest that a larger study of rCBF 
responsiveness to physostigmine may usefully clarify its relationship with 
cognitive function.
This method of analysis using a WM reference area, should be 
considered only with imaging devices of relatively good spatial resolution 
(preferably less than 10mm), such as the Novo 810. The two principal 
sources of error were a) the difficulty in outlining a region which contains only 
white matter and b) the effect of scattered radiation emanating from 
surrounding cortical regions where the radioactivity concentration is much 
higher, on measured count density within a low count ROI. These errors were 
minimised using empirically derived procedures and the correction factor 
described in the methods section, although even before correction for errors in 
this way, similar significant increases in fronto-parietal cortical/WM were also 
detected. As patients were tested on two separate occasions, a week apart, it
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is possible that matching of slices or regions may not always have been 
optimally achieved. Matching of slices and selection of regions was done by 
a technician experienced in SPECT imaging and blind to study conditions. 
The effect of mismatching of regions between conditions would be to increase 
variance and reduce the detection of differences in HMPAO uptake. It was to 
improve matching of regions between different conditions that the ‘split-dose’ 
approach of section 6.2 was developed.
It has also been shown in animals that rCBF increases after 
physostigmine, and that this is paralleled by corresponding increases in 
regional cerebral oxygen consumption (rCMR02) (Hoffman et al 1986). This 
suggests that the coupling relationship between flow and metabolism is 
maintained after physostigmine. Other animal studies show that after 
physostigmine there are similar increases in local cerebral glucose utilization 
(Nelson et al 1978; Friedland & Meibach, 1981; Dam & London, 1983). The 
nature of the coupling of rCBF and metabolism is complex and poorly 
understood, but there is evidence that cholinergic mechanisms may have an 
important role (Sokoloff, 1959; Scremin et al 1973). The abundant 
cholinergic innervation of the cerebrovasculature, could provide a mechanism 
whereby changes in cholinergic function are reflected in rCBF changes.
In humans, studies using PET show that rCBF and cerebral metabolism 
are intimately coupled, under both resting (Frackowiak et al 1981) and 
activated conditions, and that rCBF closely reflects regional glucose 
metabolism (Fox et al 1988). Therefore, the changes in rCBF detected after 
physostigmine in this study probably reflect changes in metabolic function. 
However little is known about the effect of cholinomimetics, such as 
physostigmine, on brain metabolism as only recently have techniques, such 
as PET and SPECT become available to undertake such studies. Using the 
133xenon inhalation planar imaging technique for examining cortical flow 
(section 2.2.3.3), Gustafson et al (1987) showed that small increases in
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temporo-parietal rCBF occurred after physostigmine. Although limited in 
being non-tomographic and measuring only surface cortical activity, the 
results are consistent with the present SPECT study.
Post-mortem studies suggest that there are no consistent or substantial 
changes in post-synaptic muscarinic receptor number in AD (Palacios, 1982; 
Davies & Verth, 1978), and this does not appear to be an artefact related to the 
agonal state or changes after death. SPECT imaging in AD patients using 
123lodo-QNB, a ligand for muscarinic receptors, has suggested that increased 
numbers of receptors may occur in non-atrophied areas of cortex but reduced 
numbers in areas of severe atrophy (Weinberger et al 1989). In relation to the 
use of drugs that potentiate cholinergic function, such as physostigmine, a key 
question for future investigations is do muscarinic receptors function normally 
in AD? Unfortunately, in vitro measurement of receptor function in autopsy 
specimens is technically difficult, and results have been unsatisfactory (Perry,
1986). This emphasises the potential advantage of the experimental 
approach of using SPECT to image functional changes in vivo after 
physostigmine.
6.1.4.2 Functional asymmetry after physostigmine
Alzheimer’s disease is usually described as a disorder associated with 
diffuse atrophy of the cerebral cortex (Tomlinson & Corsellis, 1984). Post­
mortem and biopsy studies of Alzheimer patients show that there are marked 
cholinergic deficits in frontal and parieto-temporal cortex (Davies & Maloney, 
1976; Bowen et al 1983; Sims et al 1983), but there appears to be no 
consistent neuropathological or neurochemical involvement of any one 
hemisphere (Rossor et al 1984). However only a few post-mortem studies 
have compared left and right sides in AD, as traditionally one side of brain is 
examined neurochemically, and the other morphologically. The few studies 
that have compared left and right sides, have reported left-right differences in
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density of plaques and tangles (Moossy et al 1985), and neurochemical 
deficits (Rossor et al 1982). Such pathological evidence is consistent with 
neuropsychological findings, that show asymmetrical patterns of cognitive 
dysfunction in AD, especially in the earlier stages (Haxby et al 1985, 1986;
Huff et al 1987; Becker et al 1988). Similarly, although a symmetrical pattern 
of regional deficit in blood flow has been observed under resting, non­
stimulated conditions with PET (Frackowiak et al 1981) and SPECT (Chapter 
5) imaging, there is evidence of lateral asymmetry in cerebral glucose 
utilization in AD patients with either marked language or visuospatial cognitive 
deficits (Haxby et al 1985,1986). It has also been reported that the left 
hemisphere may be more affected in AD (Rossor et al 1982; Friedland et al 
1985; Haxby et al 1985,1986). This was not confirmed in a recent post­
mortem study of AD, although subtle asymmetries of plaque and neurofibrillary 
tangle distribution and cholinergic enzyme activity did occur (Moossy et al 
1989). In normal brain, ChAT activity is reportedly higher in left temporal 
cortex than right, although it was not possible to decide whether this was due 
to structural or functional differences between the two sides (Amaducci et al 
1981). The asymmetric activation seen in the present study (Table 6.3) may 
reflect a functional, rather than structural change, as left/right ratios of CBF 
changed only after physostigmine, and not during basal conditions. Two 
other studies have examined the effect of physostigmine on rCBF patterns in 
AD (Gustafson et al 1987; Geaney et al 1990). Interestingly both have also 
demonstrated greater apparent increases in left hemispheric CBF compared 
with right. In the present study, left/right ratios of HMPAO uptake (asymmetry 
index, Al) were not significantly correlated with CAMTOTAL or illness duration, 
basal or physostigmine conditions (Table 6.6). Further studies with larger 
numbers of patients are needed to confirm this apparent increase in Al after 
cholinergic stimulation. Such studies should also investigate whether the 
putative CBF asymmetry reflects an ‘asymmetric’ or focal change in cognition.
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In presenile Alzheimer patients there is marked association of rCBF in 
left temporo-parietal cortex and attention/language function (chapter 5) and 
this suggests that the left sided cortical activation produced by physostigmine 
in the present study may involve similar left brain cognitive processes. 
However in the present study, patients were scanned under basal conditions, 
and therefore attention and arousal may be the more likely psychological 
functions involved. EEG brain mapping using DUP 996, a phenylindolinone 
that enhances the release of ACh in brain nerve terminals, shows attenuation 
of slow activity and increased alpha activity, normally associated with 
increased vigilance (Saletu et al 1989). Further evidence for the role of the 
cholinergic system in arousal is that physostigmine antagonises decreases in 
rCBF and rCMR02 caused by the sedative benzodiazepine, midazolam, 
probably by a central stimulatory action rather than a competitive effect at the 
benzodiazepine receptor (Hoffman et al 1986). It is therefore possible that, in 
the present study, physostigmine may have facilitated increased cortical 
vigilance by increasing brain ACh levels and the functional consequence of 
this was increased blood flow in left cortex relative to right.
Although there was a trend for an increase in left/right asymmetry in all 
regions, the magnitude of this effect reached significance only in frontal and 
high frontal cortical areas (Table 6.3). While the effect of physostigmine could 
be more specific in frontal areas, an alternative possibility is that after 
physostigmine, asymmetry increased in many brain regions (Table 6.3), but 
the measurement of this change only reached significance in frontal regions 
due to better reproducibility of head positioning in that region. This is 
supported by evidence from the reproducibility studies (section 6.2.5.2), in 
which Alzheimer patients who were scanned on two occasions a week apart 
under identical conditions, showed less variance in frontal areas compared 
with other brain regions.
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6.1.4.3 Evaluation of anti-dementia drugs
One of the difficulties in evaluating putative ‘anti-dementia’ compounds, 
such as physostigmine, is the lack of objective biological measures of effect in 
brain. Until recently few valid measures apart from clinical ratings were 
available. Although clinical indicators are clearly important, there are several 
disadvantages in their use. For instance, not all patients with AD have the 
same pattern of functional disabilities; it is this which may partly determine 
how well a patient is able to perform a given task, and not simply the global 
severity of Alzheimer pathology. This is perhaps most apparent in rating 
demented patients with communication or praxic difficulties. Impairment of 
concentration also affects how well patients perform a test, and consequently 
the manner in which the test is presented to a patient, for example as a whole 
or in sections, together with the consistency of the rater's testing technique in 
this regard, will influence the results. Another source of error in the use of 
rating scales for assessing demented patients is the large component of 
subjective clinical judgement involved which may vary between raters. These 
difficulties are perhaps even more important when rating scales are used to 
assess clinical change resulting from therapeutic intervention, as the multiple 
application of a test to the same patient requires parallel test forms with 
increased chances of compounding errors. Finally, patients who are severely 
affected by the disease and difficult to test may be excluded from clinical 
studies and thus it is possible that studies biased towards ‘testable’ patients 
may be misleading.
It follows that there may be important advantages in using biological 
measures of psychotropic drug action in humans to complement clinical rating 
measures. Regional CBF, with its intimate relationship to cerebral 
metabolism, may provide an important biological measure of 
pharmacodynamic effect, and one which has been used very successfully in 
animal models (Sokoloff 1981). This study using SPECT imaging with the
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tracer 99mTc-HMPAO to measure relative rCBF demonstrates that such an 
approach in patients is feasible, and may provide a useful way of evaluating 
the central actions of drugs, such as physostigmine, reputed to have beneficial 
effects in demented patients.
6.2 A SPECT technique to measure changes in rCBF produced 
by short term intervention using a ‘split-dose’ of "m T c-  
HMPAO: Test retest reliability studies
6.2.1 Introduction
This purpose of this section is to describe a method that allows SPECT 
imaging to be used to investigate basal and stimulated patterns of rCBF during 
a single imaging session, using a ‘split-dose1 of the flow tracer 99mTc-HMPAO. 
In addition to assessing the reliability of this split-dose method, a series of test 
retest reliability experiments are also described that examine the components 
contributing to the overal variance: statistical noise, positioning of regions of 
interest (ROIs) during analysis, positioning of patients, patient movement, and 
physiological changes between measurements which are not associated with 
deliberate challenge.
The reproducibility of the split dose method was also compared with serial 
SPECT scanning at an interval of one week, as used in section 6.1 to examine 
the effect of physostigmine.
Technetium-99m labelled hexamethyl propyleneamine oxime 
(99mjc- HMPAO) has been developed as an agent for imaging cerebral blood 
flow using SPECT (Neirinckx et al 1987). The characteristics of the molecule 
that allow it to achieve this aim have been discussed in section 2.2.5.1. 
99mxc_HMPAO has been validated against a number of other cerebral blood 
flow techniques including 133Xenon (Andersen et al 1988b), positron
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emission tomography (Yonekura et al 1988; Inugami et ai 1988) and 
microspheres (Pupi et al 1989) in humans and 14carbon labelled 
iodo-antipyrine autoradiography (Bacciottini et al 1989; Bullock et al 1989) in 
animals. The images obtained with " mTc-HMPAO demonstrate cerebral 
blood flow both in normal and in pathological states (Bullock et al 1989). The 
exact relationship between " mTc-HMPAO and CBF is non-linear (Lassen et 
al 1988) because of the partial washout of the tracer, which becomes of 
increasing importance at higher flows. In theory, above a certain flow level, 
net uptake may fail to increase as the flow increases but this has not, so far, 
been demonstrated in humans, even in hyperperfused areas. At low and 
moderate flows, as occur in AD or KOR, an essentially linear relationship can 
be assumed (Lassen et al 1988).
SPECT can be carried out using a dedicated SPECT neuroimager or a 
rotating gamma camera. There are several types of dedicated imager, such 
as the Novo 810 used in these studies, but the important common feature of 
these instruments for the technique described below, is that they are able to 
acquire data for single slice reconstruction (or multiple slices in the case of 
multi-planar instruments) in a short interval of time (of the order of 5 minutes).
6.2.2 Advantages and limitations of 99mTc-HMPAO-SPECT
The trapping model for 99mTc-HMPAO uptake allows scanning to take 
place over an extended time period after administration of the 
radiopharmaceutical. This is a considerable advantage of the method, for it 
enables brief states such as ictal episodes to be studied (Duncan et al 1990). 
However the advantage of the trapping procedure is also a limitation in 
situations where we wish to study changes in rCBF after some form of 
intervention. As a result the technique has largely been limited to imaging 
basal states (eg chapter 5) or to capture relatively brief phenomena. Repeat 
studies require a time interval of at least 24h for isotope decay and clearance,
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and it is therefore technically very difficult to use the radiotracer in situations 
where change is occurring over short time periods. This is a serious 
limitation of 99mTc-HMPAO as response to challenge, either physiological (eg 
CO2 inhalation), pharmacological, physical (eg digit movement), or cognitive 
(eg mental testing), is often of greater interest than resting flow patterns.
6.2.3 99mTc-HMPAO SPECT imaging of changes in rCBF: 
rationale and outline of split-dose method
In order to overcome these limitations a different protocol for 99mro 
HMPAO use has been developed, which extends its application for use in 
rapidly changing situations. The technique is conceptually simple, but 
demands careful attention to detail in practice. The general approach used is 
to administer 99mTC-HMPAO in two doses which in total amount to the normal 
dose of tracer and radiation (500 MBq), hence the term ‘split-dose’ technique. 
An initial 25% dose of 99mjc-HMPAO is administered, before the challenge, in 
order to image basal CBF, while during the challenge the remaining 75% 
dose of 99mTc-HMPAO is given to image CBF during the challenge. The 
experimental paradigms using this approach are shown in Figures 6.1a and
6.1 b. It follows from the trapping model that the initial scans reflect the 
distribution of 99mTc-HMPAO in the minute or so following intravenous 
injection and not the distribution at the time of scanning. Similarly, the second 
scan reflects the distribution of tracer at the time of 75% dose injection and it is 
therefore essential that the second injection is given at the time of maximum 
effect produced by the intervention. This can be illustrated by considering the 
approach used to image the effects on rCBF of administration of some 
pharmacological agent (see Figure 6.1b). The initial injection of 25% tracer 
establishes CBF patterns at that time. The drug challenge can then be 
administered but baseline imaging need not be undertaken until just before
Figure 6.1 Split-dose HMPAO SPECT challenge 
paradigm
The general form of the paradigm is illustrated in Figure 6.1a, 
showing the 1/4 dose of 99mTc-HMPAO administered for basal 
imaging, and the 3/4 dose 99mTc-HMPAO given during the 
particular form of activation. In Figure 6.1 b, the use of the 
paradigm to image the effect of drug action on brain function is 
shown. In the example illustrated, the maximal drug effect is 
expected to occur at 1.5 hours, and therefore the second dose of 
99mjc_HMPAO is given at this time.
FIG 6.1 SPET SPLIT DOSE CHALLENGE PARADIGM
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the drug effect is expected. It has been shown by Andersen et. al. (1988b) 
that the change in HMPAO distribution which takes place between 10 minutes 
and 5 hours after injection is less than 4%. Immediately following the basal 
scan the patient will be given the remaining 75% dose of 99mTc-HMPAO in 
order to image the distribution of CBF at maximal drug effect. Although the 
drug may have been administered an hour or so previously, the baseline scan 
represents the distribution of 99mTc-HMPAO before drug treatment began.
The initial 25% dose " mTc-HMPAO scans typically require 15 minutes to 
acquire sufficient data for good SPECT reconstruction. As section scanners 
have to be used, head positioning is of paramount importance therefore each 
15 minute scan was preceded with a rapid series of 2 minute positional scans 
which are sufficiently clear to enable topographic landmarks such as the 
caudate nucleus to be identified. Where possible, the two imaging sessions, 
namely the basal and challenge, should be close together so that the patient 
can lie in the same position on the scanning couch to ensure optimum 
realignment of basal and challenge scans.
In order to obtain data corresponding to the challenge condition, the 
first set of images (basal) are subtracted from the second set of images after 
correcting for length of acquisition time and isotope decay. Alternatively, 
counts within corresponding ROIs can be subtracted.
6.2.4 Aims of study
The aims of the present study were:
1) To develop and describe a method that may allow 99mTc-HMPAO 
SPECT neuroimaging to be used to investigate the effects of intervention on 
patterns of rCBF during a single imaging session, using a ‘split-dose’ of the 
tracer.
1 4 2
2) To determine the relative contributions of various sources of error to 
repeat SPECT measurements in the absence of challenge. The effects of 
data acquisition and image reconstruction, patient movement during the scan 
and patient realignment were examined.
3) To compare the reproducibility of the split-dose method with a ‘two- 
dose’ method.
6.2.5 Methods
6.2.5.1 Split-dose reliability study
(1) Data acquisition
To measure the variability associated with the split-dose paradigm, a 
control group of 10 patients of different pathologies had split-dose 
" mTc-HMPAO scans with no challenge between scans. The radio­
pharmaceutical " m jc  labelled HMPAO (99mTc-HMPAO) was prepared by 
adding " ^ T c  as pertechnetate in 5ml saline to the freeze dried mixture of 
HMPAO ligand. Each patient received an initial dose of 125MBq (25% of 
usual activity), injected intravenously while the patient lay on the imaging 
couch with eyes closed and ears unplugged. The initial scanning session 
lasted on average 45 mins and during this time pilot positional scans and two 
transverse slice images, each 12mm thick, were obtained in a plane parallel to 
the orbito-meatal (OM) line at +30 and +70 millimetres superior to this line. 
Acquisition time for each slice was 15 minutes during which between 1.5 and 
2 million counts were acquired.
After acquisition of the initial scans, and with the patient still on the 
imaging couch in the same resting position, a further 375MBq dose of "m Tc- 
HMPAO was injected. After 5 minutes image acquisition was repeated, but on 
this occasion a shorter scan time of 5 minutes could be used as the
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administered activity was higher. The imager used was a Novo 810 imager 
employing the Harvard multidetector scanning system with 12 sets of 
scintillation detectors and focussing collimators as described in section 3.6.
(2 ) Data analysis
A brain atlas was used to define brain regions. Using the low slice at 
+30mm above the OM line the following symmetrical regions of interest (ROI) 
were defined: right and left frontal (RF, LF), right and left temporal (RT, LT), 
right and left posterior temporal (RPT, LPT), right and left occipital (RO, LO), 
and right and left basal ganglia (RBG, LBG; Figure 3.7). From the high slice at 
70mm above the OM line symmetrical right and left high frontal (RHF, LHF), 
and right and left parietal (RP, LP) ROIs were also defined (Figure 3.7). Mean 
uptake for each ROI relative to total uptake in the slice, was calculated as 
follows:
Relative mean uptake in each ROI for 1st scans = Cr(*|) / C t(i)
Relative mean uptake in each ROI for 2nd scans =
Cr(2) - c r(1)/ c t(2) - °t(1)
where Cr is the number of counts in region of interest r,
Ct is the total number of counts in the slice,
and the imaging session is given in brackets (1st or 2nd).
Appropriate corrections for isotope decay were also applied.
6.2.5.2 Factors affecting reproducibility
In order to measure the size of the components contributing to 
variability in repeat scanning, the following potential sources of error were 
also investigated:
Test A: the effect of data acquisition and image reconstruction
Data acquisition (eg statistical fluctuation) and image reconstruction 
errors were measured using an anatomical phantom constructed of perspex 
with compartments designed to simulate cortical structures (Wyper et al 1988).
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These spaces were filled with a known quantity of 99mTc designed to simulate 
the typical count rate in normal HMPAO studies. The phantom was 
consecutively scanned six times without altering its position within the 
scanner.
Test B: the effect of head movement during a scan
It is not possible to rigidly immobilise the head during scanning, and 
this would clearly be very difficult to achieve in disturbed or cognitively 
impaired patients, such as those with Alzheimer’s disease. Therefore, it is 
inevitable that some degree of head movement, voluntary and involuntary, 
may occur during scans. In order to examine the effect of such movement 
artefact during scans, the same transverse brain sections from the same 
patient were scanned twice. Eight patients with Alzheimer’s disease who 
conformed to diagnostic and selection criteria described in section 3.2.1, were 
studied. Using this approach, the effect of involuntary movement or tilting of 
the head by the patient during scanning was determined. In this experiment 
scanning sessions were approximately 25 mins long.
Test C: the effect of re-aligning the patient
To assess the errors introduced by realigning the patient in the 
scanner, the above eight Alzheimer patients had repeat scans after they had 
been removed from the scanner and then repositioned in the scanner as 
accurately as possible using external landmarks and the scanner’s optical 
alignment system as a guide.
Test D: serial scanning after one week
Although attempts should be made to ensure that environmental factors 
are unchanged when repeat scans are performed, namely the same quiet 
room, the patient positioned as before with eyes closed listening to the same 
relaxing conversation from the investigator administering the 
radiopharmaceutical, this is clearly very difficult to achieve in practice. For 
example, it would be difficult to control for differences in anxiety level and its
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presumed corresponding effect on brain blood flow patterns. In order to 
investigate the variability of imaging data when patients are rescanned after a 
short interval, a test retest experiment was carried out in which the entire 
scanning procedure, including administration of the radiopharmaceutical, was 
repeated after one week. In the study, 10 patients with AD, who satisfied the 
selection criteria described in section 3.2.1, had repeat SPECT scans after an 
interval of 7 days. In this experiment it is reasonable to assume that 
differences observed between corresponding scans are unlikely to be caused 
by changes in disease process and probably reflect errors introduced in the 
procedures of rescanning or changes in the mental state of the patient 
between the two scanning sessions.
6.2.6 Results
In tests B,C, and D, the same measure of relative rCBF, as described in 
section 3.5.2, was calculated for each ROI on each of the two imaging 
occasions and used in the analysis of results. Relative rCBF in the split-dose 
experiment was calculated as described above in section 6.2.5.1. In the 
phantom experiments, raw counts were used for analysis. Measures of 
‘precision’ at P < 0.05 level were computed as twice the standard deviation of 
the difference between corresponding first and second ROI measurements, 
expressed as a percentage. It follows that the lower the precision value the 
better the reliability of the measurement and vice versa. In columns A to E of 
Table 6.7, average precision measures for left and right ROIs are shown for 
the split-dose and other reproducibility experiments for eight brain regions. 
The split-dose technique appears to have better precision than repeat scans 
after one week.
The relative rCBF values were approximately normally distributed, and 
therefore Student's paired t-test (two-tailed) was used to test the significance 
of differences between values for corresponding ROIs in pairs of scans. In all
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the above reproducibility experiments, there was no significant difference 
between relative rCBF values in any ROI in corresponding pairs of scans.
6.2.7 Discussion
The importance of this study is that it suggests how SPECT imaging 
using 99mTc-HMPAO might be extended to investigate the effect of challenge 
on patterns of rCBF. Although challenge studies have been described using 
PET, the present technique may allow wider use of challenge paradigms by 
centres which have SPECT, but not PET. This may extend functional imaging 
to a wider range of clinical groups for investigation of physiological, 
psychological and pharmacological intervention studies. Up to one hour of 
cooperation from subjects is required, but this is comparable with other 
tomographic imaging methods.
As the two imaging sessions are contiguous (see Figure 6.1), the 
subject's head remains in a constant orientation throughout both the first 
(basal) and second (interventional) scans, facilitating efficient alignment of 
brain regions under investigation (see Table 6.7). The patients in this study 
were all cooperative and therefore efficient realignment of slice position was 
straightforward. With patients less able to cooperate, it may be necessary to 
adopt other means to ensure accurate realignment of position during data 
acquisition, such as the use of external markers attached to the subject’s 
head. The problem of slice positioning is perhaps less important when 
gamma cameras are used for SPECT scanning or when instruments such as 
the Novo 810 are used with the facility to reconstruct data in any plane. This 
facility should represent a significant improvement for studies of this nature.
Not surprisingly, the poorest reproducibility is in the basal ganglia 
region, which, as well as being the smallest region with the lowest number of 
counts, is also subject to changes in the partial volume confinement caused by
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slight alterations in slice position. This is also consistent with the large 
standard errors detected for the basal ganglia ROI in all three groups in 
chapter 5 (see Figure 5.2). The reproducibility in the temporal region is also 
relatively poor. This may be due to the variability at the medial aspect of the 
ROI (Figure 3.6). To obtain better reproducibility, this ROI might be better 
redefined to exclude all medial structures.
In the other regions, the reproducibility is better than 9% varying from 
8.3% in the parietal and posterior temporal regions to 3.6% in the superior 
frontal region. This is better than for a test retest at 1 week (Table 6.7, column 
D), presumably because patients are not removed from the scanning couch 
between the two scanning sessions. The better precision found in the frontal 
regions may result from the shape of these structures making the 
measurement insensitive to slight axial misalignment.
As the activity of radiopharmaceutical administered to each patient is no 
greater than that used in a standard clinical brain SPECT scan, namely 
500MBq, the technique has dosimetry advantages. Matsuda et al 1988 have 
reported using a double dose technique, as opposed to the split-dose 
paradigm described here, in which two doses of 740MBq of 99mTc-HMPAO 
were given in order to study changes in flow during a Matas test. This differs 
from the technique reported here in two important ways. Firstly, a very high 
dose of radiation is delivered to the patient from 1480 MBq of " mTc. 
Secondly, keeping the count rate for the first scans as low as practically 
possible, results in a lower statistical error in the subtraction image compared 
to that obtained with a 50:50 split of the same dose. Electing to use 25% of 
the usual 500MBq dose for the first scan enabled an image to be obtained in 
15 minutes, which was considered to be the maximum period patients could 
tolerate for single slice data acquisition.
It should be emphasised again that 99mTc-HMPAO measures the 
pattern of cerebral blood flow and not absolute values and the split-dose
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technique therefore measures changes in pattern. The data for physiological 
state 2 is obtained by subtracting the first set of scans from the second after 
suitable correction for scan time, background activity and decay. This was 
done on a region of interest basis but small focal variations can be missed 
with this approach and pixel by pixel subtraction is better if accurate co­
registration of the two data-sets can be achieved (Friston et al 1989).
These results show the extent to which various factors contribute to the 
reproducibility of the techniques (see columns A to D of Table 6.7). Precision 
measurements for phantom ROIs were consistently below 4.2%, apart from 
simulated basal ganglia (9.2%), for apparently similar reasons as discussed 
above. This suggests that the errors involved in data acquisition and 
reconstruction are small. Similarly when the same slice image is rescanned 
without moving the subject using the couch, precision is still low, but 
comparison with phantom precision indicates the effect of unwanted 
movement during the scan. Removing the patient from the scanner and 
realigning as carefully as possible in the same position results in further 
detriment to reproducibility precision, though not as much as when the 
complete imaging protocol is repeated after one week (Test D). Thus in 
investigations where two sets of imaging data are to be compared, eg basal 
and activational scans, the split-dose paradigm seems to offer advantages for 
accuracy of reproducibility, over other paradigms in which two scanning 
sessions occur on different days, such as the study described in 6.1 .
This study has shown that changes greater than 5.7% in frontal cortex 
or 8.3% in parietal cortex may be detected by the split-dose method with a 
confidence limit of 95% in a single case. Thus the technique may be capable 
of detecting the effects of visual stimulation which can increase rCBF in 
occipital cortex by as much as 38% (Woods et al 1991) or motor tasks which 
can increase rCBF in parietal cortex by 9.4% (George et al 1991). Cognitive 
challenges, however tend to produce a much smaller change in rCBF (eg
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Ginsberg et al 1987). Parks et al (1988) found that a verbal fluency task 
produced a change of around 5% in regional cerebral metabolic rate for 
glucose in frontal cortex (with data normalised to occipital cortex) and George 
et al (1991) found an insignificant change of less than 5% in rCBF frontal 
cortex in two subjects performing the Stroop task. The split-dose technique 
as described here would be unlikely to detect the effects on rCBF of these 
cognitive challenges on individual subjects. However, significant differences 
between groups have been shown using the split-dose paradigm to examine 
the effect of verbal fluency on rCBF patterns in elderly normal females 
(Shedlack et al 1991).
In conclusion, two-dose techniques allow 99mTc-HMPAO SPECT 
imaging to be extended from its current use in basal conditions, to the wider 
application of imaging changes in brain function. In particular, the split-dose 
paradigm described above might be used to study the effects of 
pharmacological, physiological and psychological challenge to cerebral 
function. The method has the advantage of reducing the radiation dose given 
to subjects, as well as ensuring better head positioning reproducibility. In 
chapter 7 the role of the split-dose paradigm in future SPECT studies of the 
effects of activation will be considered.
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CHAPTER 7 
CONCLUSIONS
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7.1 Investigation of brain function in Alzheimer’s disease
It has been increasingly recognised in the last decade that younger 
and older AD patients are probably afflicted by the same neuropathological 
disease process. There is still considerable controversy, however, as to 
whether AD can be divided into two distinct subtypes on the basis of age (the so- 
called AD-1 and AD-2) or whether all patients with AD qualitatively show the 
same changes irrespective of age (eg Bondareff et al 1987 and Mann et al 
1988b). Investigation of patterns of neuropathological involvement during life, 
would help to resolve this question, but there are few methods available to 
address this question. Brain biopsy is not considered ethically justified in most 
centres, and in any case, provides only very limited quantities of tissue for 
examination, usually from restricted brain areas. Patterns of functional deficit 
can be assessed from detailed clinical and neuropsychological description of 
cases, but some means of determining functional neuroanatomy is clearly 
essential. Structural neuroimaging methods, such as x-ray computed 
tomography (CT) or magnetic resonance (MR) imaging, can be used to 
determine degree and topography of brain involvement. For instance CT 
imaging shows that there does appear to be a close relationship between 
cognitive impairment and ventricular enlargement in demented patients (de 
Leon et al 1979). MR imaging, at least at present, is like CT, essentially a 
structural technique. The improved tissue resolution obtained with MR allows 
grey and white matter to be differentiated clearly and this makes MR particularly 
well suited for detailed anatomical examination. Apart from the paucity of 
available MR imagers, the major limitation of CT and MR imaging is their inability 
to measure functional processes in brain, and inferences about brain function 
drawn from structural images can be problematic as the case history described 
in chapter 5 clearly showed.
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Improved nursing and medical care of patients with AD means that 
patients are living longer with two important consequences for investigation. 
Firstly, this provides an important opportunity for study of the natural course of 
the illness from early stages to death, and allows the different clinical courses of 
AD to be described. Secondly, the improved longevity of AD patients will result 
in proportionately more post mortem examinations being carried out in the later 
stages of AD. Neuropathological description after death provides useful 
information on the integrity of brain tissue at that end point, but relatively little 
information about the temporal sequence of involvement of different brain 
regions in the condition. Furthermore study of the relationships between mental 
function ante mortem and neuropathological involvement post mortem, are 
logistically difficult.
Techniques, such as PET and SPECT have the advantage that they 
provide information on regional brain function in vivo and can be employed 
repeatedly throughout the course of a patient’s illness to measure the 
relationship between brain activity (eg as measured using rCBF) and mental 
performance. The development of functional brain imaging also provides a 
potentially powerful way of measuring how brain function responds to challenge, 
such as pharmacological or neuropsychological intervention.
7.2 Summary of findings
In many circumstances, including dementia, cerebral blood flow 
appears to be a useful index of brain metabolism. Therefore imaging 
techniques, such SPECT, which estimate CBF, or at least some function of CBF, 
provide a means of studying brain function in vivo, in both basal and activated 
conditions. In this thesis, two different imaging techniques, MTT and SPECT, 
were used to study the pattern of brain function in Alzheimer’s disease and 
Korsakoff’s psychosis, and its relationship to neuropsychological performance.
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The mean transit time technique has the advantage of requiring only 
short periods of cooperation from patients. In many patients, such as those with 
major psychiatric illness, there are obvious advantages in techniques that 
require only minimal patient compliance. In both presenile AD and KOR, 
estimates of net MTT were considerably prolonged compared to those of healthy 
controls. Although these results are consistent with results from other functional 
imaging techniques, no inference can be made about CBF without cerebral 
volume of distribution estimates. Estimates of net MTT provided by the method, 
although able to differentiate, on a group basis, demented patients from healthy 
controls, were not helpful for distinguishing AD and KOR groups. Furthermore, 
examination of individual net MTT estimates indicates some overlap between 
net MTT values for all three groups studied. As this was not an epidemiological 
study and patient groups of AD and KOR carefully recruited, estimates of 
sensitivity and specificity cannot be calculated. However estimates of positive 
predictive value viz. the probability that the disease is present when the test 
result is positive, were calculated for net MTT. Positive predictive values for 
transit times in bilateral posterior cortical regions of AD patients were greater 
than 70%. The positive predictive value estimates for net MTT in AD suggest 
that the method may have some clinical utility. However in order to accurately 
assess clinical utility, an epidemiological study to calculate sensitivity and 
specificity would be required. There are difficulties in this approach also as 
pathological diagnostic criteria for dementing illnesses are by no means agreed. 
In both patient groups, the prolongation of net MTTs occurred in all cortical 
regions studied. In AD, this may reflect the well recognised patterns of cortical 
dysfunction. The cortical involvement, suggested by the MTT estimates, was 
perhaps more surprising in KOR patients, who traditionally have been viewed as 
having predominantly subcortical pathology. Indeed this was an important
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consideration in electing to study KOR patients, as it was thought that their 
subcortical pattern of involvement might contrast with the cortical involvement in 
AD, and thus provide a suitable control group. The potential significance of this 
finding with respect to cortical function in KOR patients will be discussed further 
when considering the SPECT findings. The finding of consistently negative 
correlations between neuropsychological test scores and net MTT in both AD 
and KOR groups tends to support the view that net MTT may provide a 
meaningful estimate of cortical function in dementia. Modern techniques for 
CBF imaging are expensive and require highly specialised equipment. The 
attraction of transit time measurement when this study was initiated was its low 
cost and potential availability in any department of nuclear medicine using a 
gamma camera. The main limitation of MTT is not that it is non-tomographic 
and limited to planar cortical imaging, but the difficulties in interpreting its 
physiological significance. Without information about volumes of tracer 
distribution it is not possible to determine the relationship of net MTT to CBF.
Single photon emission tomography using the flow tracer 99mjc_ 
HMPAO has several appealing characteristics for imaging CBF in dementia and 
also other psychiatric conditions. The relatively stable trapping of the 
radiotracer in brain allows the investigator reasonable control over which 
particular features of the patient's mental state will be imaged. For example, in 
chapter 5, injections of 99m7C-HMPAO were given to AD and KOR patients who 
were in a relaxed state with their eyes closed, whereas in chapter 6 the trapping 
property of the tracer was utilised in order to ‘capture’ the flow pattern during the 
effect of physostigmine on brain metabolism. The same advantages of the 
technique can also be utilized for functional imaging of other transient mental 
phenomena, such as hallucinosis, or mood disturbance, and have been used for 
investigation of temporal lobe seizure activity (Duncan et al 1990). The time
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taken to inject 99mTc-HMPAO is very brief, and is similar to that of the entire MTT 
method, thus both measure ‘function’ in a very short time interval. Unlike MTT 
however, 99mTc-HMPAO has several other advantages. In particular, the 
relative stability of 99mTc-HMPAO distribution in brain, allows adequate time for 
tomographic imaging. In this study a dedicated brain sectional scanner, the 
Novo 810, able to acquire data for single slice reconstruction in a short interval 
of time (of the order of 5 minutes) was used. SPECT can, of course, also be 
carried out using a rotating gamma camera, but with this type of instrument, a 
longer imaging session (about 45 minutes) is needed to acquire the whole data 
set, and interruptions to the scanning session eg due to patient movement, may 
result in loss of all data. The ability of the Novo 810 to acquire sectional images 
was utilised in the ‘split-dose’ paradigm described in chapter 6.
Patterns of rCBF in AD and KOR patients at rest with eyes closed, 
were studied using " mTc-HMPAO SPECT. In AD marked reduction in rCBF 
occurred in posterior temporal and parietal areas, although there was also a 
trend for relative flow to be reduced in frontal and temporal regions. Cortical 
flow reductions in resting AD patients were correlated with impairments of 
cognitive function; in particular, rCBF in left posterior temporal and left parietal 
regions were strongly correlated with most aspects of cognitive function, but 
notably language functions, memory scores, attention and praxis.
Measurements of 99mTc-HMPAO SPECT were undertaken to 
examine the patterns of perfusion deficits in AD and KOR patients, not to assess 
SPECT as a diagnostic technique. As explained above for net MTT, 
assessment of diagnostic utility would have required a very different study 
design from that used. In order to measure sensitivity and specificity all patients 
presenting with dementia would need to have been investigated with SPECT 
not, as in the present study only two carefully selected groups of patients (AD
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and KOR). Positive predictive values were not impressive and only in posterior 
temporal regions of AD patients did they exceed 50%. As an aid to 
understanding the pattern of function-related perfusion in individual patients 
SPECT may have a place.
Unlike in the AD group, flow in KOR patients was preserved at normal 
or near normal levels in temporal, posterior temporal and parietal regions, but 
tended to be reduced in frontal regions. Furthermore, flow deficits in frontal 
regions in KOR patients were correlated with impaired performance on tests of 
memory and orientation. This work suggests that in KOR, there is frontal lobe 
dysfunction as well as the more recognised subcortical lesions of thalamus and 
mamillary bodies. There has been relatively little interest in cortical dysfunction 
in KOR, and very few studies using functional imaging techniques such as 
SPECT. While the subcortical lesions have been traditionally linked to the 
amnesic features, there is increasing evidence for the role of frontal regions in 
memory function (Moscovitch, 1982). Frontal lobe dysfunction in KOR is not 
unexpected in view of the well recognised clinical features of apathy, inertia, 
loss of initiative and rather bland disposition that often characterise the 
condition.
The use of two doses of 99mTc-HMPAO described in chapter 6 
extends " mTc-HMPAO SPECT to activational states as well as basal 
conditions. Using this technique, the effects on brain metabolism, as reflected 
in rCBF distribution, of both pharmacological or neuropsychological intervention 
can be determined and compared to basal rCBF patterns. Thus the technique 
offers a novel way of assessing the effects of drugs on brain function and 
provides a means of understanding the relationship between neurotransmitter 
system dysfunction and brain metabolism. Two dose 99mTc-HMPAO SPECT 
was used to measure the effect of cholinergic potentiation on rCBF patterns in
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AD patients using the anti-cholinesterase physostigmine. After physostigmine 
there appeared to be an increase in left sided 99mTc-HMPAO uptake relative to 
that in the right side, with the most significant changes in frontal regions. These 
results, although preliminary, illustrate the potential of this approach, in which 
the functional consequences of manipulation of specific transmitter systems can 
be detected using SPECT and related to resultant changes in cognition.
7.3 Problems associated with functional imaging
A comprehensive review of the methodological problems associated 
with isotope brain imaging is outwith the scope of the present work, but some 
discussion of the more important difficulties is required.
The power of physiological imaging techniques will depend in part on 
the availability of standardized, reproducible and accurate methods of data 
analysis. PET, and potentially SPECT, have the ability to measure a wide 
range of biochemical, physiological and pharmacological processes in brain.
As discussed in chapter 2, the tracer kinetic methods for measuring such 
processes vary in temporal resolution, statistical image quality (owing to the 
constraints imposed on radioisotope counting), and degree of structural 
information incorporated into the functional image. Imaging instruments vary 
widely in spatial resolution, both within the plane of the section, and in the axial 
direction. These variables contribute to measurement errors stemming from the 
techniques of functional brain imaging themselves. Additional variability is also 
contributed by differences in brain structure between individuals. For instance 
left-right hemispheric differences have been described at macroscopic 
(Galaburda et al 1978) and ultrastructural (Amaducci et al 1981) levels. Added 
to this, pathological processes may also introduce further variability as has been
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noted in AD (eg chapter 6). Such variability in brain structure will have 
important consequences for functional imaging, and may result in global 
changes in function eg due to atrophy or more localised effects, as in some 
cases of AD.
Functional brain images can be analysed in three main ways: 1) 
quantitative values of CBF from particular brain regions can be determined; 2) 
semi-quantitative or relative measures of CBF can be determined, and 3) 
images can be qualitatively inspected by experienced observers. At present 
true quantitative SPECT imaging is limited to dynamic 133Xe rCBF imaging (see 
section 2.2.5.2), but with " mTc-HMPAO useful measures of rCBF can be 
obtained relative to some other reference brain area, such as occipital cortex, as 
in this thesis, and by others using cerebellum (Burns et al 1989). It should be 
recognised that the use of reference areas in this way is not peculiar to SPECT, 
but has also been widely used in PET. Qualitative image analysis has been 
employed by several groups (eg Neary et al 1987; Gemmell et al 1987) and 
should be viewed, not as an alternative to other methods but as a 
complementary method of analysis. Indeed pattern recognition by visual 
inspection has been employed in nuclear medicine and radiology for some time, 
and is a proven way of analysing complex data sets, such as images. Normal 
SPECT scans tend to be symmetrical and image asymmetry can be detected 
more readily by the eye, than using available quantitative protocols. The 
subjectivity of visual image recognition can be reduced by using experienced 
raters, blind to conditions or diagnosis. Such an approach was used to assign 
ROIs to SPECT images in the studies reported in chapters 5 and 6.
Thus potential sources of error in functional image analysis are 
considerable, but other sources of information can usefully contribute to image 
interpretation. In the SPECT studies in this thesis external anatomical
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landmarks, eg the orbito-meatal line and brain atlas information, were used to 
assist in the assignment of structural localization to the functional images. 
Ancillary information on brain structure can also be obtained from skull 
radiographs (eg Fox et al 1985), x-ray CT (eg de Leon et al 1983b) and MR 
imaging (eg Evans et al 1988). However access to structural imaging facilities, 
particularly for research purposes, is likely to be very limited and/or logistically 
complex. In addition, reliable positioning between the different imaging 
modalities must be employed. The matching of MRI and PET/SPECT images is 
a major computational problem that, despite the development of fitting 
algorithms, requires to be solved and validated.
Another important potential source of variance is the subject’s mental 
activity at the time of the measurement. No standard definition of ‘resting’ or 
‘basal’ mental set exists and different groups have used different definitions of 
basal conditions. In this work, subjects were examined at rest, with eyes closed 
and ears unplugged, in a quiet room with average illumination. In many ways 
this is very much a compromise, as others have defined the resting state as one 
of relative sensory deprivation, while others examine patients with eyes open 
and ears unplugged, arguing that this ‘background’ stimulation reflects the 
cognitive state commonly encountered in everyday circumstances with a 
continuous baseline of cognitive activity. It can been argued that inter-subject 
variability may be reduced by attempting to standardize mental set during 
imaging. This might be accomplished by asking subjects to undertake some 
standardized cognitive task during imaging.
The development of functional imaging of brain is still at an early 
stage, but the potential of the approach appears considerable. SPECT 
imaging is potentially widely available, for although high resolution instruments, 
such as the dedicated section imager used in the present work, are available at
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present in only a few UK centres, rotating gamma camera systems able to 
provide moderate resolution are available in most nuclear medicine 
departments. The introduction of the radiopharmaceutical " mTc-HMPAO has 
enabled high resolution SPECT images of rCBF to be obtained quickly and with 
minimum radiation exposure to patients. Reservations about the non-linearity of 
the relationship between absolute estimates of flow and 99mTc-HMPAO uptake 
at high flow values, have led to development of correction algorithms (eg Lassen 
et al 1988). However conditions of high flow (eg encephalitis) are probably 
quite unusual in psychiatric illness, and there is a good correlation between 
absolute measures of rCBF measured using PET and 99mTc-HMPAO uptake at 
normal and low flow values, as occur in AD and KOR patients (Inugami et al 
1988). Further work is required in order to verify the kinetic models used and 
overcome the disadvantage of lack of true quantification.
7.4 Future studies
Initial SPECT (and MTT) studies examined basal patterns of rCBF 
(chapters 4 and 5). Longitudinal studies in AD are essential in order to 
determine the change in patterns of rCBF and cognition occurring as the 
disease progresses. Such studies would also allow relationships between 
cerebral function and cognition to be monitored over time. There is some 
evidence that clinical course and neurochemical impairment differs in subjects 
developing AD at an older age (AD-1) compared to those developing the illness 
at a younger age (AD-2). In this thesis only AD-2 patients were studied, but 
clearly SPECT provides a suitable technique with which to examine cerebral 
function in the two putative ‘types’ of AD.
In chronic KOR syndrome neuropsychological function reputedly
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remains relatively stable over time compared with AD (Butters & Granholm,
1987). Clearly longitudinal studies of cerebral function measured by SPECT, 
and neuropsychological performance would be necessary in order to test the 
validity of this hypothesis. There are indications that cortical pathology may be 
instrumental in determining some features of the KOR syndrome and that 
attention has focussed too closely on the basal brain changes in the disorder 
(Lishman et al 1987). This is supported by the MTT and SPECT studies 
described in this thesis, and consistent with the clinical signs of KOR syndrome. 
In particular the frontal deficit in function demonstrated by SPECT deserves 
further study with a larger series of patients.
The more restricted nature of the cognitive deficits in KOR, suggest 
that it might provide a better ‘model’ system than AD in which to determine the 
relationships between regional brain function and mental impairment. Such 
information might help to target studies in AD. For example the cholinergic 
deficit in AD may be paralleled by a similar deficit in KOR that could also be 
critically involved in memory impairment (Lishman, 1986; Butters & Granholm, 
1987). Therefore investigation of putative cholinergic deficits, using SPECT to 
assess the cerebral effects of pharmacological challenge, might be better 
executed in KOR, rather than AD patient groups. The radiopharmaceutical 
" mTc-HMPAO has clear advantages for imaging the functional consequences 
of pharmacological manipulation of particular neurotransmitter systems, using 
putative receptor agonists or antagonists in both healthy controls and psychiatric 
patients. In analogous studies, the 2-deoxyglucose technique (eg Sokoloff 
1959;1982, chapter 2) has been successfully employed to map dynamic 
functional events in animals.
A similar approach is also feasible using 99mTc-HMPAO SPECT to 
investigate cerebral activity in human subjects during neuropsychological
1 6 2
challenge. The following example is described to illustrate the approach 
(Shedlack, Hunter et al 1991). The split-dose 99mTc-HMPAO SPECT imaging 
paradigm described in chapter 6 was used to compare the effects of the verbal 
fluency task (Borowski et al 1967), usually regarded as a test of the integrity of 
left frontal cortex, with simple verbalization (counting) in twenty elderly healthy 
female subjects (mean age 67 years, range 59-78 years). Each subject was 
studied under basal conditions after injection of 125MBq 99mTc-HMPAO.
Without moving the head of the subject, they were scanned again after injection 
of 375MBq " m jc  -HMPAO. The second injection was made in 10 subjects 
during the verbal fluency task and in the other 10 subjects during counting. 
Verbal fluency was associated with reduced uptake bilaterally in the region of 
the basal ganglia and in left temporal (peri-sylvian) cortex when compared with 
an occipital unstimulated reference region. By contrast, counting produced 
relative activation in frontal and parietal areas. Thus, using the split-dose 
paradigm, clinically relevant neuropsychological tests might be characterised 
functionally in AD and other neurodegenerative disorders, such as KOR, by 
pattern of regional brain activity, localization of which might not be predicted 
from classical studies of brain lesions. Such an approach complements that of 
neuropharmacological challenge described above. The split-dose tracer 
technique allows radiation dose to be minimised, and permits multiple, 
anatomically identical but metabolically distinct scans in individual subjects, thus 
allowing the use of an intravenous SPECT ligand for the dynamic investigation 
of cerebral metabolic demand during normal cognitive processes.
The relationship between cognitive function and resting or stimulated 
rCBF values suggests a useful future for SPECT measurements in psychiatry. 
The split-dose approach allows both stimulated and basal cerebral function to 
be measured, but it is likely that data obtained under challenge conditions will
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be more informative than that obtained at rest. Probably the method of choice 
for investigating the effects on brain function of cognitive or other challenge will 
remain H2O15 PET (Lammerstma et al 1990). However SPECT challenge 
paradigms such as the split-dose technique may allow findings from PET to be 
investigated further in clinical settings.
Further impetus for SPECT investigation of AD and KOR will result 
from the development of labelled receptor ligands. Table 7.1 shows some of 
the neuroreceptor ligands that have been used for SPECT imaging. The 
muscarinic cholinergic receptor ligand, 123l-3-quinuclidinyl 4-iodobenzilate 
(123|.q n b ), can be used for SPECT imaging of muscarinic receptors in vivo 
(Eckelman et al 1984). Preliminary findings with 123I-QNB SPECT in AD 
suggest that in non-atrophic areas, muscarinic receptor upregulation may occur 
(Weinberger et al 1989). Much more work will be needed to confirm such 
findings, but they demonstrate that potentially novel information may result from 
this approach.
TABLE 7.1
Neuroimaging and SPECT neuroreceptor ligands
Receptor Ligand
M1, M2 123| - q n b
1231 . Dexetimide
D2 123| - IBZM
1231 - 2 - Spiperone
1231 - iodolisuride
D1 123| - SCH 23892 
123| - SCH 23390
BZ/GABA 123| - Fumazenil
Serotonin S2 123| - Ketanserin
Opioid 123| - Diprenorphine
Amines 123| - IMP
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Appendix. Some of the results presented in this thesis have been 
published as follows:
1. Christie J E, Goodwin G M, Hunter R & Merrick M V (1987)
Measurement of regional cerebral blood flow in Alzheimer-type 
dementia using a novel approach. Journal of Physiology392, 78P.
2. Hunter R, Gordon A, McLuskie R, Wyper D, Patterson J, Christie, J E,
Fink G, & Goodwin G M (1989) Gross regional cerebral hypofunction in 
the presence of normal X-ray CT in a case of Creutzfeldt-Jacob disease. 
Lancet I, 214-215.
3. Hunter R, Merrick M V, Ferrington C, Notghi A, McLuskie R, Christie J E & 
Goodwin G M (1989) Cerebral vascular transit time in Alzheimer's 
disease and Korsakoff's psychosis and its relation to cognitive function. 
British Journal of Psychiatry 154, 790-796.
4. Hunter R, McLuskie R, Wyper D, Patterson J, Christie J E, Brooks D N, 
McCulloch J, Fink G & Goodwin G M (1989) The pattern of function- 
related regional cerebral blood flow investigated by single photon 
emission tomography with " mTc-HMPAO in patients with presenile 
Alzheimer's disease and Korsakoff's psychosis. Psychological 
Medicine 19: 847-855.
5. Hunter R, Merrick M V, Ferrington C, Notghi A, Christie J E & Goodwin G 
M (1989). Vascular transit time in dementia and its relation to 
neuropsychological function.
Journal of Cerebral Blood Flow and Metabolism 9, Suppl. 1, 5519.
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6. Hunter R, Patterson J, McLuskie R, Christie J E, Brooks D N, McCulloch J 
& Goodwin G M (1989). " mTc-HMPAO SPET imaging in presenile 
Alzheimer's disease and Korsakoff's Psychosis.
Journal of Cerebral Blood Flow and Metabolism 9, Suppl. 1, 5515.
7. Shedlack K.J, Hunter R, Wyper D, McLuskie R, Fink G, Goodwin G.M. 
The pattern of cerebral activity underlying verbal fluency shown by split- 
dose single photon emission tomography (SPET or SPECT) in normal 
volunteers.
Psychological Medicine (1991) 21, 687-696.
8 Hunter R, Goodwin G, Wyper D, Shedlack K& Fink G (1989). Imaging 
basal and activated brain function in psychiatric illness.
Psychiatry Today - Accomplishments and Promises, VIII World Congress 
of Psychiatry, Athens, 558, (Editors: CN Stefanis, CR Soldatos, AD 
Rabavilas), Elsevier, Amsterdam.
9. Hunter R, Wyper D, Patterson J, Hansen MT & Goodwin G M (1991). 
Cerebral pharmacodynamics of physostigmine in Alzheimer’s disease 
investigated using Single Photon Computerised Tomography. British 
Journal of Psychiatry (1991), 158, 351 -357.
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